
<!DOCTYPE html>
<html dir="ltr" lang="en">
<head>
 
<link rel="preconnect" href="https://cdn.cookielaw.org">
<link rel="preconnect" href="https://www.googletagmanager.com">
<link rel="dns-prefetch" href="https://www.google-analytics.com">
<link href="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" rel="preload" as="script">
 <link href="https://www.googletagmanager.com/gtm.js?id=GTM-5MKXR9" rel="preload" as="script">
<!-- OneTrust Cookies Consent Notice start --> 
<script src="" type="text/javascript" charset="UTF-8" data-domain-script="7a4eae6f-1f57-4f7c-8a64-5aa159ee745e"></script>
<script type="text/javascript">
function OptanonWrapper() { }
</script>
<!-- OneTrust Cookies Consent Notice end -->
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta lang="en">
<meta http-equiv="content-type" content="text/html; charset=utf-8">
<meta http-equiv="content-language" content="en">
<meta name="viewport" content="width=device-width, height=device-height, initial-scale=1, minimum-scale=1, maximum-scale=5, user-scalable=1">
 <!-- Title and Description -->
 <title>Tuberculosis (TB) - Infectious Diseases - MSD Manual Professional Edition</title>
 
 <!-- Schema.org/Additional markup -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 <!-- Twitter Card data -->
 
 
 
 
 
 <!-- Open Graph data -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<!-- Google Tag Manager --> <script></script> <!-- End Google Tag Manager -->
 <script type="text/javascript">
 // Way froward settings. Strongly typed for Typescript code.
 // Typescript definition file is in \src\Foundation\Presentation\code\Scripts\typings\Settings.d.ts
 MManual = window.MManual || {};
 MManual.Foundation = MManual.Foundation || {};
 MManual.Feature = MManual.Feature || {};
 MManual.Foundation.Logging = {
 Level : "WARN"
 }
 MManual.Foundation.Context = {
 Language: {
 Name: "en",
 Code: "en"
 },
 Edition: "Professional"
 }
 MManual.Foundation.Context.Item = {}
 
 MManual.Foundation.Context.Item.SitecoreId = "1fef1f26-c9f6-41ef-8c18-cb7450e146e0";
 MManual.Foundation.Context.Item.MediaId = "";
 MManual.Foundation.Context.Item.VasontId = "v1010663";
 MManual.Foundation.Context.Item.TemplateId = "9fe4ab09-1603-40e4-91f9-0ac01a474c58";
 
 
 MManual.Foundation.Context.Chapter = {
 SitecoreId : "83519cf1-e6fa-4bf6-aa1d-45ae37799a0e",
 VasontId : "v1010641"
 }
 MManual.Foundation.Context.Section = {
 SitecoreId : "31b9cca6-b744-4d01-a4c5-6642dd6c8f29",
 VasontId : "v878841"
 }
 
 MManual.Foundation.TemplateIds = {
 Topic : "9fe4ab09-1603-40e4-91f9-0ac01a474c58"
 }
 MManual.deferredScripts = [];
 // Below settings are obsolete. Please use MManual.Foundation.Context
 //////////////////
 // OBSOLETE START
 ///////////////////
 MManual.settings = MManual.settings || {};
 MManual.settings.edition = "Professional";
 MManual.settings.language = "en";
 MManual.settings.languageCode = "en";
 MManual.settings.displayDateFormat = "dd/MM/yy";
 MManual.settings.dateFormat = "dd/MM/yy";
 MManual.settings.loadLocationsGlobal = true;
 MManual.settings.LexicompEnabled = false;
 MManual.settings.topic = MManual.settings.topic || {};
 MManual.settings.topic.getTopicsForResourceUrl = "/Redesign/Topic/GetTopicsForResource";
 MManual.settings.topic.getTopicHelpfulUrl = "/Redesign/Topic/GetTopicHelpful";
 MManual.settings.topic.wasThisTopicHelpfulUrl = "/Redesign/Topic/WasThisTopicHelpful";
 MManual.settings.topic.getTableBodyUrl = "/Redesign/Topic/GetTableBody";
 MManual.settings.socialMedia = MManual.settings.socialMedia || {};
 MManual.settings.socialMedia.enableMultimediaPopupShareButton = true;
 MManual.CommonLetters = ['A', 'B', 'C', 'D', 'E', 'F', 'G', 'H', 'I', 'J', 'K', 'L', 'M', 'N', 'O', 'P', 'Q', 'R', 'S', 'T', 'U', 'V', 'W', 'X', 'Y', 'Z'];
 MManual.CommonNumbers = ['0', '1', '2', '3', '4', '5', '6', '7', '8', '9'];
 MManual.Context = MManual.settings;
 MManual.Context.Item = MManual.Foundation.Context.Item;
 /////////////////
 // OBSOLETE END
 /////////////////
 </script>
 <script src="./Content/Scripts/Redesign/Lib/jquery-3.5.1.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/jquery-ui-1.13.1.custom/jquery-ui.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Foundation/Presentation/Library/Knockout/knockout-3.5.1.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/hammer.2.0.7.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/polyfills/es5-shim.4.5.13.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/polyfills/es6-shim.0.35.4.min.js" type="text/javascript"></script>
 <script src="./Content/Scripts/Redesign/Lib/slick-1.8.0/slick.1.8.0.min.js" type="text/javascript"></script>
<!--[if (gte IE 9)|!(IE)]><!-->
<script src="./bundles/redesign/libsjsv4.1.2.2-13178e13ca.js?v=9oeWsccS0AXvU_mpLneFQpk81D2qyviYAadBAspEdRc1"></script>
<!--<![endif]-->
<!--[if lt IE 9]>
 <script src="/bundles/redesign/ie8libsjsv4.1.2.2-13178e13ca.js?v=NYMKNIKPtdByxJkp3-a4OoxrVMsYmUh3Th334huO0BY1"></script>
<![endif]-->
<!-- Add custom class to categorize all cookies as functional. -->
<script src='./bundles/redesign/mmanualjsv4.1.2.2-13178e13ca.js?v=qZy1l8ugVchOqoSbrCHnQvB_O3jXnpspHrGZgwDHF0I1' class='optanon-category-C0002'></script>
<script defer="" src='./bundles/redesign/mmanualTopicjsv4.1.2.2-13178e13ca.js?v=kSA_yN8XuMyhoVC1QLzYxWJE66uhmC-mSc_-tgT27II1' class='optanon-category-C0002'></script>
<script defer="" src='./bundles/redesign/mmanualTopicResourceSearchjsv4.1.2.2-13178e13ca.js?v=iHsFLQRu7O1_jYYodP5cLz5m6_oggwQ97PNvPDyRMrw1' class='optanon-category-C0002'></script>
<!--Region information -->
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<link rel="preload" href="/Content/Fonts/Redesign/oldrambla/Rambla-Latin-webfont.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-700-Bold.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-700-Bold-Italic.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-400-Regular.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-400-Regular-Italic.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-300-Light.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link rel="preload" href="/Content/Fonts/Redesign/OpenSans/OpenSans-600-SemiBold.woff2" as="font" type="font/woff2" crossorigin="anonymous">
<link href="./bundles/redesign/mmanualcssv4.1.2.2-13178e13ca.css?v=RUczVKOp43QqHlIomZoV4XMWus4DZWBAeuESVt-1iCc1" rel="stylesheet" type="text/css" media="screen">
<link href="./bundles/redesign/jqueryuicssv4.1.2.2-13178e13ca.css?v=3k6hV5TZDiil7_Jv0lADrVVLB9hJfoX2PenhijDq_d81" rel="stylesheet" type="text/css" media="screen">
 <link href="./bundles/redesign/mmanualprofessionalcssv4.1.2.2-13178e13ca.css?v=mbUz3b7WGmUBumHpYEaEcWfHb1bxVAgvrA5uGMAlaJ81" rel="stylesheet" type="text/css">
<!--[if lt IE 9]><link href="/bundles/redesign/ie8cssv4.1.2.2-13178e13ca.css?v=" rel="stylesheet"/>
<![endif]-->
<link href="./bundles/redesign/mmanualcssprintv4.1.2.2-13178e13ca.css?v=2xJ7o27xwBLBtbGx65XzwLYcjgNEMec7qcBRi3GYAM01" rel="stylesheet" type="text/css" media="print">
<link href="./bundles/redesign/mmanualcsshybridv4.1.2.2-13178e13ca.css?v=LCUeOfwqiGi437ffhbWXxV6YW74rb9NUl93CESRStCs1" rel="stylesheet" type="text/css" media="hybrid">
<!--[if lt IE 9]>
 <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
<![endif]-->
<script type="text/javascript">
 function msieversion() {
 var ua = window.navigator.userAgent;
 var msie = ua.indexOf("MSIE ");
 if (msie > 0 || !!navigator.userAgent.match(/Trident.*rv\:11\./) || msie == NaN)
 var test = $('li.no-children');
 test.addClass("noSpace");
 return false;
 };
 //msieversion();
</script>
<div style="display: none">
 <div class="confirmationpopup__container" id="access-confirmation-popup" style="z-index: 10000;">
 <div>
 <div>
 <div>
 <div class="confirmationpopup__container">
 <span class="confirmationpopup__logo"></span>
 <div class="confirmationpopup__title">
 <span class="confirmationpopup__text">MSD Manual</span>
 </div>
 <div class="confirmationpopup__description">
 <p>Please confirm that you are a health care professional</p>
 </div>
 <div class="confirmationpopup__answer">
 <a class="confirmationpopup__button confirmationpopup__button--yes" role="button">Yes</a>
 <a class="confirmationpopup__button confirmationpopup__button--no" role="button">No</a>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
<div style="display: none">
 <div class="confirmationpopup__container" id="external-link-confirmation-popup" style="z-index: 10000;">
 <div>
 <div>
 <div>
 <div class="confirmationpopup__container">
 <span class="confirmationpopup__logo"></span>
 <div class="confirmationpopup__title">
 <span class="confirmationpopup__text">Leave this Site?</span>
 </div>
 <div class="confirmationpopup__description">
 <p>The link you have selected will take you to a third-party website. We do not control or have responsibility for the content of any third-party site.</p>
 </div>
 <div class="confirmationpopup__answer">
 <a class="confirmationpopup__button confirmationpopup__button--yes" role="button">Continue </a>
 <a class="confirmationpopup__button confirmationpopup__button--no" role="button">Cancel</a>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
 <script> 
 var externalUrls = JSON.parse(atob('["www.cdc.gov/mmwr/preview/mmwrhtml/rr58e324a1.htm","www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm","www.cdc.gov/vaccines/vpd/hepb/hcp/faqs-hcp-pediarix.html","cid.oxfordjournals.org/content/53/7/e25.full.pdf html?sid=67183860-0d8a-4d54-9d57-fd12d5682421","www.nature.com/articles/s41467-022-32936-3","pubmed.ncbi.nlm.nih.gov/35772465","pubmed.ncbi.nlm.nih.gov/31515408","www.ncbi.nlm.nih.gov/pmc/articles/PMC4028378","www.drugs-porphyria.org","porphyriafoundation.org/drugdatabase","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31060","academic.oup.com/cid/article/58/1/e1/374007","www.cdc.gov/hepatitis/hav/havfaq.htm","journals.lww.com/ajg/Fulltext/2018/02000/ACG_Clinical_Guideline__Alcoholic_Liver_Disease.9.aspx","www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm","jama.jamanetwork.com/article.aspx?articleid=2492881","www.nhlbi.nih.gov/health-pro/guidelines/current/cardiovascular-health-pediatric-guidelines","gi.org/guideline/genetic-testing-and-management-of-hereditary-gastrointestinal-cancer-syndromes","rheumatology.oxfordjournals.org/content/42/2/235.full.pdf","onlinelibrary.wiley.com/doi/10.1002/14651858.CD003448.pub4/abstract?systemMessage=Wiley Online Library will be unavailable on Saturday 17th December 2016 at 09:00 GMT/ 04:00 EST/ 17:00 SGT for 4hrs due to essential maintenance.Apologies for the inconvenience","cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full","www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm","onlinelibrary.wiley.com/doi/10.1111/apt.13148/abstract","onlinelibrary.wiley.com/doi/10.1359/jbmr.06s204/abstract","onlinelibrary.wiley.com/doi/10.1002/jbmr.438/abstract","journals.lww.com/infectdis/Fulltext/2013/05000/New_Guidelines_for_Antimicrobial_Prophylaxis_in.10.aspx","jama.jamanetwork.com/article.aspx?articleid=1487498","cid.oxfordjournals.org/content/46/12/1801.full","www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm","www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm","www.onlinejacc.org/content/64/22/e77","jamanetwork.com/journals/jamasurgery/fullarticle/2623725","www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-01","www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm","www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm","www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html","www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm","www.onlinejacc.org/content/56/22/1864","www.idsociety.org/practice-guideline/hap_vap","academic.oup.com/cid/article-lookup/doi/10.1086/649858","acp.silverchair-cdn.com/acp/content_public/journal/aim/937814/m183600ff3_panel_2.jpeg?Expires=1556744998&amp;Signature=Oc7aO8PzGrh4tsbJzhWwSTvws~WHIkN~BaNqycHCh1TDufduqpbjgojduPU-8q5Owv2tym0x3HekrEXjegtUiZ2C15Qag5cNuhdxGu84JMb5nLmefg~ofSQfhTAdRWr9ECrJt4a1nu0Rl2crQwlTdDcL4Q8k9MGLgeg6yqGHzJGmlul2E8fEWxiP1ivlR9GypBYLjQ-B3eUH4hi-SYVCDfitv2zjW01hFzUlZM6OSXb5yEGThsimV8yQSCxcSLwaaY~CnZZ96lrcrr87nkPmtyvM9iPUUs-ix3Be5lXTIDWuIRrY3xmWXTnpNu7fxROSemZYm5ESTXbpGdJH6gMyuA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA","www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm","www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm","www.ncbi.nlm.nih.gov/pubmed?term=Crit Care Med[Jour] AND 42[volume] AND 1157[page] AND 2014[pdat] AND Karvellas CJ[first author] AND Outcomes and complications of intracranial pressure monitoring in acute liver failure&amp;TransSchema=title&amp;cmd=detailssearch","www.ncbi.nlm.nih.gov/pubmed?term=\"Hepatology (Baltimore, Md.)\"[Jour] AND 66[volume] AND 1219[page] AND 2017[pdat] AND Albillos A[author] AND Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. &amp;TransSchema=title&amp;cmd=detailssearch","fascrs.org/ascrs/media/files/downloads/Clinical Practice Guidelines/the-american-society-of-colon-practical-guideline-sinus-pilonidalis.pdf","fascrs.org/ascrs/media/files/downloads/Clinical Practice Guidelines/practice_parameters_for_the_management_of_hemorrhoids.pdf\"","www.cdc.gov/mmwr/preview/mmwrhtml/mm5803a4.htm","www.cdc.gov/mmwr/volumes/67/wr/mm6722a5.htm","pubmed.ncbi.nlm.nih.gov/21956720-evidence-report-genetic-and-metabolic-testing-on-children-with-global-developmental-delay-report-of-the-quality-standards-subcommittee-of-the-american-academy-of-neurology-and-the-practice-committee-of-the-child-neurology-society?from_term=\"Neurology\"[Jour] AND 2011[pdat]&amp;from_pos=7","www.nal.usda.gov/fnic/vitamins-and-minerals","www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management","www.willseye.org/doctor/melvin-roat-md-facs","faculty.mdanderson.org/profiles/pedro_ramirez.html","pharmacy.ucsf.edu/shalini-lynch","weillcornell.org/jwbarnhill","profiles.stanford.edu/david-spiegel","www.umc.edu/doctors/Huang_Juebin","www.chop.edu/doctors/moldenhauer-julie-s","www.urmc.rochester.edu/people/20996734-stephen-brian-sulkes","podiatry.temple.edu/kendrick-whitney","www.med.upenn.edu/apps/faculty/index.php/g275/p8178541","www.urmc.rochester.edu/people/21136627-ronald-rabinowitz","psychiatry.ubc.ca/person/rosemary-basson","profiles.utsouthwestern.edu/profile/48082/ravindra-sarode.html","sop.washington.edu/people/brian-werth","pharmacy.ucsd.edu/faculty/le","www.chop.edu/doctors/calabria-andrew-c","medicine.uiowa.edu/psychiatry/profile/william-coryell","www.chop.edu/doctors/mehta-jay","www.adelphi.edu/faculty/profiles/profile.php?PID=0649","www.ot.wustl.edu/about/our-people/peggy-barco-8","www.urmc.rochester.edu/people/21411717-jimena-cubillos","www.mlanet.org/resources/userguide.html","www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet#how-effective-are-hpv-vaccines","www.ncbi.nlm.nih.gov/books/NBK25349","www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf","academic.oup.com/cid/article/45/7/941/544359","academic.oup.com/cid/article/55/10/e86/321183","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","www.cdc.gov/hepatitis/hav/havfaq.htm","www.nejm.org/doi/10.1056/NEJMoa1613512?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0www.ncbi.nlm.nih.gov","www.ncbi.nlm.nih.gov/pmc/articles/PMC5848239","pubmed.ncbi.nlm.nih.gov/29260225","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","www.cdc.gov/hepatitis/hav/havfaq.htm","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800","jamanetwork.com/article.aspx?articleid=1487498","www.nejm.org/doi/10.1056/NEJMoa1613512?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0www.ncbi.nlm.nih.gov","circ.ahajournals.org/content/132/15/1435.long","www.porphyriafoundation.com","porphyriafoundation.org/for-healthcare-professionals/drug-safety","www.porphyria-europe.com","www.drugs-porphyria.org","profiles.stanford.edu/judith-prochaska","circ.ahajournals.org/content/132/15/1435.long","aasld.org/publications/practice-guidelines","www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/hepatitis-c-screening","aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.31065","www.ncbi.nlm.nih.gov/pubmed/22972059","aasldv2019stg.aasld.org/sites/default/files/2019-06/NAFLD Guidance 2018.pdf","academic.oup.com/cid/article/53/7/e25/424286","www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults","www.idsociety.org/practice-guideline/hap_vap","www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html","porphyriafoundation.org","www.ncbi.nlm.nih.gov/pmc/articles/PMC4695986","www.lajh.org/about/the-jewish-home-team/meet-our-clinicians","www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html","www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966","www.the-scientist.com/news-opinion/vector-based-vaccines-come-to-the-fore-in-the-covid-19-pandemic-67915","www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext","www.med.upenn.edu/apps/faculty/index.php/g275/p8841440","www.cdc.gov/mmwr/volumes/70/rr/rr7001a1.htm","www.essentialaccessibility.com/merck","www.menopause.org/docs/default-source/2017/nams-2017-hormone-therapy-position-statement.pdf","www.ncbi.nlm.nih.gov/pmc/articles/PMC4028378","www.nejm.org/doi/10.1056/NEJMoa2112435?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(21)00963-7/fulltext","www.ajog.org/article/S0002-9378(20)30861-9/fulltext","ascopubs.org/doi/full/10.1200/JCO.21.00006","www.nejm.org/doi/10.1056/NEJMoa2112435?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(21)00963-7/fulltext","www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30020-8/fulltext","ascopubs.org/doi/full/10.1200/JCO.2014.58.3401?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","ascopubs.org/doi/full/10.1200/JCO.2017.76.5966?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ajog.org/article/S0002-9378(20)30861-9/fulltext","www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","jamanetwork.com/journals/jamaoncology/fullarticle/2773114","ascopubs.org/doi/full/10.1200/JCO.21.00006","pubmed.ncbi.nlm.nih.gov/36107786","pubmed.ncbi.nlm.nih.gov/30304427","www.ncbi.nlm.nih.gov/pmc/articles/PMC5958910","www.ahajournals.org/doi/10.1161/HYP.0000000000000084","pubmed.ncbi.nlm.nih.gov/27195814","pubmed.ncbi.nlm.nih.gov/36130612","www.ncbi.nlm.nih.gov/pmc/articles/PMC9940918","pubmed.ncbi.nlm.nih.gov/36351458","pubmed.ncbi.nlm.nih.gov/36041474","pubmed.ncbi.nlm.nih.gov/29608107","pubmed.ncbi.nlm.nih.gov/35316839","pubmed.ncbi.nlm.nih.gov/36148880","pubmed.ncbi.nlm.nih.gov/37295445","www.ncbi.nlm.nih.gov/pmc/articles/PMC7652033","www.nejm.org/doi/10.1056/NEJMoa2032183?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub  0pubmed","www.ahajournals.org/doi/full/10.1161/CIR.0000000000000678?rfr_dat=cr_pub  0pubmed&url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org","diabetesjournals.org/care/article/42/1/126/36330/Racial-and-Ethnic-Differences-in-Anthropometric","agsjournals.onlinelibrary.wiley.com/doi/abs","www.ncbi.nlm.nih.gov/pubmed/31515408","opendata.ncats.nih.gov/covid19/variant/activity","opendata.ncats.nih.gov/variant/activity","diabetesjournals.org/care/article/41/12/2669/36544/Management-of-Hyperglycemia-in-Type-2-Diabetes","pubmed.ncbi.nlm.nih.gov/35772465","pubmed.ncbi.nlm.nih.gov/34004177","pubmed.ncbi.nlm.nih.gov/35973577","www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30925-9/fulltext","pubmed.ncbi.nlm.nih.gov/33349658","pubmed.ncbi.nlm.nih.gov/35834240","pubmed.ncbi.nlm.nih.gov/38319329","www.ncbi.nlm.nih.gov/pmc/articles/PMC10752259","pubmed.ncbi.nlm.nih.gov/35449407","pubmed.ncbi.nlm.nih.gov/19502645","pubmed.ncbi.nlm.nih.gov/35483753","pubmed.ncbi.nlm.nih.gov/3404868"]'));
 $(document).ready(function () {
 $("a").click(function() {
 var href = $(this).attr('href');
 if (MManual.Foundation.Url.IsAbsoluteUrl(href)) {
 var hrefWithoutProtocol = MManual.Foundation.Url.RemoveProtocol(href);
 var match = externalUrls.some(function(url) {
 return url.length > 0 && hrefWithoutProtocol.startsWith(url);
 });
 if (match) {
 externalLinkConfirmation.showConfirmationModal(href);
 } else {
 return true;
 }
 } else {
 return true;
 }
 return false;
 });
 });
 </script>
 <!-- AddToAny script remove-->
<script></script>
 
<script type="text/html" id="audio-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__audio hide-on-print">
 <div class="multimedia__audio--wrapper">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content">
 <p data-bind="html: Description"></p>
 </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits">
 <p data-bind="html: Credits"></p>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/html" id="inlinemedia-audio-template">
 <!-- ko if: isSideline-->
 <div class="inlinebox inlinebox--right inlinebox--clickable" data-bind="attr: {id: ItemId}, css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Audio</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl}">
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses(), attr: {id: ItemId}">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 <!-- ko if: detailsAvailable -->
 <div class="inlinemedia__more">
 <div class="inlinemedia__action inlinemedia__action--show" data-bind="event: {click: toggleDetailsFunction, keypress: toggleDetailsFunction}">
 <i class="inlinemedia__eye"></i>
 <span class="inlinemedia__details hide" role="button" tabindex="0">
 Show Details
 </span>
 <span class="inlinemedia__details show" role="button" tabindex="0">
 Hide Details
 </span>
 <div class="inlinemedia__information" data-bind="html: Description"></div>
 <div class="inlinemedia__credits" data-bind="html: Credits"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="biodigital-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, iOSresizeIframeToParent : attachResizeCallback, swipe: {next: parentContext.showNext, prev: parentContext.showPrev}" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description" data-bind="getDivRef : $parent.descriptionDivRef">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="inlinemedia-biodigital-template">
 <!-- ko ifnot: isText-->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title, width:ImageWidth, height:ImageHeight}" />
 <div class="box__action"></div>
 <div class="box__label">3D MODEL</div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 <!-- ko ifnot: isInline -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
 
<script type="text/html" id="image-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__image" data-bind="css: zoomClass">
 <div class="multimedia__image--spacer hide-on-print"></div>
 <div class="multimedia__image--wrapper">
 <img oncontextmenu="return false;" loading="lazy" data-bind="attr: { src: ImageUrl, alt: Alt}, getImageDimensions: imageDimensions, pinchZoom: { pinchZoomActive: pinchZoomActive, isZoomed: isZoomed}">
 </div>
 <!-- ko if: zoomEnabled -->
 
 <!-- /ko -->
 <div class="multimedia__image--spacer hide-on-print"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content" data-bind="html: Description"> </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits" data-bind="html: Credits"> </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/javascript">
 (function (MManual) {
 var deferredScripts = [];
 
 deferredScripts.push("./bundles/redesign/imageplayerv4.1.2.2-13178e13ca.js?v=sWgoLvG7zFKbYfkOiaTYY5tBk5gefAsRS0qs0ENFdUc1");
 
 MManual.ImagePlayerScripts = deferredScripts;
 }(window.MManual = window.MManual || {}));
</script>
<script type="text/html" id="inlinemedia-photo-template">
 <!-- ko ifnot: isText-->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__innerwrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 </div>
 <div class="inlinemedia__content">
 <div class="inlinemedia__image--container">
 <img class="h-nocopy" loading="lazy" oncontextmenu="return false;" data-bind="attr: { src: ThumbnailUrl, alt: Alt, width:ImageWidth, height:ImageHeight }" />
 </div>
 <!-- ko if: isSideline -->
 <div class="inlinemedia__subtitle" data-bind="html: Credits"></div>
 <!-- /ko -->
 </div>
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isInline() && detailsAvailable() -->
 <div class="inlinemedia__more">
 <div class="inlinemedia__action inlinemedia__action--show" data-bind="event: {click: toggleDetailsFunction, keypress: toggleDetailsFunction}">
 <i class="inlinemedia__eye"></i>
 <span class="inlinemedia__details hide" role="button" tabindex="0">
 Show Details
 </span>
 <span class="inlinemedia__details show" role="button" tabindex="0">
 Hide Details
 </span>
 <div class="inlinemedia__information" data-bind="html: Description"></div>
 <div class="inlinemedia__credits" data-bind="html: Credits"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="infographic-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__image" data-bind="css: zoomClass">
 <div class="multimedia__image--spacer hide-on-print"></div>
 <div class="multimedia__image--wrapper h-nocopy">
 <img oncontextmenu="return false;" loading="lazy" data-bind="attr: { src: ImageUrl, alt: Title}, getImageDimensions: imageDimensions, pinchZoom: { pinchZoomActive: pinchZoomActive, isZoomed: isZoomed}">
 </div>
 <!-- ko if: zoomEnabled -->
 <div class="multimedia__image--actions hide-on-print">
 <div class="multimedia__image--actionzoom" data-bind="click: toggleZoom"></div>
 </div>
 <!-- /ko -->
 <div class="multimedia__image--spacer hide-on-print"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: CitationLink -->
 <div class="multimedia__description--source">
 <span class="multimedia__description--sourcetitle">Source:</span>
 <!-- ko if: CitationText -->
 <a href="#" class="multimedia__description--citation" data-bind="text: CitationText, attr: { href: CitationLink }"></a>
 <!-- /ko -->
 <!-- ko ifnot: CitationText -->
 <a href="#" class="multimedia__description--citation" data-bind="text: CitationLink, attr: { href: CitationLink }"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 </div>
 </div>
 </div>
</script>
<script type="text/html" id="inlinemedia-labtest-template">
 <!-- ko if: isSideline -->
 <div class="inlinebox inlinebox--clickable" data-bind="css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Lab Test</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img class="labtest-icon" loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl }" width="55" height="55" />
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="yes" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script><script type="text/html" id="labtest-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, setIframePrintTarget: setIframePrintTarget" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">Â«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">â€¹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">â€º</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">Â»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<script type="text/html" id="mediawidget-labtest-template">
 <!-- ko component: {name: 'multimedia-link-text', params: { item: ko.mapping.fromJS({
 ItemId: ItemId,
 IframeSrc: MediaUrl,
 Title: Title,
 ShareUrlTitle: ShareUrlTitle,
 Description: Description,
 ThumbnailUrl: ThumbnailUrl,
 Credits: Credits,
 MediaType: 'labest',
 MediaNameTranslated: 'Lab Test' ,
 UniqueId: UniqueId
 }),
 linkText: Title,
 showTooltip: false,
 listName: 'LabTestResources' + $parent.key
 } } -->
 <!-- /ko -->
</script>
<script type="text/html" id="mediawidget-labtest-list-template">
 <!-- ko component: {name: 'multimedia-link-text', params: { item: ko.mapping.fromJS({
 ItemId: ItemId,
 IframeSrc: MediaUrl,
 Title: Title,
 ShareUrlTitle: ShareUrlTitle,
 Description: Description,
 ThumbnailUrl: ThumbnailUrl,
 Credits: Credits,
 MediaType: 'labtest',
 MediaNameTranslated: 'Lab Test',
 UniqueId: UniqueId
 }),
 linkText: Title,
 showTooltip: false,
 listName: 'LabTestResources' + $parent.key
 } } -->
 <!-- /ko -->
</script>
<script type="text/html" id="inlinemedia-featuredlink-template">
 <!-- ko ifnot: isText-->
 <!-- ko ifnot: isModal -->
 <a data-bind="attr: {href: IframeSrcComputed, target: Target}">
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title}" />
 <div class="box__action"></div>
 <div class="box__label" data-bind="text:MediaNameTranslated"></div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 </div>
 </div>
 </a>
 <!-- /ko -->
 <!-- /ko -->
 <!-- ko if: isModal -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 <!-- ko if: isSideline() && !IsInCarousel() -->
 <div class="inlinemedia__open hide-on-print">
 <i class="inlinemedia__icon--open"></i>
 </div>
 <!-- /ko -->
 </div>
 <div class="inlinemedia__content">
 <!-- ko if: isSideline -->
 <figure class="box__figure">
 <img oncontextmenu="return false;" loading="lazy" class="box__picture" data-bind="attr: {src: ThumbnailUrl, alt: Title}" />
 <div class="box__action"></div>
 <div class="box__label" data-bind="text:MediaNameTranslated"></div>
 </figure>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <!-- /ko -->
 </div>
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }">
 </div>
 <!-- /ko -->
</script><script type="text/html" id="featuredlink-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="yes" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, iOSresizeIframeToParent : attachResizeCallback" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description" data-bind="getDivRef : $parent.descriptionDivRef">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="iframe-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="multimedia-thumbnail-template">
 <div class="modalcarousel__item" data-bind="event:{click: $parentContext.$parent.navToClick.bind($index()), keypress: $parentContext.$parent.navToClickKeyPress.bind($index())}, css: {'modalcarousel__item--active' : $parentContext.$parent.activeIndex() == $index()}, attr: { title: item.Title}, modalCarousel, css-static: 'modalcarousel__item--' + item.MediaType()" tabindex="0" role="button">
 <div class="modalcarousel__item--wrapper">
 <div class="modalcarousel__item--imagewrapper h-nocopy">
 <img oncontextmenu="return false;" data-bind="lazyload: {src: item.ThumbnailUrl, options: {loadOnlyInViewport: true} , updateTick: $parentContext.$parent.carouselScrollTick}, attr: {alt: item.Title }, scrollIntoView:$parentContext.$parent.activeIndex() == $index()" />
 </div>
 <div class="modalcarousel__item--text" data-bind="html: item.Title"> </div>
 </div>
 <div class="modalcarousel__item--number" data-bind="text: ($index() + 1)"></div>
 </div>
</script>
<script type="text/html" id="text-player-template">
 <div class="multimedia">
 <div class="multimedia__text" data-bind="html: Text"> </div>
 </div>
</script>
<script type="text/html" id="multimedia-link-block-template">
 <i class="inlinemedia__icon--open"
 data-bind="hoverVisible: enableHover, hoverTargetId: '.multimedia__link'"></i>
 <button class="multimedia__link--block" aria-expanded="false" data-bind="shortClick: showPlayer, attr : {'aria-label':'Expand the'+' '+ item.MediaNameTranslated()}"></button>
</script>
<script type="text/html" id="multimedia-link-text-template">
 <a class="multimedia__link--text" role="button" tabindex="0" aria-expanded="false" data-bind="shortClick: showPlayer, html: linkText, css: cssClass"></a>
</script><div class="multimedia__popup l-viewport" data-bind="component: { name: 'multimedia-popup'}">
 <!-- Placeholder for media players. -->
</div>
<script type="text/html" id="multimedia-popup-template">
 <!-- ko if: playerVisible -->
 <div class="modal" role="dialog" tabindex="-1" aria-labelledby="exampleModalLabel">
 <div class="modal--shade" data-bind="click: hidePopup"></div>
 <div class="modaldialog" data-bind=" arrowKeys: {left: showPrev, right: showNext}, css : {'h-expanded' : expanded }">
 <div class="modaldialog__header hide-on-print">
 <div class="modaldialog__header--wrapper">
 <div class="modaldialog__header--title modaldialog__header--element" data-bind="html: popupTitle(), scaleText: popupTitle"></div>
 <div tabindex="0" role="button" class="modaldialog__header--close modaldialog__header--element" data-bind="event: { click: hidePopup, keypress: hidePopupKeyPress }">
 Close
 </div>
 </div>
 </div>
 <div class="modaldialog__content">
 <div class="modaldialog__content--wrapper" data-bind="swipe: {next: showNext, prev: showPrev, canSwipe: canSwipe}">
 <div class="modaldialog__media" data-bind="css :{ 'modaldialog__media--withcarousel': !(displaySingle() || hideCarousel()), 'modaldialog__media--single': displaySingle }">
 <!-- ko ifnot: (displaySingle() || hideMainArrows()) -->
 <div class="modaldialog__media--sidemargin hide-on-print">
 <div class="modaldialog__media--nav modaldialog__media--prev" tabindex="0" role="button" aria-label="Previous" data-bind="event: { click: showPrev, keypress: showPrevKeyPress }">
 <div class="mm-icon" data-bind="css : showPrevClass()"></div>
 </div>
 </div>
 <!-- /ko -->
 <div class="modaldialog__media--wrapper">
 
 <!-- ko component: {name: activeEntry().item.MediaType() + '-player', params: activeEntry} -->
 <!-- /ko -->
 
 </div>
 <!-- ko ifnot: (displaySingle() || hideMainArrows()) -->
 <div class="modaldialog__media--sidemargin hide-on-print">
 <div class="modaldialog__media--nav modaldialog__media--next" tabindex="0" role="button" aria-label="Next" data-bind="event: { click: showNext, keypress: showNextKeyPress }">
 <div class="mm-icon" data-bind="css: showNextClass()"></div>
 </div>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko ifnot: (displaySingle() || hideCarousel()) -->
 <div class="modaldialog__carousel hide-on-print">
 <div class="modaldialog__carousel--sidemargin modaldialog__carousel--prev" tabindex="0" role="button" data-bind="event:{click: carouselShowPrev, keypress:carouselShowPrevKeyPress}, css : { 'modaldialog__carousel--sidemargin--disabled' : isCarouselShowPrevDisabled() } "></div>
 <div class="modaldialog__carousel--wrapper">
 <div class="modalcarousel" data-bind="scrollTick : carouselScrollTick, scroll : carouselIsScrolled ">
 <!-- ko foreach: {data: activeList, as: 'entry'} -->
 <!-- ko template: {name: 'multimedia-thumbnail-template', data: entry} -->
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
 <div class="modaldialog__carousel--sidemargin modaldialog__carousel--next" tabindex="0" role="button" data-bind="event:{click: carouselShowNext, keypress:carouselShowNextKeyPress}, css : { 'modaldialog__carousel--sidemargin--disabled' : isCarouselShowNextDisabled() }"></div>
 </div>
 <!-- /ko -->
 <div class="modaldialog__toolbar hide-on-print">
 <!-- ko ifnot: displaySingle -->
 <div class="modaldialog__pager">
 <a class="modaldialog__pager--nav modaldialog__pager--navfirst" data-bind="click: showFirst">«</a>
 <a class="modaldialog__pager--nav modaldialog__pager--navleft" data-bind="click: showPrev">‹</a>
 <span class="modaldialog__pager--number" data-bind="text: activeEntry().index + 1"></span>/<span class="modaldialog__pager--number" data-bind="text: activeList().length"></span>
 <a class="modaldialog__pager--nav modaldialog__pager--navright" data-bind="click: showNext">›</a>
 <a class="modaldialog__pager--nav modaldialog__pager--navlast" data-bind="click: showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="modaldialog__actions">
 <!-- ko if: detailsAvailable -->
 <div class="modaldialog__action modaldialog__action--description modaldialog__action--description-show" data-bind="click: toggleExpanded">
 <i class="modaldialog__icon--show"></i>
 <span class="modaldialog__action--text">
 Show Details
 </span>
 </div>
 <div class="modaldialog__action modaldialog__action--description modaldialog__action--description-hide" data-bind="click: toggleExpanded">
 <i class="modaldialog__icon--hide"></i>
 <span class="modaldialog__action--text">
 Hide Details
 </span>
 </div>
 <!-- /ko -->
 <!-- ko if: MManual.settings.socialMedia.enableMultimediaPopupShareButton -->
 <div class="modaldialog__action modaldialog__action--share a2a_kit" data-a2a-icon-color="transparent,transparent" data-bind="attr:{'data-a2a-url': shareUrl}">
 <a class="modaldialog__icon--share a2a_dd" href="https://www.addtoany.com/share" data-a2a-icon-color="transparent,transparent" role="button"></a>
 </div>
 <!-- /ko -->
 <div class="modaldialog__action modaldialog__action--print" data-bind="event:{click: printPopupContent, keypress:printPopupContentKeyPress}" tabindex="0" role="button" aria-label="print">
 <div class="modaldialog__icon--print"></div>
 </div>
 </div>
 </div>
 <div class="modaldialog__copyright-print">
 <div class="modaldialog__copyright-print--logo">
<img src="/Content/Images/msd_foot_logo.png" alt="" class="badge msd" loading="lazy" width="240" height="71" />
 </div>
 <div class="modaldialog__copyright-print--text">
 © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
</script>
<script type="text/html" id="podcast-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__audio hide-on-print">
 <div class="multimedia__audio--wrapper">
 <audio>
 <source data-bind="attr: { src: AudioUrl, type: MimeType }" />
 </audio>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content">
 <p data-bind="html: Description"></p>
 </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits">
 <p data-bind="html: Credits"></p>
 </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
 <script type="text/html" id="quiz-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <h3 class="multimedia__title" data-bind="html: Title"> </h3>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe frameBorder="0" scrolling="auto" data-bind="attr: { src: IframeSrcComputed, title: Title }" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation, swipe: {left: parentContext.showNext, right: parentContext.showPrev}"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 </div>
</script>
<script type="text/html" id="table-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__table">
 <div class="multimedia__table--wrapper">
 <div data-bind="html: tableBody, stickyHeaderTable: tableBody" class="modaltable"> </div>
 </div>
 </div>
 <div class="multimedia__description">
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="m-link-text-template">
 <!-- ko if: isModal -->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="shortClick: showPlayer, html: linkText, css: cssClass, attr: { title: item.Title }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target }"></a>
 <!-- /ko -->
 <!-- ko ifnot: isModal -->
 <!--ko if: item.MediaType()=='podcast'-->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="html: linkText, css: cssClass, attr: { title: item.Title, target: target, href: target=='_blank'? url :'https://www.msdmanuals.com/'+ url }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target, url:url}"></a>
 <!-- /ko -->
 <!--ko ifnot: item.MediaType()=='podcast'-->
 <a class="multimedia__link--text" tabindex="0" role="button" data-bind="html: linkText, css: cssClass, attr: { title: item.Title, target: target, href: 'https://www.msdmanuals.com/'+'/professional/multimedia'+ url }, mlinkToolTip: { thumbnail: item.ThumbnailUrl, title: item.Title, show: showTooltip, target: target, url:'/professional/multimedia'+ url}"></a>
 <!-- /ko -->
 <!-- /ko -->
</script>
<script type="text/html" id="clinicalcalculator-player-template">
 <div class="multimedia" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__iframe">
 <div class="multimedia__iframe--spacer"></div>
 <div class="multimedia__iframe--wrapper h-ios-iframe-scroll">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="auto" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }, setIframePrintTarget: setIframePrintTarget" sandbox="allow-modals allow-scripts allow-same-origin allow-forms allow-popups allow-top-navigation"></iframe>
 </div>
 <div class="multimedia__iframe--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">‹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">›</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">»</a>
 </div>
 <!-- /ko -->
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script><script type="text/html" id="inlinemedia-calculator-template">
 <!-- ko if: isSideline -->
 <div class="inlinebox inlinebox--clickable" data-bind="css: {'inlinebox--right': !IsInCarousel(), 'inlinebox--full': IsInCarousel}">
 <div class="inlinebox__wrapper">
 <!-- ko ifnot: IsInCarousel-->
 <div class="inlinebox__header">Clinical Calculator:</div>
 <!-- /ko -->
 <div class="inlinebox__content">
 <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: multimediaLinkModel }"></div>
 <div class="inlinebox__button">
 <img class="labtest-icon" loading="lazy" alt="icon" data-bind="attr: {src: ThumbnailUrl }" width="48" height="48" />
 </div>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isInline -->
 <div data-bind="css: componentClasses()">
 <div class="inlinemedia__wrapper">
 <div class="inlinemedia__header">
 <div class="inlinemedia__title" data-bind="html: Title"></div>
 </div>
 <div class="inlinemedia__content">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrc, title: Title }"></iframe>
 </div>
 </div>
 </div>
 <!-- /ko -->
 <!-- ko if: isText -->
 <div class="multimedia__link" data-bind="component: { name: multimediaLinkComponentName, params: multimediaLinkModel }"></div>
 <!-- /ko -->
</script>
<script type="text/html" id="video-player-template">
 <div class="multimedia multimedia--withdescription" data-bind="css: {'multimedia--single': parentContext.displaySingle}">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__title" data-bind="html: Title"> </div>
 <!-- /ko -->
 <div class="multimedia__video">
 <div class="multimedia__video--spacer"></div>
 <div class="multimedia__video--wrapper">
 <iframe allowfullscreen webkitallowfullscreen mozallowfullscreen scrolling="no" seamless="seamless" frameBorder="0" data-bind="attr: { src: IframeSrcComputed, title: Title }"></iframe>
 <div class="multimedia__video--print" onclick="$(this).hide(); return true;">
 <img loading="lazy" data-bind="attr: { src: ThumbnailUrl, alt: Title }">
 </div>
 </div>
 <div class="multimedia__video--spacer"></div>
 </div>
 <div class="multimedia__description">
 <!-- ko ifnot: hideTitle -->
 <div class="multimedia__description--title" data-bind="html: Title"></div>
 <!-- /ko -->
 <!-- ko ifnot: parentContext.displaySingle -->
 <div class="multimedia__pager hide-on-print">
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showFirst">Â«</a>
 <a class="multimedia__pager--nav multimedia__pager--navleft" data-bind="click: parentContext.showPrev">â€¹</a>
 <span class="multimedia__pager--number" data-bind="text: $parent.activeEntry().index + 1"></span>/<span class="multimedia__pager--number" data-bind="text: $parent.activeList().length"></span>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showNext">â€º</a>
 <a class="multimedia__pager--nav multimedia__pager--navright" data-bind="click: parentContext.showLast">Â»</a>
 </div>
 <!-- /ko -->
 <div class="multimedia__description--wrapper">
 <!-- ko if: $data.Description -->
 <div class="multimedia__description--content" data-bind="html: Description"> </div>
 <!-- /ko -->
 <!-- ko if: $data.Credits -->
 <div class="multimedia__description--credits" data-bind="html: Credits"> </div>
 <!-- /ko -->
 </div>
 <!-- ko if: loadLocations -->
 <!-- ko ifnot: topicsWithResource().length == 0 -->
 <div id="multimedia__locations" class="multimedia__description--locations" data-bind="modalLocations: topicsWithResource().length">
 <div class="multimedia__description--readmore">In these topics</div>
 <!-- ko foreach: topicsWithResource-->
 <a class="multimedia__description--location" data-bind="attr: { href: PublicUrl }, html: Title"></a>
 <!-- /ko -->
 </div>
 <!-- /ko -->
 <!-- /ko -->
 </div>
 </div>
</script>
<link rel="stylesheet" href="./Content/Styles/fa/fonts/font-awesome.css" type="text/css" media="screen"><link rel="stylesheet" href="./CustomCss/custom_mobile_styles.css"><script type="text/javascript" src="./customscript/videodetail.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/VideoPath.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/Appdetail.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script><script type="text/javascript" src="./customscript/customscript.js?v=j6lqWQ_gaVddXSzk8oBfSqpw8iTwpNFAslFpddsSyrM1"></script></head>
<body class="professional msd ">
 <a href="/n3wbr@nds" rel="nofollow" style="display:none" arial-hidden="true">honeypot link</a>
 <!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5MKXR9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
 <div id="testone"> <div class="l-viewport">
 
<input type="hidden" id="currentSitecoreItemId" value="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">
<input type="hidden" id="wasThisTopicHelpfulUrl" value="/Custom/Topic/WasThisTopicHelpful">
<input type="hidden" id="getTopicHelpfulUrl" value="/Custom/Topic/GetTopicHelpful">
<input type="hidden" id="languageSwitchUrl" value="/professional/LanguageSwitch">
<input type="hidden" id="resourceServiceUrl" value="/custom/Topic/GetTopicsForResource">
<input type="hidden" id="tableBodyServiceUrl" value="/custom/Topic/GetTableBody">
<input type="hidden" id="getAlphabetUrl" value="/Redesign/Widgets/GetAlphabet">
<input type="hidden" id="landingPageUrl" value="https://www.msdmanuals.com/">
<input type="hidden" id="standaloneMultimediaBaseUrl" value="/professional/multimedia">
<input type="hidden" id="currentEdition" value="Professional">
<input type="hidden" id="currentLanguage" value="en">
<input type="hidden" id="currentLanguage2LetterISO" value="en">
<input type="hidden" id="oldRestrictedBrightcovePlayer" value="3851244774001">
<input type="hidden" id="restrictedBrightcovePlayer" value="5qrY5f1MK_default">
<input type="hidden" id="shareableBrightcovePlayer" value="6CaKiGXJD_default">
<input type="hidden" id="selectLanguageLabel" value="Select Language">
<input type="hidden" id="commonCloseText" value="close">
<input type="hidden" id="readAllText" value="Read All">
 
 <!-- New div groups for LetterSpine and Header has been created
 due to problems with existing styling
 ToDo rewrite whole header and letter spine as one component -->
 <div id="l-group--header-letterpine" class="main-header sticky-header">
 <div class="l-group l-group--header">
 <div id="l-layer--header" class="l-layer l-layer--header" data-header-element-position="static" data-header-element-order="0">
 
 
 
 </div>
 </div>
 </div>
 
 
<script>
 MManual.Feature = MManual.Feature || {};
 MManual.Feature.LetterSpine = MManual.Feature.LetterSpine || {};
 MManual.Feature.LetterSpine.Id = 'daa474c9-0bc0-4713-a85d-86e71af7bb5f';
</script>
 <!-- <div id="l-group--header-letterpine--fixed" class="main-header l-group--header-letterpine-fixed l-group--header-letterpine-fixed--hidden l-group--header-letterpine-fixed--animate">
 <div class="l-group l-group--headerfixed hide-on-print">
 <div class="l-layer l-layer--header l-layer--fixed" data-header-element-position="fixed" data-header-element-order="0">
 
 
 </div>
 </div>
 <div class="l-group l-group--letterspinefixed"></div>
 </div>
 <div class="l-layer l-layer--underskirt">
 </div>-->
 
 
 
 <div class="l-layer l-layer--actiontoolbar">
 
 <div class="l-layer__content">
 <aside class="actiontoolbar hide-on-print">
 <!--<a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--bookmark" onclick="bookmarkPage(this);" href="#"></a>-->
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--download" style="display: none" href="#"></a>
 
 <ul>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--share a2a_dd" href="https://www.addtoany.com/share" rel="noopener" role="button" aria-expanded="false" aria-label="Share in"></a>
 </li>
 <li>
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--print" href="#" onclick="window.print(); MManual.analytics.notifyOpenModal(MManual.analytics.eventPrintAnArticle);" role="button" title="print"></a>
 </li>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--email a2a_button_email" href="#" role="button" title="Mail"></a>
 </li>
 <li class="scroll-to-top">
 <a href="#top" role="button" aria-label="Go To Top" title="Go To Top"><span class="scroll-to-top-img"></span></a>
 </li>
 <li class="scroll-to-bottom">
 <a href="#" role="button" aria-label="Go To Top"><span class="scroll-to-bottom-img"></span></a>
 </li>
 </ul>
 </aside>
 </div>
 
 </div>
 <main id="maincontent" class="l-layer l-layer--main">
 
 <section class="l-layer__content main">
 
 <div class="orderize"></div>
<div class="main__content">
 <div class="topic__wrapper">
 
<script type="text/javascript">
 var resources = [];
 var resourcesIdList = [];
 $.each(resources, function() {
 if (this.MultimediaItem != null) {
 resourcesIdList.push({"itemId": this.MultimediaItem.ItemId, "uniqueId": this.MultimediaItem.UniqueId});
 }
 });
 $('a[href="#also-of-interest-news"],a[href="#also-of-interest-video"],a[href="#also-of-interest-biodigital"],a[href="#also-of-interest-student-stories"]').click(function ()
 {
 window.scrollTo(0, $("#Ph-Item-Lazyloading").offset().top - 230);
 });
</script>
<div class="orderize__candidate" data-orderize="100" itemscope="" itemtype="http://schema.org/MedicalCondition" data-preview-container='.topic__article'>
 <input type="hidden" value="" id="hdnTopicTopTile">
 <div class="autoload-placeholder-top hide-on-print" style="display:none">
 <a class="pre-topic hide-on-print" role="button" aria-hidden="true"></a>
 </div>
 <div class="autoloadSettings" name="Up Next:">
 <a id="autoloadEnable" class="false" role="button" tabindex="-1"></a>
 <a id="autoloadChapter" class="false" role="button" tabindex="-1"></a>
 <a id="autoloadSection" class="false" role="button" tabindex="-1"></a>
 <a id="stopAutoloadChapterCircular" class="false" role="button" tabindex="-1"></a>
 </div>
 <article class="topic__article">
 
<div class="tablebox tablebox--headings">
 <div class="tablebox__cell tablebox__cell--headings">
 <div class="topic__headings">
 <span itemprop="code" itemscope="" itemtype="http://schema.org/MedicalCode">

 </span>
 <span itemprop="code" itemscope="" itemtype="http://schema.org/MedicalCode">

 </span>
 <div class="topic__header--container">
 <div class="topic__authors topic__authors--container">
 <a id="top" role="button" tabindex="-1"></a>
 <h1 class="topic__header__headermodify--title topic__header__headermodify--title--animate" itemprop="name">
 Tuberculosis (TB)
 </h1>
 <div class="topic__authors-main-cont">
 <p class="topic__authors--description">By </p>
 
 <strong class="topic__label topic__label--author"><a href="./Contributors/nardell-edward.html">Edward A. Nardell</a></strong>
 <p class="topic__authors--description">, MD, Harvard Medical School</p>
 <div class="topic__revision">
 <div class="topic__authors">
 Reviewed/Revised Jul 2022 
 </div>
 </div>
 </div>
 </div>
 <div class="topic__buttons hide-on-print">
 <div class="topicswitch topic__patient-education topic__patient-education--top" data-icd9="010;011;012;013;014;015;016;017;018;771.2;137" tabindex="0" role="link">
 <div class="topic__patient-education--container">
 <div class="topic__patient-education--icon"></div>
 <div class="topic__patient-education--text">
 View PATIENT EDUCATION
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
 </div>
</div>
 <div class="box topicmenu hide-on-print">
 <div class="topic-section-heading-list">
 <ul>
 <li>
 <a href="#v1010685" class="topicmenu_mobile__paragraph">Etiology</a>
 </li>
 <li>
 <a href="#v1010704" class="topicmenu_mobile__paragraph">Epidemiology</a>
 </li>
 <li>
 <a href="#v1010710" class="topicmenu_mobile__paragraph">Pathophysiology</a>
 </li>
 <li>
 <a href="#v1010739" class="topicmenu_mobile__paragraph">Symptoms and Signs</a>
 </li>
 <li>
 <a href="#v1010743" class="topicmenu_mobile__paragraph">Diagnosis</a>
 </li>
 <li>
 <a href="#v1010794" class="topicmenu_mobile__paragraph">Prognosis</a>
 </li>
 <li>
 <a href="#v1010798" class="topicmenu_mobile__paragraph">Treatment</a>
 </li>
 <li>
 <a href="#v1011185" class="topicmenu_mobile__paragraph">Screening for TB</a>
 </li>
 <li>
 <a href="#v1011229" class="topicmenu_mobile__paragraph">Prevention</a>
 </li>
 <li>
 <a href="#v1011242" class="topicmenu_mobile__paragraph">Special Populations</a>
 </li>
 <li>
 <a href="#v11555492" class="topicmenu_mobile__paragraph">Key Points</a>
 </li>
 <li>
 <a href="#v13952583" class="topicmenu_mobile__paragraph">More Information</a>
 </li>
 </ul>
 </div>
 </div>
<div class="topic__resources--title hide-on-print">
 Topic Resources
</div>
<div id="topicResources" class="hero hide-on-print">
 <div class="hero__tabs">
 <ul class="hero__header">
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Biodigitals'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 3D Models (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Biodigitals" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Biodigitals'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Audios'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 Audios (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Audios" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Audios'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell hero__cell--empty" data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Calculators'}">
 <a data-bind="" class="hero__link" tabindex="0" role="tab" aria-expanded="false" aria-disabled="true">
 <span class="hero__title">
 Calculators (0)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Calculators" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Calculators'}">
 <div class="floatbox">
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell " data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Images'}">
 <a data-bind="event: { click: function() { $data.activateGroup('Images'); }, keypress: function() { $data.activateGroup('Images'); }}" class="hero__link" tabindex="0" role="tab" aria-expanded="false" false="">
 <span class="hero__title">
 Images (1)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Images" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Images'}">
 <div class="floatbox">
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--image" data-group-name="image" title="Tuberculosis (Chest X-Ray)">
 <div class="hero__image--image">
 <div class="hero__container">
 <img class="hero__image--image" src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?mw=350&amp;thn=0&amp;sc_lang=en" width="1000" height="857" loading="lazy">
 </div>
 <span class="hero__description">
 Tuberculosis (Chest X-Ray)
 </span>
 </div>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"Alt":"Tuberculosis (Chest X-Ray)","Credits":"\u003cspan id=\u0022v85663379\u0022 class=\u0022anchor\u0022 \u003e\u003c/span\u003e\u003cdiv class=\u0022para\u0022 \u003e \u003cp \u003eZEPHYR/SCIENCE PHOTO LIBRARY\u003c/p\u003e\u003c/div\u003e","IsRestricted":true,"ItemId":"5145746a-29d6-4ea1-9a10-3ddcfdead4c8","Title":"Tuberculosis%20%28Chest%20X-Ray%29","ShareUrlTitle":"tuberculosis-chest-x-ray","Description":"%3Cp%3EA%20right%20upper%20lobe%20cavitary%20lesion%20on%20a%20chest%20x-ray%20of%20a%20patient%20with%20tuberculosis.%3C%2Fp%3E","ImageUrl":"./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0\u0026sc_lang=en","ThumbnailUrl":"./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?mw=350\u0026amp;thn=0\u0026amp;sc_lang=en","MediaType":"image","MediaNameTranslated":"Image","UniqueId":"v27304822","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":"1000","ImageHeight":"857","IframeSrc":null,"Target":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Tuberculosis%20%28Chest%20X-Ray%29","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Image","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell " data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Tables'}">
 <a data-bind="event: { click: function() { $data.activateGroup('Tables'); }, keypress: function() { $data.activateGroup('Tables'); }}" class="hero__link" tabindex="0" role="tab" aria-expanded="false" false="">
 <span class="hero__title">
 Tables (1)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Tables" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Tables'}">
 <div class="floatbox">
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--table" data-group-name="table" title="Dosing of Oral First-Line Anti-TB Drugs*">
 <div class="hero__table">
 <img class="hero__table--image" src="./Content/Images/Redesign/table/icon_table_red.png" loading="lazy">
 </div>
 <span class="hero__description">
 Dosing of Oral First-Line...
 </span>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"ItemId":"bfcd24ba-a4ff-4757-81de-32bb9b0aa521","Title":"Dosing%20of%20Oral%20First-Line%20Anti-TB%20Drugs%2A","ShareUrlTitle":"dosing-of-oral-first-line-anti-tb-drugs","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1010853","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Dosing%20of%20Oral%20First-Line%20Anti-TB%20Drugs%2A","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 <li class="hero__cell " data-bind="css:{'hero__cell--active': $root.activeGroup() === 'Videos'}">
 <a data-bind="event: { click: function() { $data.activateGroup('Videos'); }, keypress: function() { $data.activateGroup('Videos'); }}" class="hero__link" tabindex="0" role="tab" aria-expanded="false" false="">
 <span class="hero__title">
 Videos (1)
 </span>
 </a>
 <!-- ko if: $data.activeGroup() === "Videos" -->
 <div class="hero__content" data-bind="css:{'hero__content--active': $root.activeGroup() === 'Videos'}">
 <div class="floatbox">
 <div class="floatbox__item floatbox__item--hero">
 
<a class="hero__figure hero__figure--video" href="#" title="Overview of Tuberculosis (TB)">
 <div class="hero__wrapper--video">
 <img src="https://cf-images.us-east-1.prod.boltdns.net/v1/static/3850378299001/4222c17a-e46d-4df2-b3ac-7f0e6adaab6d/d9f87986-7bbc-497e-88ab-4f2cef66626a/1280x719/match/image.jpg" loading="lazy" width="142" height="80">
 <div class="hero__overlay">
 <div class="tablebox tablebox--heroplay">
 <div class="tablebox__cell">
 <div class="hero__play">	</div>
 </div>
 </div>
 </div>
 </div>
 <span class="hero__description">
 Overview of Tuberculosis (TB)
 </span>
 
<div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: {data: $data, root: $root, element: $element} }" data-popup-model='{"VideoId":"5219630283001","PlayerId":"6CaKiGXJD_default","Credits":"%3Cspan%20id%3D%22v38408710%22%20class%3D%22anchor%22%20%3E%3C%2Fspan%3E%3Cdiv%20class%3D%22para%22%20%3E%20%3Cp%20%3ETuberculosis%20%28https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DyR51KVF4OX0%29%20by%20Osmosis%20%28https%3A%2F%2Fopen.osmosis.org%2F%29%20is%20licensed%20under%20CC-BY-SA%204.0%20%28https%3A%2F%2Fcreativecommons.org%2Flicenses%2Fby-sa%2F4.0%2F%29.%20%3C%2Fp%3E%3C%2Fdiv%3E","IsRestricted":false,"Type":1,"ItemId":"5dac1114-ab60-3396-a8cf-c11c7aedc58d","Title":"Overview%20of%20Tuberculosis%20%28TB%29","ShareUrlTitle":"overview-of-tuberculosis-tb","Description":"","ImageUrl":"https://cf-images.us-east-1.prod.boltdns.net/v1/static/3850378299001/4222c17a-e46d-4df2-b3ac-7f0e6adaab6d/d9f87986-7bbc-497e-88ab-4f2cef66626a/1280x719/match/image.jpg","ThumbnailUrl":"https://cf-images.us-east-1.prod.boltdns.net/v1/static/3850378299001/4222c17a-e46d-4df2-b3ac-7f0e6adaab6d/d9f87986-7bbc-497e-88ab-4f2cef66626a/1280x719/match/image.jpg","MediaType":"video","MediaNameTranslated":"video","UniqueId":"v38408707","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicResources","LinkText":"Overview%20of%20Tuberculosis%20%28TB%29","CssClass":null,"LoadLocations":true,"ShowTooltip":false,"SingleItem":false,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Topic%20Resources%20%3A%20video","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":null,"Url":null,"HideMainArrows":false}'>
</div>
</a>
 </div>
 </div>
 <br class="floatbox__clear">
 </div>
 <!-- /ko -->
 </li>
 </ul>
 </div>
</div>
<div class="topic__accordion">
 <span id="v1010682" class="anchor"></span><div class="para"> <p><div class='topic__explanation'>Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include productive cough, fever, weight loss, and malaise. Diagnosis is most often by sputum smear and culture and, when available, by nucleic acid amplification tests. Treatment is with multiple antimicrobial drugs given for at least 4 months.</div></p></div><span id="v1010680" class="anchor"></span><div class="para"> <p>(See also <a href="./{A8714A3D-4F14-4D70-982B-78165645C2F4}.html" data-toggle="tooltip" title="Perinatal Tuberculosis (TB)" data-id="f16212a9-fb64-4dbb-93ee-eb58dcfa6fa5" data-itemid="a8714a3d-4f14-4d70-982b-78165645c2f4">Perinatal Tuberculosis</a><span id="f16212a9-fb64-4dbb-93ee-eb58dcfa6fa5" class="d-none xref"> <span class="tooltip-container"> <a href="./{A8714A3D-4F14-4D70-982B-78165645C2F4}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Perinatal Tuberculosis (TB) </span> Tuberculosis can be acquired during the perinatal period. Symptoms and signs are nonspecific. Diagnosis is by culture and sometimes x-ray and biopsy. Treatment is with isoniazid and other antituberculous... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> and <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html" data-toggle="tooltip" title="Extrapulmonary Tuberculosis (TB)" data-id="7d1e270d-f76e-4fc5-b376-23276297bbf8" data-itemid="5db9fccd-8e55-41d4-844a-c3552b8447ac">Extrapulmonary Tuberculosis</a><span id="7d1e270d-f76e-4fc5-b376-23276297bbf8" class="d-none xref"> <span class="tooltip-container"> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Extrapulmonary Tuberculosis (TB) </span> Tuberculosis outside the lung usually results from hematogenous dissemination. Sometimes infection directly extends from an adjacent organ. Symptoms vary by site but generally include fever... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/8/4/484-cutaneous-tuberculosis-scrofuloderma-slide-20-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Extrapulmonary Tuberculosis (TB)" loading="lazy"> </span> </a> </span> </span>.)</p></div><span id="v38408720" class="anchor"></span><div class="para"> <p>Mycobacteria are small, slow-growing, aerobic bacilli. They are distinguished by a complex, lipid-rich cell envelope that makes them acid-fast (ie, resistant to decolorization by acid after staining with carbolfuchsin) and relatively resistant to Gram stain. The most common mycobacterial infection is tuberculosis; others include <a href="./{D5D8C58A-5DFC-4E5A-A5AE-1A01C8325E23}.html" data-toggle="tooltip" title="Leprosy" data-id="00fdf88d-14d4-4037-a2d4-675a900cdf63" data-itemid="d5d8c58a-5dfc-4e5a-a5ae-1a01c8325e23">leprosy</a><span id="00fdf88d-14d4-4037-a2d4-675a900cdf63" class="d-none xref"> <span class="tooltip-container"> <a href="./{D5D8C58A-5DFC-4E5A-A5AE-1A01C8325E23}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Leprosy </span> Leprosy is a chronic infection usually caused by the acid-fast bacilli <i>Mycobacterium leprae</i> or the closely related organism <i>M. lepromatosis</i>. These organisms have a unique tropism... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/0/m2000171_tuberculoid_leprosy_science_photo_library_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Leprosy" loading="lazy"> </span> </a> </span> </span> and various environmental <a href="./{63A6B149-4646-4855-A582-04E280558007}.html" data-toggle="tooltip" title="Nontuberculous Mycobacterial Infections" data-id="51c5febe-219c-4e06-8e03-bb9eb25fa83c" data-itemid="63a6b149-4646-4855-a582-04e280558007">nontuberculous mycobacterial infections</a><span id="51c5febe-219c-4e06-8e03-bb9eb25fa83c" class="d-none xref"> <span class="tooltip-container"> <a href="./{63A6B149-4646-4855-A582-04E280558007}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Nontuberculous Mycobacterial Infections </span> There are over 170 recognized species of mycobacteria, mostly environmental. Environmental exposure to many of these organisms is common, but most exposures do not cause infection and many infections... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, such as those caused by <i>Mycobacterium avium</i> complex.</p></div><span id="v1010684" class="anchor"></span><div class="para"> <p>Tuberculosis (TB) is a leading infectious cause of death in adults worldwide, killing about 1.5 million people in 2020, most of them in low- and middle-income countries (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425434" data-toggle="tooltip" title="General reference" data-id="7ca26406-ccec-4655-82f2-ec3a86405e43" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">1</a><span id="7ca26406-ccec-4655-82f2-ec3a86405e43" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425434"> <span class="tooltip-content"> <span class="tooltip-heading"> General reference </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="General reference" loading="lazy"> </span> </a> </span> </span>). HIV/AIDS is the most important factor predisposing to TB infection and mortality in parts of the world where both infections are prevalent.</p></div> <div class="inlinemedia-component " data-ko-rebind="5219630283001"> <div class="inlinemedia--video inlinemedia--right"> <div class="inlinemedia__wrapper"> <div class="inlinemedia__header"> <div class="inlinemedia__title">Overview of Tuberculosis (TB)</div> <div class="inlinemedia__open hide-on-print"> <i class="inlinemedia__icon--open"></i> </div> </div> <div class="inlinemedia__content"> <div class="inlinemedia__image--container"> <figure class="inlinemedia__figure"> <img oncontextmenu="return false;" src="https://cf-images.us-east-1.prod.boltdns.net/v1/static/3850378299001/4222c17a-e46d-4df2-b3ac-7f0e6adaab6d/d9f87986-7bbc-497e-88ab-4f2cef66626a/1280x719/match/image.jpg?mw=350" width="267" height="150"> <div class="inlinemedia__overlay hide-on-print"> <div class="inlinemedia__play"></div> </div> <div class="box__label">VIDEO</div> </figure> </div> </div> <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-block', params: $data }" data-popup-model='{"VideoId":"5219630283001","PlayerId":"6CaKiGXJD_default","Credits":"%3Cspan%20id%3D%22v38408710%22%20class%3D%22anchor%22%20%3E%3C%2Fspan%3E%3Cdiv%20class%3D%22para%22%20%3E%20%3Cp%20%3ETuberculosis%20%28https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DyR51KVF4OX0%29%20by%20Osmosis%20%28https%3A%2F%2Fopen.osmosis.org%2F%29%20is%20licensed%20under%20CC-BY-SA%204.0%20%28https%3A%2F%2Fcreativecommons.org%2Flicenses%2Fby-sa%2F4.0%2F%29.%20%3C%2Fp%3E%3C%2Fdiv%3E","IsRestricted":false,"Type":1,"ItemId":"5dac1114-ab60-3396-a8cf-c11c7aedc58d","Title":"Overview%20of%20Tuberculosis%20%28TB%29","ShareUrlTitle":"overview-of-tuberculosis-tb","Description":"","ImageUrl":"https://cf-images.us-east-1.prod.boltdns.net/v1/static/3850378299001/4222c17a-e46d-4df2-b3ac-7f0e6adaab6d/d9f87986-7bbc-497e-88ab-4f2cef66626a/1280x719/match/image.jpg","ThumbnailUrl":"https://cf-images.us-east-1.prod.boltdns.net/v1/static/3850378299001/4222c17a-e46d-4df2-b3ac-7f0e6adaab6d/d9f87986-7bbc-497e-88ab-4f2cef66626a/1280x719/match/image.jpg","MediaType":"video","MediaNameTranslated":"video","UniqueId":"v38408707","Placement":"sideline","IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"video","LinkText":"Overview%20of%20Tuberculosis%20%28TB%29","CssClass":null,"LoadLocations":false,"ShowTooltip":false,"SingleItem":true,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"video","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":true,"ShowTitleInHeader":false,"HideCarousel":true,"Target":null,"Url":null,"HideMainArrows":false}'> </div> </div> </div> </div> <section id="v68425433" class="topic__section GHead"> <span></span> <h2 id="" class="topic__header--section"> <span id="v68425434" class="anchor"></span> General reference </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v68425437" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://www.who.int/publications/i/item/9789240037021">World Health Organization (WHO)</a>: Global Tuberculosis Report 2021. Accessed on 5/9/2022.</p></div></li></ul></div> </div> </section> <section id="v1010685" class="topic__section FHead" itemprop="cause" itemscope="" itemtype="http://schema.org/MedicalCause"> <h2 id="Etiology_v1010686" class="topic__header--section" data-originaltitle="Etiology"> <span id="v1010686" class="anchor"></span> Etiology of TB </h2> <div class="topic__content"> <span id="v1010687" class="anchor"></span><div class="para"> <p>Tuberculosis properly refers only to disease caused by <i>Mycobacterium tuberculosis</i> (for which humans are the main reservoir). Similar disease occasionally results from the closely related mycobacteria, <i>M. bovis</i>, <i>M. africanum</i>, and <i>M. microti</i>. These three bacteria, together with <i>M. tuberculosis</i> and other less common mycobacteria, are known as the <i>Mycobacterium tuberculosis</i> complex.</p></div><span id="v1010692" class="anchor"></span><div class="para"> <p>TB results almost exclusively from inhalation of airborne particles (droplet nuclei) containing <i>M. tuberculosis</i>. They disperse primarily through coughing, singing, and other forced respiratory maneuvers by people who have active pulmonary or laryngeal TB and whose sputum contains a large number of organisms (about 10,000 organisms/mL, the limit of detection by fluorescent microscopy). People with pulmonary cavitary lesions are especially contagious because of the large number of bacteria contained within a lesion.</p></div><span id="v38408726" class="anchor"></span><div class="para"> <p>Droplet nuclei (particles < 5 micrometers in diameter) containing tubercle bacilli may remain suspended in room air currents for several hours, increasing the chance of spread. However, once these droplets land on a surface, it is difficult to resuspend the organisms (eg, by sweeping the floor, shaking out bed linens) as respirable particles. Although such actions can resuspend dust particles containing tubercle bacilli, these particles are far too large to reach the alveolar surfaces necessary to initiate infection. Contact with fomites (eg, contaminated surfaces, food, personal respirators) do not appear to facilitate spread.</p></div><span id="v1010694" class="anchor"></span><div class="para"> <p>Untreated active pulmonary TB is highly variable in contagiousness. Certain strains of <i>M. tuberculosis</i> are more contagious, and patients with <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010762" data-toggle="tooltip" title="Sputum examination, culture, and testing" data-id="f4a264da-43e8-496e-9651-db8ad8398f44" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">positive sputum smears</a><span id="f4a264da-43e8-496e-9651-db8ad8398f44" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010762"> <span class="tooltip-content"> <span class="tooltip-heading"> Sputum examination, culture, and testing </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Sputum examination, culture, and testing" loading="lazy"> </span> </a> </span> </span> are more contagious than those with positive results only on culture. Patients with cavitary disease (which is closely associated with mycobacterial burden in sputum) are more contagious than those without. Respiratory secretions with lower viscosity are more easily aerosolized, and the effectiveness of cough and other respiratory maneuvers in generating aerosol varies greatly.</p></div><span id="v38408727" class="anchor"></span><div class="para"> <p>Environmental factors also are important. Transmission is enhanced by frequent or prolonged exposure to untreated patients who are generating large numbers of tubercle bacilli in overcrowded, poorly ventilated, enclosed spaces; consequently, people living in poverty or in institutions are at particular risk. Health care practitioners who have close contact with active cases have increased risk.</p></div><span id="v38408728" class="anchor"></span><div class="para"> <p>Thus, estimates of contagiousness vary widely. Some studies suggest that only 1 in 3 patients with untreated pulmonary TB infect any close contacts, but the World Health Organization (WHO) estimates that each untreated patient may infect 10 to 15 people per year. However, most of those who are infected do not develop active disease.</p></div><span id="v38408729" class="anchor"></span><div class="para"> <p>Contagiousness decreases rapidly once effective treatment begins; cough decreases, and organisms are noninfectious even if they persist in sputum. Epidemiologic studies of household contacts suggest that transmission ends within 2 weeks of patients starting effective treatment, but more precise human-to-animal studies suggest that transmission ends within a few days of starting treatment.</p></div><span id="v1010695" class="anchor"></span><div class="para"> <p>Much less commonly, contagion results from aerosolization of organisms after irrigation of infected wounds, in mycobacteriology laboratories, or by aerosol or direct puncture in autopsy rooms.</p></div><span id="v38408730" class="anchor"></span><div class="para"> <p>TB of the tonsils, lymph nodes, abdominal organs, bones, and joints was once commonly caused by ingestion of milk or milk products (eg, cheese) contaminated with <i>M. bovis</i>, but this transmission route has been largely eradicated in countries where milk is pasteurized and cows that have a positive tuberculin skin test result are slaughtered. Tuberculosis due to <i>M. bovis</i> still occurs in countries where bovine tuberculosis is endemic (eg, some Latin American countries) and in immigrants from those countries. The increasing popularity of cheese made from unpasteurized milk raises new concerns if the cheeses come from countries with a bovine TB problem (eg, Mexico, the United Kingdom). Bovine and human TB can be transmitted to other species such as badgers, deer, primates, and zoo animals. Slaughterhouses have been associated with zoonotic TB transmission. </p></div> </div> </section> <section id="v1010704" class="topic__section FHead"> <h2 id="Epidemiology_v1010705" class="topic__header--section" data-originaltitle="Epidemiology"> <span id="v1010705" class="anchor"></span> Epidemiology of TB </h2> <div class="topic__content"> <span id="v1010706" class="anchor"></span><div class="para"> <p>Based on tuberculin skin testing surveys, it is estimated that about one fourth of the world’s population is infected. Of those infected, perhaps 15 million have active disease at any given time. </p></div><span id="v68425442" class="anchor"></span><div class="para"> <p>In 2020, an estimated 9.9 million (127/100,000) new tuberculosis cases occurred worldwide. Most new cases occurred in Southeast Asia (43%), Africa (25%), and the Western Pacific (18%) (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="2422a83d-3067-4b6a-b5d9-67152e2aed23" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">1)</a><span id="2422a83d-3067-4b6a-b5d9-67152e2aed23" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>.</p></div><span id="v68425444" class="anchor"></span><div class="para"> <p>Case rates vary widely by country, age, race, sex, and socioeconomic status. In 2020, two thirds of new cases occurred in 8 countries; most occurred in India (26%), followed by Indonesia (8.4%), China (8.5%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%), and South Africa (3.3%) (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="8ca96113-4ec7-4d0e-b79a-a2f1a171d50d" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">1</a><span id="8ca96113-4ec7-4d0e-b79a-a2f1a171d50d" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). A few countries, including North Korea, Lesotho, Mozambique, the Philippines, and South Africa, had incidence rates above 500/100,000 (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="6f16cb57-7bea-4b7a-be2f-ab06641ed4ee" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">1</a><span id="6f16cb57-7bea-4b7a-be2f-ab06641ed4ee" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>).</p></div><span id="v1010707" class="anchor"></span><div class="para"> <p>Globally, drug-susceptible TB incidence and mortality are slowly decreasing. The cumulative reduction from 2015 to 2019 was 9% (from 142 to 130 new cases per 100,000), including a reduction of 2.3% between 2018 and 2019. These trends are likely due in part to global TB control efforts that have provided more people with access to drugs for TB and HIV infections. However, the 2020 to 2021 global COVID-19 pandemic disrupted other public health programs, including TB control, and although it is too soon to quantify, the WHO predicts a stalling or reversal of these decreasing global trends (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="83ce881f-c448-414f-9edd-0615b26f3f63" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">1</a><span id="83ce881f-c448-414f-9edd-0615b26f3f63" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). </p></div><span id="v11555445" class="anchor"></span><div class="para"> <p>In the US in 2021, 7860 new cases of TB were reported to the CDC for a case rate of 2.4/100,000 (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="38a6fdf4-e11d-4b9e-ae97-370aca4e05cf" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">2</a><span id="38a6fdf4-e11d-4b9e-ae97-370aca4e05cf" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). During the COVID-19 pandemic in 2020, there was a 20% decrease from 2019 rates (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="64ffeb69-cea1-44e4-ba36-022df4f50034" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">3</a><span id="64ffeb69-cea1-44e4-ba36-022df4f50034" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>). The breadth and magnitude of this 20% decrease compared to the usual 2 to 3% per year decrease suggest there was under-reporting of TB during the COVID-19 pandemic and/or delayed diagnosis of a substantial number of cases. During 2020, 71% of US TB cases occurred in patients born outside the US in high-prevalence areas. The TB rate among non–US-born people (11.5/100,000) was much higher than the rate among US-born people (0.7/100,000 [ <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741" data-toggle="tooltip" title="Epidemiology references" data-id="d169ef6c-a825-4672-8ed6-a867a6bc597c" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">3</a><span id="d169ef6c-a825-4672-8ed6-a867a6bc597c" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v38408741"> <span class="tooltip-content"> <span class="tooltip-heading"> Epidemiology references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Epidemiology references" loading="lazy"> </span> </a> </span> </span>]). Risk of TB is increased for people who live in group facilities, such as shelters, long-term care facilities, or correctional facilities, and for those who have been homeless in the past year. In such high-risk populations, case rates can approach those in high-burden parts of the world.</p></div><span id="v1010708" class="anchor"></span><div class="para"> <p>A resurgence of TB occurred in parts of the US and other economically advanced countries between 1985 and 1992; it was associated with several factors, including HIV coinfection, homelessness, a deteriorated public health infrastructure, and the appearance of multidrug-resistant TB (MDR-TB, defined as resistance to at least <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>). MDR-TB and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>-resistant TB (MDR/RR-TB) have been substantially controlled in the US by effective public health and institutional infection control measures, but until recently, infection caused by these organisms had been increasing around the world. However, the incidence appears to be slowly decreasing worldwide. Decreasing TB incidence and improved (molecular) diagnostics, treatment, and case management of drug-sensitive and drug-resistant TB are the likely explanations. Although MDR/RR-TB cases make up less than 4% of incident cases, the diagnosis and treatment of these cases consume a disproportionate fraction of TB control resources. MDR/RR-TB results in a disproportionate share of human suffering, death, and economic consequences for impacted people and their families. </p></div><span id="v38408739" class="anchor"></span><div class="para"> <p>Still, in many parts of the world, MDR/RR-TB cannot be rapidly diagnosed and promptly treated with effective regimens, including effective management of adverse effects of second-line drugs. This situation results in ongoing transmission, low cure rates, and amplified resistance. Treatment of highly drug-resistant TB cases has had even less favorable outcomes, including high mortality rates, especially in patients coinfected with HIV, even when they are being treated with antiretroviral drugs. Newer, shorter, more effective (noninjectable) treatment regimens combined with adverse effect management, community outreach, and social support have resulted in more favorable downward epidemiologic trends for drug-resistant TB globally, especially in a few areas (eg, Peru, the Tomsk region of Russia). India and China are implementing countrywide MDR-TB programs, and the future of MDR-TB may be greatly influenced by the success or failure of these programs.</p></div> <section id="v38408740" class="topic__section GHead"> <span></span> <h3 id="Epidemiology_v1010705_v38408741" class="topic__header--subsection"> <span id="v38408741" class="anchor"></span> Epidemiology references </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v38408744" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://www.who.int/publications/i/item/9789240037021">World Health Organization (WHO)</a>: Global Tuberculosis Report 2021. Accessed on 4/17/2022.</p></div></li><li class="topic__listitem"><span id="v68425451" class="anchor"></span><div class="para"> <p>2. <a rel="nofollow" target="_blank" href="https://www.cdc.gov/tb/statistics/default.htm">Centers for Disease Control and Prevention (CDC)</a>: Tuberculosis—Data and Statistics. Accessed on 4/19/2022.</p></div></li><li class="topic__listitem"><span id="v38408750" class="anchor"></span><div class="para"> <p>3. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993554/">Deutsch-Feldman M, Pratt RH, Price SF, et al</a>: Tuberculosis—United States, 2020. <span data-mmanualobjecttype="pubtitle">MMWR Morb Mortal Wkly Rep</span> 70:409–414, 2021. doi: 10.15585/mmwr.mm7012a1</p></div></li></ul></div> </div> </section> </div> </section> <section id="v1010710" class="topic__section FHead"> <h2 id="Pathophysiology_v1010711" class="topic__header--section" data-originaltitle="Pathophysiology"> <span id="v1010711" class="anchor"></span> Pathophysiology of TB </h2> <div class="topic__content"> <span id="v38408752" class="anchor"></span><div class="para"> <p>Tuberculosis may occur in 3 stages:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408755" class="anchor"></span><div class="para"> <p>Primary infection</p></div></li><li class="topic__listitem"><span id="v38408757" class="anchor"></span><div class="para"> <p>Latent infection</p></div></li><li class="topic__listitem"><span id="v38408759" class="anchor"></span><div class="para"> <p>Active infection</p></div></li></ul></div><span id="v1010712" class="anchor"></span><div class="para"> <p><i>M. tuberculosis</i> bacilli initially cause a primary infection, a small percentage of which eventually progress to clinical disease of variable severity. However, most (about 95%) primary infections are asymptomatic. An unknown percentage of primary infections resolve spontaneously, but the majority are followed by a latent (dormant) phase. A variable percentage (5 to 10%) of latent infections subsequently reactivate with symptoms and signs of disease.</p></div><span id="v38408760" class="anchor"></span><div class="para"> <p>Infection is usually not transmissible in the primary stage and is never contagious in the latent stage.</p></div> <section id="v1010713" class="topic__section GHead"> <span></span> <h3 id="Pathophysiology_v1010711_v1010714" class="topic__header--subsection"> <span id="v1010714" class="anchor"></span> Primary TB infection </h3> <div class="topic__content"> <span id="v1010715" class="anchor"></span><div class="para"> <p>Infection requires inhalation of particles small enough to traverse the upper respiratory defenses and deposit deep in the lungs, usually in the subpleural airspaces of the middle or lower lobes. Larger droplets tend to lodge in the more proximal airways and typically do not result in infection. Infection usually begins from a single droplet nucleus, which typically carries few organisms. Perhaps only a single organism may suffice to cause infection in susceptible people, but less susceptible people may require repeated exposure to develop infection. </p></div><span id="v1010716" class="anchor"></span><div class="para"> <p>To initiate infection, <i>M. tuberculosis</i> bacilli must be ingested by alveolar macrophages. Bacilli that are not killed by the macrophages actually replicate inside them, ultimately killing the host macrophage (with the help of CD8 lymphocytes); inflammatory cells are attracted to the area, causing a focal pneumonitis that coalesces into the characteristic tubercles seen histologically.</p></div><span id="v38408761" class="anchor"></span><div class="para"> <p>In the early weeks of infection, some infected macrophages migrate to regional lymph nodes (eg, hilar, mediastinal), where they access the bloodstream. Organisms may then spread hematogenously to any part of the body, particularly the apical-posterior portion of the lungs, epiphyses of the long bones, kidneys, vertebral bodies, and meninges. Hematogenous dissemination is less likely in patients with partial immunity due to vaccination or to prior natural infection with <i>M. tuberculosis</i> or environmental mycobacteria.</p></div><span id="v1010717" class="anchor"></span><div class="para"> <p><b>Latent TB infection</b> occurs after most primary infections. In about 95% of cases, after about 3 weeks of uninhibited growth, the immune system suppresses bacillary replication, usually before symptoms or signs develop. Foci of bacilli in the lung or other sites resolve into epithelioid cell granulomas, which may have caseous and necrotic centers. Tubercle bacilli can survive in this material for years; the balance between the host’s resistance and microbial virulence determines whether the infection ultimately resolves without treatment, remains dormant, or becomes active. Infectious foci may leave fibronodular scars in the apices of one or both lungs (Simon foci, which usually result from hematogenous seeding from another site of infection) or small areas of consolidation (Ghon foci). A Ghon focus with lymph node involvement is a Ghon complex, which, if calcified, is called a Ranke complex. The <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775" data-toggle="tooltip" title="Skin testing" data-id="c7ef422e-f2d5-4a3c-9cb6-4bfc04504d68" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">tuberculin skin test</a><span id="c7ef422e-f2d5-4a3c-9cb6-4bfc04504d68" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775"> <span class="tooltip-content"> <span class="tooltip-heading"> Skin testing </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Skin testing" loading="lazy"> </span> </a> </span> </span> and interferon-gamma release blood assays (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792" data-toggle="tooltip" title="IGRA (interferon-gamma release assay)" data-id="ac5d08f1-e117-4d58-8d3a-a58ad59b1631" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">IGRA</a><span id="ac5d08f1-e117-4d58-8d3a-a58ad59b1631" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792"> <span class="tooltip-content"> <span class="tooltip-heading"> IGRA (interferon-gamma release assay) </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="IGRA (interferon-gamma release assay)" loading="lazy"> </span> </a> </span> </span>) become positive during the latent stage of infection. Sites of latent infection are dynamic processes and are not entirely dormant as was once believed.</p></div><span id="v1010722" class="anchor"></span><div class="para"> <p>Less often, the primary focus progresses immediately, causing acute illness with pneumonia (sometimes cavitary), pleural effusion, and marked mediastinal or hilar lymph node enlargement (which, in children, may compress bronchi). Small pleural effusions are predominantly lymphocytic, typically contain few organisms, and clear within a few weeks. This sequence may be more common among young children and recently infected or reinfected immunosuppressed patients.</p></div><span id="v38408765" class="anchor"></span><div class="para"> <p> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html" data-toggle="tooltip" title="Extrapulmonary Tuberculosis (TB)" data-id="ec6bccf4-7e79-40ca-bb6d-2dd350b96dc9" data-itemid="5db9fccd-8e55-41d4-844a-c3552b8447ac">Extrapulmonary TB</a><span id="ec6bccf4-7e79-40ca-bb6d-2dd350b96dc9" class="d-none xref"> <span class="tooltip-container"> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Extrapulmonary Tuberculosis (TB) </span> Tuberculosis outside the lung usually results from hematogenous dissemination. Sometimes infection directly extends from an adjacent organ. Symptoms vary by site but generally include fever... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/8/4/484-cutaneous-tuberculosis-scrofuloderma-slide-20-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Extrapulmonary Tuberculosis (TB)" loading="lazy"> </span> </a> </span> </span> at any site can sometimes manifest without evidence of lung involvement. TB lymphadenopathy is the most common extrapulmonary manifestation; however, meningitis is the most feared because of its high mortality in the very young and very old.</p></div> </div> </section> <section id="v1010726" class="topic__section GHead"> <span></span> <h3 id="Pathophysiology_v1010711_v1010727" class="topic__header--subsection"> <span id="v1010727" class="anchor"></span> Active TB disease </h3> <div class="topic__content"> <span id="v1010728" class="anchor"></span><div class="para"> <p>Healthy people who are infected with tuberculosis have about a 5 to 10% lifetime risk of developing active disease, although the percentage varies significantly by age and other risk factors. </p></div><span id="v38408767" class="anchor"></span><div class="para"> <p>In 50 to 80% of those who develop active disease, TB reactivates within the first 2 years, but it can also reactivate decades later.</p></div><span id="v38408768" class="anchor"></span><div class="para"> <p>Any organ initially seeded may become a site of reactivation, but reactivation occurs most often in the lung apices, presumably because of favorable local conditions such as high oxygen tension. Ghon foci and affected hilar lymph nodes are much less likely to be sites of reactivation. </p></div><span id="v1010729" class="anchor"></span><div class="para"> <p>Conditions that impair cellular immunity (which is essential for defense against TB) significantly facilitate reactivation. Thus, patients coinfected with <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html" data-toggle="tooltip" title="Human Immunodeficiency Virus (HIV) Infection" data-id="6b741d10-7c58-470d-b1f6-0d61a701ab2c" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">HIV</a><span id="6b741d10-7c58-470d-b1f6-0d61a701ab2c" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Human Immunodeficiency Virus (HIV) Infection </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Human Immunodeficiency Virus (HIV) Infection" loading="lazy"> </span> </a> </span> </span> and not receiving appropriate antiretroviral therapy (ART) have about a 10% annual risk of developing active disease.</p></div><span id="v38408770" class="anchor"></span><div class="para"> <p>Other risk factors that facilitate reactivation, but to a lesser extent than HIV infection, include</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408773" class="anchor"></span><div class="para"> <p> <a href="./{C638B386-4B60-444C-8A50-BD90E6B9D85D}.html" data-toggle="tooltip" title="Diabetes Mellitus (DM)" data-id="355bcb27-547e-4152-9350-0bd6997d981b" data-itemid="c638b386-4b60-444c-8a50-bd90e6b9d85d">Diabetes</a><span id="355bcb27-547e-4152-9350-0bd6997d981b" class="d-none xref"> <span class="tooltip-container"> <a href="./{C638B386-4B60-444C-8A50-BD90E6B9D85D}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Diabetes Mellitus (DM) </span> Diabetes mellitus is impaired insulin secretion and variable degrees of peripheral insulin resistance leading to hyperglycemia. Early symptoms are related to hyperglycemia and include polydipsia... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v38408776" class="anchor"></span><div class="para"> <p> <a href="./{3E1A2048-9B9D-4C8F-B5FE-1F20BD6CE4B1}.html" data-toggle="tooltip" title="Overview of Head and Neck Tumors" data-id="42f7b2c8-4b99-4996-be99-148613138a71" data-itemid="3e1a2048-9b9d-4c8f-b5fe-1f20bd6ce4b1">Head and neck cancer</a><span id="42f7b2c8-4b99-4996-be99-148613138a71" class="d-none xref"> <span class="tooltip-container"> <a href="./{3E1A2048-9B9D-4C8F-B5FE-1F20BD6CE4B1}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Overview of Head and Neck Tumors </span> Head and neck cancer develops in almost 65,000 people in the United States each year. Excluding skin and thyroid cancers, > 90% of head and neck cancers are squamous cell (epidermoid) carcinomas... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v38408779" class="anchor"></span><div class="para"> <p>Gastrectomy</p></div></li><li class="topic__listitem"><span id="v38408781" class="anchor"></span><div class="para"> <p>Jejunoileal bypass surgery</p></div></li><li class="topic__listitem"><span id="v38408783" class="anchor"></span><div class="para"> <p>Dialysis-dependent <a href="./{291C26B0-7C10-48A8-8057-7D2D9EE60EE6}.html" data-toggle="tooltip" title="Chronic Kidney Disease" data-id="dd201b12-dedf-436b-b8cf-97bed4aaa281" data-itemid="291c26b0-7c10-48a8-8057-7d2d9ee60ee6">chronic kidney disease</a><span id="dd201b12-dedf-436b-b8cf-97bed4aaa281" class="d-none xref"> <span class="tooltip-container"> <a href="./{291C26B0-7C10-48A8-8057-7D2D9EE60EE6}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Chronic Kidney Disease </span> Chronic kidney disease (CKD) is long-standing, progressive deterioration of renal function. Symptoms develop slowly and in advanced stages include anorexia, nausea, vomiting, stomatitis, dysgeusia... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/6/3/3/633-uremic-frost-springer-high-with-arrow-cropped.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Chronic Kidney Disease" loading="lazy"> </span> </a> </span> </span></p></div></li><li class="topic__listitem"><span id="v38408786" class="anchor"></span><div class="para"> <p>Significant weight loss</p></div></li><li class="topic__listitem"><span id="v38408788" class="anchor"></span><div class="para"> <p>Use of drugs that suppress the immune system</p></div></li></ul></div><span id="v38408789" class="anchor"></span><div class="para"> <p>Patients who require immunosuppression after solid organ transplantation are at the highest risk, but other immunosuppressants such as corticosteroids and tumor necrosis factor (TNF) inhibitors also commonly cause reactivation. Tobacco use also is a risk factor.</p></div><span id="v11555449" class="anchor"></span><div class="para"> <p>In some patients, active disease develops when they are reinfected rather than when latent disease reactivates. Reinfection is more likely to be the mechanism in areas where TB is prevalent and patients are exposed to a large inoculum of bacilli. Reactivation of latent infection predominates in low-prevalence areas. In a given patient, it is difficult to determine whether active disease resulted from reinfection or reactivation.</p></div><span id="v1010730" class="anchor"></span><div class="para"> <p>TB damages tissues through <a href="./{1976D4ED-C3E9-4923-8419-915FA5450B70}.html#v994907" data-toggle="tooltip" title="Type IV" data-id="ca6156e7-c2bb-42eb-9d15-21bdf3203b62" data-itemid="1976d4ed-c3e9-4923-8419-915fa5450b70">delayed-type hypersensitivity</a><span id="ca6156e7-c2bb-42eb-9d15-21bdf3203b62" class="d-none xref"> <span class="tooltip-container"> <a href="./{1976D4ED-C3E9-4923-8419-915FA5450B70}.html#v994907"> <span class="tooltip-content"> <span class="tooltip-heading"> Type IV </span> <span class="tooltip-readmore"> </span> </span> </a> </span> </span> (DTH), typically producing granulomatous necrosis with a caseous histologic appearance. Lung lesions are characteristically but not invariably cavitary, especially in immunosuppressed patients with impaired DTH. Pleural effusion is less common than in progressive primary TB but may result from direct extension or hematogenous spread. Rupture of a large tuberculous lesion into the pleural space may cause empyema with or without bronchopleural fistula and sometimes causes pneumothorax. In the prechemotherapy era, TB empyema sometimes complicated medically induced pneumothorax therapy and was usually rapidly fatal, as was sudden massive hemoptysis due to erosion of a pulmonary artery by an enlarging cavity.</p></div><span id="v1010736" class="anchor"></span><div class="para"> <p>The course of TB varies greatly, depending on the virulence of the organism and the state of host defenses. The course may be rapid in members of isolated populations (eg, Native Americans) who, unlike many Europeans and their American descendents, have not experienced centuries of selective pressure to develop innate or natural immunity to the disease. The course is often more indolent in these European and American populations. </p></div><span id="v1010737" class="anchor"></span><div class="para"> <p> <a href="./{E5694A16-9F21-42DA-9472-818020AF6C25}.html" data-toggle="tooltip" title="Acute Hypoxemic Respiratory Failure (AHRF, ARDS)" data-id="ebda073b-7b0a-411f-81f4-7f76096c5025" data-itemid="e5694a16-9f21-42da-9472-818020af6c25">Acute respiratory distress syndrome</a><span id="ebda073b-7b0a-411f-81f4-7f76096c5025" class="d-none xref"> <span class="tooltip-container"> <a href="./{E5694A16-9F21-42DA-9472-818020AF6C25}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Acute Hypoxemic Respiratory Failure (AHRF, ARDS) </span> Acute hypoxemic respiratory failure is defined as severe hypoxemia (PaO2 (See also Overview of Mechanical Ventilation.) Airspace filling in acute hypoxemic respiratory failure (AHRF) may result... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/p/u/l/pulmonary_edema_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Acute Hypoxemic Respiratory Failure (AHRF, ARDS)" loading="lazy"> </span> </a> </span> </span> (ARDS), which appears to be due to hypersensitivity to TB antigens, develops rarely after diffuse hematogenous spread or rupture of a large cavity with spillage into the lungs.</p></div> </div> </section> </div> </section> <section id="v1010739" class="topic__section FHead"> <h2 id="SymptomsAndSigns_v1010740" class="topic__header--section" data-originaltitle="Symptoms and Signs"> <span id="v1010740" class="anchor"></span> Symptoms and Signs of TB </h2> <div class="topic__content"> <span id="v68425457" class="anchor"></span><div class="para" itemprop="signOrSymptom" itemscope="" itemtype="http://schema.org/MedicalSignOrSymptom"> <p><b>Primary infection</b> is almost always asymptomatic, but when symptoms occur, they typically are nonspecific and include low-grade fever and fatigue without a prominent cough.</p></div><span id="v1010741" class="anchor"></span><div class="para"> <p>In <b>active pulmonary tuberculosis</b>, even moderate or severe disease, patients may have no symptoms, except “not feeling well,” along with anorexia, fatigue, and weight loss, which develop gradually over several weeks, or they may have more specific symptoms. Cough is most common. At first, it may be minimally productive of yellow or green sputum, usually when awakening in the morning, but cough may become more productive as the disease progresses. Hemoptysis occurs only with cavitary TB (due to granulomatous damage to vessels but sometimes due to fungal growth in a cavity).</p></div><span id="v38408792" class="anchor"></span><div class="para"> <p>Low-grade fever is common but not invariable. Drenching night sweats are a classic symptom but are neither common in nor specific for TB. Dyspnea may result from lung parenchymal damage, spontaneous pneumothorax, or pleural TB with effusion. </p></div><span id="v1010742" class="anchor"></span><div class="para"> <p>With HIV coinfection, the clinical presentation is often atypical because delayed hypersensitivity is impaired; patients are more likely to have symptoms of extrapulmonary or disseminated disease.</p></div><span id="v11555450" class="anchor"></span><div class="para"> <p> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html" data-toggle="tooltip" title="Extrapulmonary Tuberculosis (TB)" data-id="4054f805-4ec0-4647-851e-80af29d11292" data-itemid="5db9fccd-8e55-41d4-844a-c3552b8447ac">Extrapulmonary TB</a><span id="4054f805-4ec0-4647-851e-80af29d11292" class="d-none xref"> <span class="tooltip-container"> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Extrapulmonary Tuberculosis (TB) </span> Tuberculosis outside the lung usually results from hematogenous dissemination. Sometimes infection directly extends from an adjacent organ. Symptoms vary by site but generally include fever... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/8/4/484-cutaneous-tuberculosis-scrofuloderma-slide-20-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Extrapulmonary Tuberculosis (TB)" loading="lazy"> </span> </a> </span> </span> causes various systemic and localized manifestations depending on the affected organs.</p></div> </div> </section> <section id="v1010743" class="topic__section FHead"> <h2 id="Diagnosis_v1010744" class="topic__header--section" data-originaltitle="Diagnosis"> <span id="v1010744" class="anchor"></span> Diagnosis of TB </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v11555453" class="anchor"></span><div class="para"> <p>Chest x-ray</p></div></li><li class="topic__listitem"><span id="v1010752" class="anchor"></span><div class="para"> <p>Acid-fast stain and culture</p></div></li><li class="topic__listitem"><span id="v1010750" class="anchor"></span><div class="para"> <p>Tuberculin skin test (TST) or interferon-gamma release assay (IGRA)</p></div></li><li class="topic__listitem"><span id="v1010754" class="anchor"></span><div class="para"> <p>When available, nucleic acid amplification test (NAAT)</p></div></li></ul></div><span id="v1010755" class="anchor"></span><div class="para"> <p>Pulmonary tuberculosis is often suspected based on one of the following:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408796" class="anchor"></span><div class="para"> <p>Chest x-rays taken while evaluating respiratory symptoms (cough lasting > 3 weeks, hemoptysis, chest pain, dyspnea), an unexplained illness, fever of unknown origin (FUO), or a positive <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775" data-toggle="tooltip" title="Skin testing" data-id="4469ca3c-9ea5-49a0-a32b-30bcad5fbc20" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">tuberculin skin test</a><span id="4469ca3c-9ea5-49a0-a32b-30bcad5fbc20" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775"> <span class="tooltip-content"> <span class="tooltip-heading"> Skin testing </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Skin testing" loading="lazy"> </span> </a> </span> </span> (TST)</p></div></li><li class="topic__listitem"><span id="v38408799" class="anchor"></span><div class="para"> <p> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792" data-toggle="tooltip" title="IGRA (interferon-gamma release assay)" data-id="ce00c461-9db4-4bca-bc7d-9ed3afdef4d1" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">IGRA</a><span id="ce00c461-9db4-4bca-bc7d-9ed3afdef4d1" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792"> <span class="tooltip-content"> <span class="tooltip-heading"> IGRA (interferon-gamma release assay) </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="IGRA (interferon-gamma release assay)" loading="lazy"> </span> </a> </span> </span> done as a screening test or during contact investigation</p></div></li></ul></div><span id="v38408801" class="anchor"></span><div class="para"> <p>Suspicion for TB is higher in patients who have fever, cough lasting > 2 to 3 weeks, night sweats, weight loss, and/or lymphadenopathy and in patients with possible TB exposure (eg, via infectious family members, friends, or other contacts; institutional exposure; or travel to TB-endemic areas).</p></div><span id="v1010757" class="anchor"></span><div class="para"> <p>Initial tests are chest x-ray and sputum examination and culture. If the diagnosis of active TB is still unclear after chest imaging and sputum examination, TST or IGRA may be done, but these are tests for infection not active disease. NAATs (eg, polymerase chain reaction [PCR]–based) are rapid and can be diagnostic.</p></div><span id="v68425459" class="anchor"></span><div class="para"> <p>Like most clinical tests, positive TB test results are statistically more likely to be false positives when the prior probability of TB infection is low (see also <a href="./{FFD8C031-7081-4310-8529-525752F52179}.html" data-toggle="tooltip" title="Understanding Medical Tests and Test Results" data-id="339732d1-6328-47ba-8bf6-5f2ef09b5693" data-itemid="ffd8c031-7081-4310-8529-525752f52179">Understanding Medical Tests and Test Results</a><span id="339732d1-6328-47ba-8bf6-5f2ef09b5693" class="d-none xref"> <span class="tooltip-container"> <a href="./{FFD8C031-7081-4310-8529-525752F52179}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Understanding Medical Tests and Test Results </span> Test results may help make a diagnosis in symptomatic patients (diagnostic testing) or identify occult disease in asymptomatic patients (screening). If the tests were appropriately ordered on... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). </p></div><span id="v11555454" class="anchor"></span><div class="para"> <p>Once TB is diagnosed, patients should be <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v26306816" data-toggle="tooltip" title="Diagnostic tests" data-id="b386fa10-6d29-4ea8-a3f9-07e74d4ea48c" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">tested for HIV infection</a><span id="b386fa10-6d29-4ea8-a3f9-07e74d4ea48c" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v26306816"> <span class="tooltip-content"> <span class="tooltip-heading"> Diagnostic tests </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Diagnostic tests" loading="lazy"> </span> </a> </span> </span>, and those with risk factors for <a href="./{4563CDC7-B126-42E7-B728-8A7E93249166}.html" data-toggle="tooltip" title="Hepatitis B, Acute" data-id="e4162098-c977-4a76-beb5-83621ca64128" data-itemid="4563cdc7-b126-42e7-b728-8a7e93249166">hepatitis B</a><span id="e4162098-c977-4a76-beb5-83621ca64128" class="d-none xref"> <span class="tooltip-container"> <a href="./{4563CDC7-B126-42E7-B728-8A7E93249166}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hepatitis B, Acute </span> Hepatitis B is caused by a DNA virus that is often parenterally transmitted. It causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice. Fulminant hepatitis and... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> or <a href="./{8140F216-53D3-4EB3-9FB0-8CC655C9FB4F}.html" data-toggle="tooltip" title="Hepatitis C, Acute" data-id="e433a051-fa93-4ec2-b143-44fc59a71cd0" data-itemid="8140f216-53d3-4eb3-9fb0-8cc655c9fb4f">hepatitis C</a><span id="e433a051-fa93-4ec2-b143-44fc59a71cd0" class="d-none xref"> <span class="tooltip-container"> <a href="./{8140F216-53D3-4EB3-9FB0-8CC655C9FB4F}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Hepatitis C, Acute </span> Hepatitis C is caused by an RNA virus that is often parenterally transmitted. It sometimes causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice but may be asymptomatic... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> should be tested for those viruses. Baseline tests (eg, complete blood count, basic blood chemistry including hepatic and renal function) should be done.</p></div> <section id="v1010758" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1010744_v1010759" class="topic__header--subsection"> <span id="v1010759" class="anchor"></span> Chest x-ray </h3> <div class="topic__content"> <span id="v1010760" class="anchor"></span><div class="para"> <p>In adults, a multinodular infiltrate above or behind the clavicle is most characteristic of active TB; it suggests reactivation of disease. It is best visualized in an apical-lordotic view or with chest CT.</p></div><span id="v38408802" class="anchor"></span><div class="para"> <p>Middle and lower lung infiltrates are nonspecific but should prompt suspicion of primary TB in patients (usually younger) whose symptoms or exposure history suggests recent infection, particularly if there is pleural effusion.</p></div><span id="v38408803" class="anchor"></span><div class="para"> <p>Calcified hilar nodes may be present; they may result from primary TB infection but may also result from <a href="./{3B2680A1-0848-4BF4-B5D9-CB1D70385ECB}.html" data-toggle="tooltip" title="Histoplasmosis" data-id="5a643a64-ed01-40d9-8513-d473f652a081" data-itemid="3b2680a1-0848-4bf4-b5d9-cb1d70385ecb">histoplasmosis</a><span id="5a643a64-ed01-40d9-8513-d473f652a081" class="d-none xref"> <span class="tooltip-container"> <a href="./{3B2680A1-0848-4BF4-B5D9-CB1D70385ECB}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Histoplasmosis </span> Histoplasmosis is a pulmonary and hematogenous disease caused by <i>Histoplasma capsulatum</i>; it is often chronic and usually follows an asymptomatic primary infection. Symptoms are those... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/h/i/s/histoplasmosis_orig.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Histoplasmosis" loading="lazy"> </span> </a> </span> </span> in areas where histoplasmosis is endemic (eg, the Ohio River Valley).</p></div> <div class="inlinemedia-component " data-ko-rebind="v27304822" data-bind="component: {name: 'inlinemedia-photo', params: $data}" data-inline-model='{"Alt":"Tuberculosis (Chest X-Ray)","Credits":"\u003cspan id=\u0022v85663379\u0022 class=\u0022anchor\u0022 \u003e\u003c/span\u003e\u003cdiv class=\u0022para\u0022 \u003e \u003cp \u003eZEPHYR/SCIENCE PHOTO LIBRARY\u003c/p\u003e\u003c/div\u003e","IsRestricted":true,"ItemId":"5145746a-29d6-4ea1-9a10-3ddcfdead4c8","Title":"Tuberculosis (Chest X-Ray)","ShareUrlTitle":"tuberculosis-chest-x-ray","Description":"\u003cul\u003e\u003cspan id=\u0022v88841298\u0022 class=\u0022anchor\u0022\u003e\u003c/span\u003e\u003cdiv class=\u0022para\u0022\u003e \u003cp\u003eA right upper lobe cavitary lesion on a chest x-ray of a patient with tuberculosis.\u003c/p\u003e\u003c/div\u003e\u003c/ul\u003e","ImageUrl":"./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0\u0026sc_lang=en","ThumbnailUrl":"./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?mw=350\u0026amp;thn=0\u0026amp;sc_lang=en","MediaType":"image","MediaNameTranslated":"Image","UniqueId":"v27304822","Placement":"inline","IsInCarousel":false,"Edition":0,"ImageWidth":"1000","ImageHeight":"857","IframeSrc":null,"Target":null}'> </div> </div> </section> <section id="v1010761" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1010744_v1010762" class="topic__header--subsection"> <span id="v1010762" class="anchor"></span> Sputum examination, culture, and testing </h3> <div class="topic__content"> <span id="v1010763" class="anchor"></span><div class="para"> <p>Sputum testing is the mainstay for diagnosis of pulmonary tuberculosis. A nonsputum-based diagnostic test has long been sought because sputum is often difficult to collect; breath and urine tests are available, and the urine tests have proved useful in diagnosing TB disease in people with HIV infection. If patients cannot produce sputum spontaneously, aerosolized hypertonic saline can be used to induce it. If induction is unsuccessful, bronchial washings, which are particularly sensitive, can be obtained by fiberoptic bronchoscopy. Because induction of sputum and bronchoscopy entail some risk of infection for medical staff, these procedures should be done as a last resort in selected cases. Appropriate precautions (eg, negative-pressure room, N-95 or other fitted respirators) should be used.</p></div><span id="v11555456" class="anchor"></span><div class="para"> <p>The first step in sputum examination is typically microscopic examination to check for acid-fast bacilli (AFB). Tubercle bacilli are nominally gram-positive but take up Gram stain inconsistently; samples are best prepared with Ziehl-Neelsen or Kinyoun stains for conventional light microscopy or fluorochrome stains for the more sensitive fluorescent microscopy. Smear microscopy can detect about 10,000 bacilli/mL of sputum, making it insensitive when fewer bacilli are present, as occurs in early reactivation or in patients with HIV coinfection.</p></div><span id="v11555457" class="anchor"></span><div class="para"> <p>Although finding AFB in a sputum smear is strong presumptive evidence of TB in the presence of TB risk factors, in other settings environmental mycobacteria may be more likely, and definitive diagnosis requires a positive mycobacterial culture or NAAT.</p></div><span id="v38408805" class="anchor"></span><div class="para"> <p>Culture is also required to isolate bacteria for conventional drug susceptibility testing and genotyping. However, molecular drug susceptibility testing is increasingly replacing culture-based methods. Culture can detect as few as 10 bacilli/mL of sputum and can be done using solid or liquid media. However, it can take up to 3 months for final confirmation of culture results. Liquid media are more sensitive and faster that solid media, with results available in 2 to 3 weeks. Rapid antigen testing to detect the MPB64 antigen can confirm that organisms growing on mycobacterial culture are <i>M. tuberculosis</i>.</p></div><span id="v11555458" class="anchor"></span><div class="para"> <p>Two types of NAAT are available for TB diagnosis:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408809" class="anchor"></span><div class="para"> <p>Xpert MTB/RIF</p></div></li><li class="topic__listitem"><span id="v38408811" class="anchor"></span><div class="para"> <p>Line probe assay</p></div></li></ul></div><span id="v38408812" class="anchor"></span><div class="para"> <p><b>Xpert MTB/RIF</b> is an automated rapid NAAT that can simultaneously identify <i>M. tuberculosis</i> DNA in a sputum sample and detect resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> (rifampicin) in as little as 2 hours. The Xpert MTB/RIF NAAT is more sensitive than sputum smear microscopy and about as sensitive as culture for diagnosing TB. Newer versions of Xpert MTB/RIF Ultra (Xpert Ultra) can detect resistance mutations to both <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010840" data-toggle="tooltip" title="First-line drugs for TB" data-id="58efee93-3c4f-4187-9fff-4935e5a727b2" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">first-line drugs</a><span id="58efee93-3c4f-4187-9fff-4935e5a727b2" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010840"> <span class="tooltip-content"> <span class="tooltip-heading"> First-line drugs for TB </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="First-line drugs for TB" loading="lazy"> </span> </a> </span> </span> and many <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011141" data-toggle="tooltip" title="Second-line drugs for TB" data-id="87da7295-3ff9-42f4-b04b-0bd7e1101274" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">second-line drugs</a><span id="87da7295-3ff9-42f4-b04b-0bd7e1101274" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011141"> <span class="tooltip-content"> <span class="tooltip-heading"> Second-line drugs for TB </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Second-line drugs for TB" loading="lazy"> </span> </a> </span> </span>.</p></div><span id="v38408814" class="anchor"></span><div class="para"> <p>The <b>line probe assay</b> can identify the presence of <i>M. tuberculosis</i> and resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span>. However, sensitivity is lower than that of Xpert MTB/RIF. This test is usually done only on smear-positive specimens. Probes for several second-line drugs are available. </p></div><span id="v1010767" class="anchor"></span><div class="para"> <p>There are a variety of diagnostic algorithms that differ based on the tests available.</p></div><span id="v38408816" class="anchor"></span><div class="para"> <p>If an Xpert MTB/RIF or Xpert Ultra test on a sputum sample is positive, the diagnosis of pulmonary TB is considered confirmed. In such cases, treatment can be started based on local drug susceptibility patterns.</p></div><span id="v38408817" class="anchor"></span><div class="para"> <p>If NAAT and AFB smear results are negative or if AFB smear results are positive and NAAT results are negative, clinical judgment is used to determine whether to begin anti-TB treatment while awaiting results of culture.</p></div> </div> </section> <section id="v38408818" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1010744_v38408819" class="topic__header--subsection"> <span id="v38408819" class="anchor"></span> Drug susceptibility tests </h3> <div class="topic__content"> <span id="v38408820" class="anchor"></span><div class="para"> <p>Drug susceptibility tests should be done on initial isolates from all patients to identify an effective anti-TB regimen. These tests should be repeated if patients continue to produce culture-positive sputum after 3 months of treatment or if cultures become positive after a period of negative cultures. TB disease can be caused by more than one strain, each with different drug resistance patterns, especially in settings of high transmission. </p></div><span id="v38408821" class="anchor"></span><div class="para"> <p>Results of susceptibility tests may take up to 8 weeks if conventional bacteriologic methods are used, but as noted above, several molecular DSTs can rapidly (within hours) detect drug resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> and other first- and second-line drugs.</p></div> </div> </section> <section id="v1010770" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1010744_v1010771" class="topic__header--subsection"> <span id="v1010771" class="anchor"></span> Tests of other specimens </h3> <div class="topic__content"> <span id="v1010772" class="anchor"></span><div class="para"> <p>Transbronchial biopsies can be done on infiltrative lesions, and samples are submitted for culture, histologic evaluation, and molecular testing.</p></div><span id="v38408822" class="anchor"></span><div class="para"> <p>Gastric washings, which are culture-positive in a minority of samples, are no longer commonly used except in small children, who usually cannot produce a good sputum specimen. However, sputum induction is being used in young children who are able to cooperate.</p></div><span id="v38408823" class="anchor"></span><div class="para"> <p>Ideally, biopsy samples of other tissue should be cultured fresh. Culture of fresh specimens remains the gold standard for the detection of <i>M. tuberculosis</i> in tissue because fixation can inhibit PCR, and PCR does not distinguish viable from dead organisms. However, NAAT can be used for fixed tissues when necessary (eg, for biopsied lymph node if histologic examination unexpectedly detects granulomatous changes). This use of NAAT has not been approved, but it can be extremely useful, although positive and negative predictive values have not been established. </p></div> </div> </section> <section id="v1010774" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1010744_v1010775" class="topic__header--subsection"> <span id="v1010775" class="anchor"></span> Skin testing </h3> <div class="topic__content"> <span id="v1010782" class="anchor"></span><div class="para"> <p>Multiple-puncture devices (tine test) are no longer recommended.</p></div><span id="v38408824" class="anchor"></span><div class="para"> <p>The tuberculin skin test (TST—Mantoux intradermal method) using purified protein derivative (PPD) is usually done. The TST measures the immunologic response to <i>M. tuberculosis</i> and thus should be positive in both latent and active infection and so cannot distinguish between the two. </p></div><span id="v68425468" class="anchor"></span><div class="para"> <p>The standard dose in the US of 5 tuberculin units (TU) of PPD in 0.1 mL of solution is injected on the volar forearm. It is critical to give the injection intradermally, not subcutaneously. A well-demarcated bleb or wheal upon injection indicates a properly placed injection. The diameter of induration (not erythema) transverse to the long axis of the arm is measured 48 to 72 hours after injection. Use of a pen to demarcate the boundaries of induration on the skin can help produce more precise measurements, but reading skin tests is inherently variable and subject to a number of errors, including terminal digit preference, that is, a tendency to favor recording 5-, 10-, 15- and 20-mm results. In research studies, measurements done with a caliper or ruler where measurement numbers were not immediately visible to the reader produced less biased readings. </p></div><span id="v68425469" class="anchor"></span><div class="para"> <p>Given the difficulty of demarcating and accurately measuring the induration, it is ill-advised to attach clinical significance to minor differences. For example, a 9-mm reading should probably not be interpreted as different from an 11-mm reading (ie, treating the 11-mm reading as latent infection while dismissing the 9-mm reading as uninfected). Among household contacts, and in other settings where recent transmission is considered certain, TST results average about 17 mm in induration. Clinically, it is useful to remember that recently infected people are at greatest risk of reactivation and that, if they are immunocompetent, they usually have a vigorous immune response, manifested by a large TST or interferon gamma release test (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792" data-toggle="tooltip" title="IGRA (interferon-gamma release assay)" data-id="a7336923-034b-453c-a990-32ae5b5541e5" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">IGRA</a><span id="a7336923-034b-453c-a990-32ae5b5541e5" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792"> <span class="tooltip-content"> <span class="tooltip-heading"> IGRA (interferon-gamma release assay) </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="IGRA (interferon-gamma release assay)" loading="lazy"> </span> </a> </span> </span>) result.</p></div> <a id="v68425138"></a> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--right inlinebox--pearlsandpitfalls "> <div class="inlinebox__wrapper" id="v68425140"> <div class="inlinebox__content"> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v68425140"></span> <div class="TableHalfPage" id="v68425139"> <h3 class="title">Pearls & Pitfalls</h3> <div class="tableWrapper"> <table> <tbody><tr class="odd"><td><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v68425148" class="anchor"></span><div class="para"> <p>With the tuberculin skin test, it is the diameter of induration, not erythema, that is measured.</p></div></li></ul></div></td></tr></tbody> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div> <div> </div> </div> </div> <!-- Type: PearlsAndPitfalls --> </div><span id="v68425472" class="anchor"></span><div class="para"> <p>TST responses tend to decrease over time, commonly long outlasting the presence of viable <i>M. tuberculosis</i> organisms capable of reactivation. Although late reactivation is well documented, most reactivation of latent infection occurs within a year to 18 months of initial infection. Treating latent TB many years after infection likely occurred may be advisable when immunosuppression is contemplated, but residual infection that is likely to reactivate may no longer be present. Reversion of skin tests that occurs in the absence of treatment or anergy (no reaction to any skin test) is often missed because follow-up testing is not done. Spontaneous cure is the likely reason. In settings of high transmission, disease often results from <i>recent</i> rather than <i>remote</i> infection, although both can occur. </p></div><span id="v68425474" class="anchor"></span><div class="para"> <p>Repeated administration of TSTs can cause the immune system to recall previous hypersensitivity that has waned over time, so-called boosting. Unrecognized, boosting can result in unnecessary treatment of contacts, for example, in the context of an outbreak investigation. To avoid misinterpreting boosting as recent infection in settings where serial testing is indicated, two-step baseline testing is recommended. The idea is to retest people with a negative TST result within a 1 to 4 weeks to see whether there is recall of previous hypersensitivity. If not, that result is a true negative. However, a positive TST result on retesting 1 to 4 weeks after the first test is assumed to indicate pre-existing latent infection and patients are treated or not treated based on clinical criteria. Boosting is not a problem with repeated IGRA testing because no antigens are injected.</p></div><span id="v38408825" class="anchor"></span><div class="para"> <p><b>Recommended cutoff points for a positive TST reaction</b> depend on the clinical setting:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1010785" class="anchor"></span><div class="para"> <p><b>5 mm:</b> Patients at high risk of developing active TB if infected, such as those who have chest x-ray evidence of past TB, who are immunosuppressed because of HIV infection or drugs (eg, TNF-alpha inhibitors, corticosteroid use equivalent to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>prednisone</span> 15 mg/day for <span class='symbol'>></span> 1 month), or who are close contacts of patients with infectious TB</p></div></li><li class="topic__listitem"><span id="v1010787" class="anchor"></span><div class="para"> <p><b>10 mm:</b> Patients with some risk factors, such as injection drug users, recent immigrants from high-prevalence areas, residents of high-risk settings (eg, prisons, homeless shelters), patients with certain disorders (eg, silicosis, renal insufficiency, diabetes, head or neck cancer), and those who have had gastrectomy or jejunoileal bypass surgery</p></div></li><li class="topic__listitem"><span id="v1010789" class="anchor"></span><div class="para"> <p><b>15 mm:</b> Patients with no risk factors (who typically should not be tested)</p></div></li></ul></div><span id="v1010790" class="anchor"></span><div class="para"> <p><b>False-negative TST results</b> can occur, most often in patients who are febrile, older, HIV-infected (especially if CD4 count is <span class='symbol'>&lt</span> 200 cells/mcL [0.2 x 10<sup>9</sup>/L]), immune-suppressed because of a disorder or use of certain drugs (eg, corticosteroids, certain biologic immune modulators, certain cancer drugs), or very ill. Many of these people show no reaction to any skin test (anergy). Anergy probably occurs because inhibiting antibodies are present or because so many T cells have been mobilized to the disease site that too few remain to produce a significant skin reaction.</p></div><span id="v38408826" class="anchor"></span><div class="para"> <p><b>False-positive TST results</b> may occur if patients have <a href="./{63A6B149-4646-4855-A582-04E280558007}.html" data-toggle="tooltip" title="Nontuberculous Mycobacterial Infections" data-id="71aa41ed-870b-4f94-bed1-3fc114df678a" data-itemid="63a6b149-4646-4855-a582-04e280558007">nontuberculous mycobacterial infections</a><span id="71aa41ed-870b-4f94-bed1-3fc114df678a" class="d-none xref"> <span class="tooltip-container"> <a href="./{63A6B149-4646-4855-A582-04E280558007}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Nontuberculous Mycobacterial Infections </span> There are over 170 recognized species of mycobacteria, mostly environmental. Environmental exposure to many of these organisms is common, but most exposures do not cause infection and many infections... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span> or have received the bacille Calmette-Guérin (BCG) vaccine. However, the effect of BCG vaccination on TST usually wanes after several years; after this time, a positive test is likely to be due to TB infection. Infection after BCG vaccination occurs in high-transmission settings. People arriving in the US from high-burden areas often cite BCG as the reason for their positive TST, rather than get stigmatized by a diagnosis of TB, and resist treatment for latent infection even when it is clearly indicated. Authorities suggest that BCG vaccination status should be ignored and infection assumed, but this leads to overdiagnosis of latent TB infection, unnecessary concern and treatment, and potential drug adverse effects. The use of IGRAs to diagnose TB infection, although not also without interpretation problems, has largely solved the BCG/latent TB infection controversy. </p></div> </div> </section> <section id="v1010791" class="topic__section GHead"> <span></span> <h3 id="Diagnosis_v1010744_v1010792" class="topic__header--subsection"> <span id="v1010792" class="anchor"></span> IGRA (interferon-gamma release assay) </h3> <div class="topic__content"> <span id="v68425476" class="anchor"></span><div class="para"> <p>Two commercial IGRAs with different testing platforms exist, but many comparative studies reveal very similar performance. The choice of IGRA is often dictated by availability in a given clinical setting. </p></div><span id="v1010793" class="anchor"></span><div class="para"> <p>The IGRA is a blood test based on the release of interferon gamma by lymphocytes exposed in vitro to TB-specific antigens. Although results of IGRAs are not always concordant with TST, these tests appear to be as sensitive as and more specific than TST in contact investigations. Unlike the TST, prior BCG vaccination does not cause a false-positive test result on IGRA, but repeat TST testing itself can cause low-level positive IGRA results. Like the TST, IGRAs do not distinguish active from latent TB and although lymphocyte hypersensitivity occurs in both conditions, because in vitro lymphocyte stimulation with TB antigens is brief, IGRAs are thought more likely to reflect recent (sensitized circulating lymphocytes) rather than remote (sensitized memory lymphocytes) TB infection. Therefore, IGRAs are thought to better correlate with a risk of reactivation compared to the TST. </p></div><span id="v38408827" class="anchor"></span><div class="para"> <p>In low-TB burden areas where more resources are available to focus on latent infection, IGRAs have largely replaced the TST because they have less operator-related variability, lack BCG interference, lack <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011206" data-toggle="tooltip" title="Booster reaction" data-id="60dda115-d668-43db-81f1-470bde920f87" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">boosting</a><span id="60dda115-d668-43db-81f1-470bde920f87" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011206"> <span class="tooltip-content"> <span class="tooltip-heading"> Booster reaction </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Booster reaction" loading="lazy"> </span> </a> </span> </span>, and people do not have to return for a reading. However, in low-TB burden areas like the US, fewer and fewer people are at sufficient risk to warrant even one-time much less serial TB testing.</p></div><span id="v38408828" class="anchor"></span><div class="para"> <p>Use of IGRA is limited in low-resource settings because of its relatively high cost. However, the WHO is emphasizing the treatment of latent infection in high-TB burden as a necessary component of TB elimination globally. Because of BCG interference with the TST, IGRAs are clearly more specific for latent TB.</p></div> </div> </section> </div> </section> <section id="v1010794" class="topic__section FHead"> <h2 id="Prognosis_v1010795" class="topic__header--section" data-originaltitle="Prognosis"> <span id="v1010795" class="anchor"></span> Prognosis for TB </h2> <div class="topic__content"> <span id="v1010796" class="anchor"></span><div class="para"> <p>In immunocompetent patients with drug-susceptible pulmonary tuberculosis, even severe disease with large cavities, appropriate, drug susceptibility test–directed therapy is usually curative if it is instituted promptly and completed. Still, TB causes or contributes to death in about 10% of cases, often in patients who are debilitated for other reasons. Disseminated TB and TB meningitis may be fatal in up to 25% of cases despite optimal treatment. In addition, there is substantial morbidity resulting from residual tissue damage (lungs especially, but any organ) remaining after bacteriological cure. Tissue damage often results from the immune response to infection, most dramatically in the <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v26307332" data-toggle="tooltip" title="Immune reconstitution inflammatory syndrome (IRIS)" data-id="846f7b97-0464-41c4-88c2-fd507250563d" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">immune reconstitution inflammatory syndrome</a><span id="846f7b97-0464-41c4-88c2-fd507250563d" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v26307332"> <span class="tooltip-content"> <span class="tooltip-heading"> Immune reconstitution inflammatory syndrome (IRIS) </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Immune reconstitution inflammatory syndrome (IRIS)" loading="lazy"> </span> </a> </span> </span> (IRIS), but is increasingly recognized in advanced cases of TB, where TB-induced inflammation can lead to, for example, chronic respiratory insufficiency, upper airway stenosis, constrictive pericarditis, and skeletal deformities. </p></div><span id="v1010797" class="anchor"></span><div class="para"> <p>Although immune-induced tissue damage is a major problem, the lack of an immune response is an even greater problem. TB progresses more rapidly and more extensively in immunocompromised patients and, if not appropriately and aggressively treated, can be fatal in as little as 2 months from a patient's initial presentation, especially with multidrug-resistant TB (MDR-TB). However, with effective antiretroviral therapy (and appropriate anti-TB treatment), the prognosis for patients with HIV infection, even those with MDR-TB, may approach that of immunocompetent patients. Poorer outcomes have occurred in patients with extensively drug-resistant TB because of less effective treatment, but this is rapidly changing as new regimens address highly drug-resistant TB.</p></div> </div> </section> <section id="v1010798" class="topic__section FHead" itemprop="possibleTreatment" itemscope="" itemtype="http://schema.org/MedicalTherapy"> <h2 id="Treatment_v1010799" class="topic__header--section" data-originaltitle="Treatment"> <span id="v1010799" class="anchor"></span> Treatment of TB </h2> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408831" class="anchor"></span><div class="para"> <p>Measures to prevent transmission, sometimes including respiratory isolation</p></div></li><li class="topic__listitem"><span id="v38408833" class="anchor"></span><div class="para"> <p>Antibiotics</p></div></li></ul></div><span id="v1010800" class="anchor"></span><div class="para"> <p>Most patients with uncomplicated TB and all patients with complicating illnesses (eg, <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1021396" data-toggle="tooltip" title="Immune system" data-id="05cff5af-b281-4485-8f79-4ee87c24257a" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">AIDS</a><span id="05cff5af-b281-4485-8f79-4ee87c24257a" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v1021396"> <span class="tooltip-content"> <span class="tooltip-heading"> Immune system </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Immune system" loading="lazy"> </span> </a> </span> </span>, <a href="./{2636C596-EBE7-40B5-ADA0-4D8F7A187139}.html" data-toggle="tooltip" title="Causes of Hepatitis" data-id="82c29027-a811-4c7a-b5c6-69f19dc2c5cb" data-itemid="2636c596-ebe7-40b5-ada0-4d8f7a187139">hepatitis</a><span id="82c29027-a811-4c7a-b5c6-69f19dc2c5cb" class="d-none xref"> <span class="tooltip-container"> <a href="./{2636C596-EBE7-40B5-ADA0-4D8F7A187139}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Causes of Hepatitis </span> Hepatitis is inflammation of the liver characterized by diffuse or patchy necrosis. Hepatitis may be acute or chronic (usually defined as lasting > 6 months). Most cases of acute viral hepatitis... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>, <a href="./{C638B386-4B60-444C-8A50-BD90E6B9D85D}.html" data-toggle="tooltip" title="Diabetes Mellitus (DM)" data-id="fd535deb-aaa7-471a-8dba-01450240460f" data-itemid="c638b386-4b60-444c-8a50-bd90e6b9d85d">diabetes</a><span id="fd535deb-aaa7-471a-8dba-01450240460f" class="d-none xref"> <span class="tooltip-container"> <a href="./{C638B386-4B60-444C-8A50-BD90E6B9D85D}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Diabetes Mellitus (DM) </span> Diabetes mellitus is impaired insulin secretion and variable degrees of peripheral insulin resistance leading to hyperglycemia. Early symptoms are related to hyperglycemia and include polydipsia... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>), adverse drug reactions, or drug resistance should be referred to a TB specialist. See also the Official American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America's <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/27516382"> 2016 Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis</a>.</p></div><span id="v38408838" class="anchor"></span><div class="para"> <p>Depending on the degree of illness and social circumstances, most patients with TB can be treated as outpatients. Instructions on how to prevent transmission usually include </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1010805" class="anchor"></span><div class="para"> <p>Staying at home</p></div></li><li class="topic__listitem"><span id="v1010807" class="anchor"></span><div class="para"> <p>Avoiding visitors (except for previously exposed family members)</p></div></li><li class="topic__listitem"><span id="v1010809" class="anchor"></span><div class="para"> <p>Covering coughs with a tissue</p></div></li></ul></div><span id="v1010810" class="anchor"></span><div class="para"> <p>Surgical face masks for patients with TB are effective at limiting transmission but can be stigmatizing and are typically not recommended for cooperative patients except, for example, those who need pretreatment in a hospital or clinic. Longstanding expert advice has been to maintain transmission control precautions for at least 2 weeks after initiation of treatment that the patient is responding to (as noted by decreased cough, fever, and fatigue). However, there is strong evidence indicating that effective treatment stops transmission much more quickly, within hours or days of initiation through sublethal effects on organisms, which is long before sputum conversion by sputum smear or culture (usually takes 2 months). This finding appears to be true even in most drug-resistant cases (when effectively treated). However, accurately predicting the likelihood that treatment will be effective requires drug susceptibility test (DST) data on the patient's TB isolate, and ideally enough time to judge a good clinical response. Also, drugs must match the DST profile, must be reliably ingested, and achieve therapeutic blood levels. Thus, although effective drugs may stop transmission within hours, a few days of observing the patient undergoing treatment may be needed to ensure a good clinical response. For highly drug-resistant TB, the consequences of transmission are greater and the response to treatment may be slower, so greater caution is used before transmission control precautions are removed.</p></div> <section id="v1010811" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1010799_v1010812" class="topic__header--subsection"> <span id="v1010812" class="anchor"></span> Hospitalization </h3> <div class="topic__content"> <span id="v1010813" class="anchor"></span><div class="para"> <p>The main indications for hospitalization for active TB are</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1010816" class="anchor"></span><div class="para"> <p>Serious concomitant illness</p></div></li><li class="topic__listitem"><span id="v1010818" class="anchor"></span><div class="para"> <p>Need for diagnostic procedures</p></div></li><li class="topic__listitem"><span id="v1010820" class="anchor"></span><div class="para"> <p>Social issues (eg, homelessness)</p></div></li><li class="topic__listitem"><span id="v1010822" class="anchor"></span><div class="para"> <p>Need for respiratory isolation, as for people living in congregate settings where previously unexposed people would be regularly encountered (important primarily if effective treatment cannot be ensured)</p></div></li></ul></div><span id="v1010823" class="anchor"></span><div class="para"> <p>Because the consequences of drug-resistant TB are so great, hospitalization with respiratory isolation for treatment initiation is warranted at least until a clinical response to treatment is certain. Ideally, all hospitalized patients should be in a negative-pressure room with 6 to 12 air changes/hour. Healthcare personnel entering the room should wear a respirator (not a surgical mask) that has been appropriately fitted and that meets National Institute for Occupational Safety and Health certification (N-95 or greater). Because consequences of infecting other vulnerable hospitalized patients is high, even though patients receiving effective treatment become noncontagious before sputum smears become negative, release from respiratory isolation usually requires 3 negative sputum smears over 2 days, including at least one early-morning negative specimen. Two negative sputum NAATs can be used to rule out TB for isolation purposes in patients under evaluation based on symptoms or signs but cannot be used in patients with known TB because <i>M. tuberculosis</i> DNA may be detected by NAATs long after treatment renders patients noninfectious. However, discharging patients directly home from isolation rooms regardless of sputum smear status often makes good sense because household members (who have been previously exposed) are likely at less risk than hospital patients whose illnesses render them more vulnerable. </p></div><span id="v68425482" class="anchor"></span><div class="para"> <p>A frequent question is how long patients require hospitalization for TB. Given that most patients with TB, regardless of sputum smear status, can be diagnosed and treated entirely on an ambulatory basis while living at home, there should be no required amount of hospitalization before discharge nor should discharge be based on sputum smear or culture status. As noted, the start of effective treatment rapidly reduces transmission. In the US, patients with TB are often first encountered in the hospital emergency department, admitted for diagnosis, and started on treatment while the health department is notified of the case and arrangements are made for contact investigations and supervised treatment. Because this sequence of admission and respiratory isolation occurs often, the false impression exists that hospitalization and respiratory isolation are required until a person is deemed not contagious based on sputum tests. This requirement is incorrect, and clinicians should focus on clinically responsible early discharge. </p></div> <a id="v11555460"></a> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--right inlinebox--pearlsandpitfalls "> <div class="inlinebox__wrapper" id="v11555462"> <div class="inlinebox__content"> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v11555462"></span> <div class="SidebarHalfPage" id="v68425150"> <h3 class="title">Pearls & Pitfalls</h3> <div class="tableWrapper"> <table> <tbody><tr class="odd"><td><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v68425159" class="anchor"></span><div class="para"> <p>In hospitals and clinics, the highest risk of TB transmission is from patients who have undiagnosed TB or unidentified drug resistance and are receiving inadequate treatment, not from known TB patients who are receiving effective treatment.</p></div></li></ul></div></td></tr></tbody> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div> <div> </div> </div> </div> <!-- Type: PearlsAndPitfalls --> </div> </div> </section> <section id="v1010824" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1010799_v1010825" class="topic__header--subsection"> <span id="v1010825" class="anchor"></span> Public health considerations </h3> <div class="topic__content"> <span id="v1010827" class="anchor"></span><div class="para"> <p>To improve treatment adherence, ensure cure, and limit transmission and the development of drug-resistant strains, public health programs closely monitor treatment, even if patients are being treated by a private physician. In most US states, TB care (including skin testing, chest x-rays, and drugs) is available free through public health clinics to reduce barriers to treatment.</p></div><span id="v1010828" class="anchor"></span><div class="para"> <p>Increasingly, <b>directly observed therapy</b> (DOT) is part of optimal patient case management; DOT involves supervision by public health personnel (ideally not family members) of the ingestion of every dose of drug. DOT increases the likelihood from 61% to 86% that the full treatment course will be completed. Enhanced DOT, in which incentives and enablers such as transportation vouchers, child care, outreach workers, and meals are provided, increases the likelihood to 91%.</p></div><span id="v38408840" class="anchor"></span><div class="para"> <p>DOT is particularly important </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1010831" class="anchor"></span><div class="para"> <p>For children and adolescents</p></div></li><li class="topic__listitem"><span id="v1010833" class="anchor"></span><div class="para"> <p>For patients with HIV infection, psychiatric illness, or substance abuse</p></div></li><li class="topic__listitem"><span id="v1010835" class="anchor"></span><div class="para"> <p>After treatment failure, relapse, or development of drug resistance</p></div></li></ul></div><span id="v1010836" class="anchor"></span><div class="para"> <p>In some programs, <b>selective self-administered treatment</b> (SAT) is an option for patients who are judged committed to treatment; ideally, fixed-dose combination drug preparations are used to avoid the possibility of monotherapy, which can lead to drug resistance. Mechanical drug monitoring devices have been advocated to improve adherence with SAT. </p></div><span id="v1010837" class="anchor"></span><div class="para"> <p>Public health departments usually visit homes to do the following:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408843" class="anchor"></span><div class="para"> <p>Evaluate potential barriers to treatment (eg, extreme poverty, unstable housing, child care problems, alcohol use disorder, mental illness)</p></div></li><li class="topic__listitem"><span id="v38408845" class="anchor"></span><div class="para"> <p>Check for other active cases</p></div></li><li class="topic__listitem"><span id="v38408847" class="anchor"></span><div class="para"> <p>Assess close contacts</p></div></li></ul></div><span id="v38408848" class="anchor"></span><div class="para"> <p><b>Close contacts</b> are people who share the same breathing space for prolonged periods, typically household residents, but often include people at work, school, and places of recreation. The precise duration and degree of contact that constitute risk vary because patients with TB vary greatly in contagiousness. For patients who are highly contagious as evidenced by multiple family members with disease or positive skin tests, even relatively casual contacts (eg, passengers on the bus they ride) should be referred for skin testing and <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011186" data-toggle="tooltip" title="Screening for TB" data-id="ae7ad343-2fd5-4262-9d9b-f4fd64d74e4c" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">evaluation for latent infection</a><span id="ae7ad343-2fd5-4262-9d9b-f4fd64d74e4c" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011186"> <span class="tooltip-content"> <span class="tooltip-heading"> Screening for TB </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Screening for TB" loading="lazy"> </span> </a> </span> </span> and <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011213" data-toggle="tooltip" title="Treatment of LTBI" data-id="71b9a3ae-895e-41b9-9fde-fdf607555d3a" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">preventive treatment</a><span id="71b9a3ae-895e-41b9-9fde-fdf607555d3a" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011213"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment of LTBI </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment of LTBI " loading="lazy"> </span> </a> </span> </span> if needed. Patients who do not infect any household contacts are less likely to infect casual contacts.</p></div> </div> </section> <section id="v1010839" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1010799_v1010840" class="topic__header--subsection"> <span id="v1010840" class="anchor"></span> First-line drugs for TB </h3> <div class="topic__content"> <span id="v1010842" class="anchor"></span><div class="para"> <p>The first-line drugs <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> (INH), <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> (RIF), <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pyrazinamide</span> (PZA), and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ethambutol</span> (EMB) are used together in initial treatment. There are a several different <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011166" data-toggle="tooltip" title="Treatment regimens" data-id="c8f3e5cf-da86-46a3-9fea-0d87de24ebf2" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">TB treatment regimens</a><span id="c8f3e5cf-da86-46a3-9fea-0d87de24ebf2" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011166"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment regimens </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment regimens" loading="lazy"> </span> </a> </span> </span>, chosen based on numerous factors. <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010855" data-toggle="tooltip" title="Dosing of Oral First-Line Anti-TB Drugs*" data-id="3286e518-3be6-4bab-a67b-4621df756ca2" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">Dosing of first-line drugs</a><span id="3286e518-3be6-4bab-a67b-4621df756ca2" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010855"> <span class="tooltip-content"> <span class="tooltip-heading"> Dosing of Oral First-Line Anti-TB Drugs* </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="./Content/Images/Redesign/table/icon_table_red.png?mh=160&mw=160" class="tooltip-Preview" alt="Dosing of Oral First-Line Anti-TB Drugs*" loading="lazy"> </span> </a> </span> </span> can be done at different intervals.</p></div><span id="v1011120" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isoniazid</span> (INH)</b> is given orally once/day, has good tissue penetration (including cerebrospinal fluid), and is highly bactericidal. It remains the single most useful and least expensive drug for TB treatment. Decades of uncontrolled use—often as monotherapy—in many countries (especially in East Asia) have greatly increased the percentage of resistant strains. In the US, about 10% of isolates are INH-resistant.</p></div><span id="v1435190" class="anchor"></span><div class="para"> <p>Adverse effects of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> include rash, fever, and, rarely, anemia and agranulocytosis. INH causes asymptomatic, transient aminotransferase elevations in up to 20% of patients and clinical (usually reversible) hepatitis in about 1/1000. Clinical hepatitis occurs more often in patients<span class='symbol'> ></span> 35 years old, patients with alcohol use disorder, postpartum women, and patients with chronic liver disease. Monthly liver testing is not recommended unless patients have risk factors for liver disease. Patients with unexplained fatigue, anorexia, nausea, vomiting, or jaundice may have hepatic toxicity; treatment is suspended and liver tests are done. Those with symptoms and any significant aminotransferase elevation (or asymptomatic elevation <span class='symbol'>></span> 5 times normal) by definition have hepatic toxicity, and INH is stopped. </p></div><span id="v38408856" class="anchor"></span><div class="para"> <p>After recovery from mild aminotransferase elevations and symptoms, patients can be safely challenged with a half dose for 2 to 3 days. If this dose is tolerated (typically in about half of patients), the full dose may be restarted with close monitoring for recurrence of symptoms and deterioration of liver function. If patients are receiving INH, RIF, and PZA, all drugs must be stopped, and the challenge done with each drug separately. INH or PZA, rather than RIF, is the more likely cause of hepatotoxicity. </p></div><span id="v38408857" class="anchor"></span><div class="para"> <p>Peripheral neuropathy can result from INH-induced <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pyridoxine</span> (vitamin B6) deficiency, most likely in pregnant or breastfeeding women, undernourished patients, patients with diabetes mellitus or HIV infection, patients with alcohol use disorder, patients with cancer or uremia, and older patients. A daily dose of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pyridoxine</span> 25 to 50 mg can prevent this complication, although <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pyridoxine</span> is usually not needed in children and healthy young adults.</p></div><span id="v38408858" class="anchor"></span><div class="para"> <p>INH delays hepatic metabolism of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>phenytoin</span>, requiring dose reduction. It can also cause a violent reaction to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>disulfiram</span>, a drug occasionally used for alcohol use disorder. INH is safe during pregnancy.</p></div><span id="v1011124" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifampin</span> (RIF),</b> given orally, is bactericidal, is well-absorbed, penetrates well into cells and cerebrospinal fluid, and acts rapidly. It also eliminates dormant organisms in macrophages or caseous lesions that can cause late relapse. Thus, RIF should be used throughout the course of therapy. </p></div><span id="v38408859" class="anchor"></span><div class="para"> <p>Adverse effects of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> include cholestatic jaundice (rare), fever, thrombocytopenia, and renal failure. RIF has a lower rate of hepatotoxicity than INH. Drug interactions must be considered when using RIF. It accelerates metabolism of anticoagulants, oral contraceptives, corticosteroids, digitoxin, oral antihyperglycemic drugs, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>methadone</span>, and many other drugs. The interactions of rifamycins and many antiretroviral drugs are particularly complex; combined use requires specialized expertise. RIF is safe during pregnancy. </p></div><span id="v1435206" class="anchor"></span><div class="para"> <p>The following newer rifamycins are available for special situations: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1011131" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifabutin</span></b> is used for patients taking drugs (particularly antiretroviral drugs) that have unacceptable interactions with RIF. Its action is similar to RIF, but it affects the metabolism of other drugs less. When used with <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>clarithromycin</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>fluconazole</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifabutin</span> has been associated with uveitis.</p></div></li><li class="topic__listitem"><span id="v1011133" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifapentine</span></b> is used in one dose/week regimens and the new 4-month treatment regimen but is not used in children or patients with HIV (because of unacceptable treatment failure rates) or <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html" data-toggle="tooltip" title="Extrapulmonary Tuberculosis (TB)" data-id="6e013b5c-eac9-4361-b63b-876d11239ea4" data-itemid="5db9fccd-8e55-41d4-844a-c3552b8447ac">extrapulmonary TB</a><span id="6e013b5c-eac9-4361-b63b-876d11239ea4" class="d-none xref"> <span class="tooltip-container"> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Extrapulmonary Tuberculosis (TB) </span> Tuberculosis outside the lung usually results from hematogenous dissemination. Sometimes infection directly extends from an adjacent organ. Symptoms vary by site but generally include fever... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/8/4/484-cutaneous-tuberculosis-scrofuloderma-slide-20-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Extrapulmonary Tuberculosis (TB)" loading="lazy"> </span> </a> </span> </span>. It is also used in a 12-dose, once/week DOT regimen with INH for TB prophylaxis. This prophylactic combination is not recommended for children < 2 years old, HIV-infected patients receiving antiretroviral treatment, pregnant women, or women expecting to become pregnant during treatment because safety in these groups is unknown.</p></div></li></ul></div><span id="v68425488" class="anchor"></span><div class="para"> <p>In 2020, nitrosamine impurities were found in samples of RIF and <span class="genericDrug" data-showrollover="false">rifapentine</span>. Some of these impurities have been implicated as possible carcinogens in long-term animal studies, with toxicity largely related to cumulative exposure. However, for treatment of TB disease, the Centers for Disease Control and Prevention (CDC) favors continued use of RIF, if acceptable to the patient, because exposure is time-limited and the risks of not taking RIF likely outweigh any potential risks of nitrosamine impurities. </p></div><span id="v1011135" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Pyrazinamide</span> (PZA)</b> is an oral bactericidal drug. When used during the intensive initial 2 months of treatment, it shortens the duration of therapy to 6 months and prevents development of resistance to RIF.</p></div><span id="v1435210" class="anchor"></span><div class="para"> <p>The major adverse effects of PZA are gastrointestinal upset and hepatitis. It often causes hyperuricemia, which is generally mild and only rarely induces gout. PZA is commonly used during pregnancy, but its safety has not been confirmed. </p></div><span id="v1011137" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ethambutol</span> (EMB)</b> is given orally and is the best-tolerated of the first-line drugs. Its main toxicity is optic neuritis, which is more common at higher doses (eg, 25 mg/kg) and in patients with impaired renal function. Patients with optic neuritis present initially with an inability to distinguish blue from green, followed by impairment of visual acuity. Because both symptoms are reversible if detected early, patients should have a baseline test of visual acuity and color vision and should be questioned monthly regarding their vision. Patients taking EMB for > 2 months or at doses higher than those listed in the <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"bfcd24ba-a4ff-4757-81de-32bb9b0aa521","Title":"Dosing%20of%20Oral%20First-Line%20Anti-TB%20Drugs%2A","ShareUrlTitle":"dosing-of-oral-first-line-anti-tb-drugs","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1010853","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3Etable%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span> should have monthly visual acuity and color vision testing. Caution is warranted if communication is limited by language and cultural barriers. For similar reasons, EMB is usually avoided in young children who cannot read eye charts but can be used if needed because of drug resistance or drug intolerance. Another drug is substituted for EMB if optic neuritis occurs. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ethambutol</span> can be used safely during pregnancy. Resistance to EMB is less common than to the other first-line drugs. </p></div> <span id="v1010845"></span> <div data-mmanualobjecttype="illustrativeMaterial" class="inlinebox--full inlinebox--table inlinebox--clickable illustrativeMaterialTable "> <div class="inlinebox__wrapper" id="v1010855"> <div class="inlinebox__header">Table</div> <div class="inlinebox__content"> <div class="multimedia__link" data-bind="component: { name: 'multimedia-link-text', params: $data }" data-popup-model='{"ItemId":"bfcd24ba-a4ff-4757-81de-32bb9b0aa521","Title":"Dosing%20of%20Oral%20First-Line%20Anti-TB%20Drugs%2A","ShareUrlTitle":"dosing-of-oral-first-line-anti-tb-drugs","Description":"","ImageUrl":null,"ThumbnailUrl":"./Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1010853","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"","LinkText":"Dosing%20of%20Oral%20First-Line%20Anti-TB%20Drugs%2A","CssClass":null,"LoadLocations":false,"ShowTooltip":false,"SingleItem":true,"ExcludeFromBrand":null,"ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":true,"Target":null,"Url":null,"HideMainArrows":false}'> </div> <div class="inlinebox__button"> <img src="./Content/Images/Redesign/table/icon_table_red.png" alt="" loading="lazy" width="55" height="42"> </div> <div class="inlinebox__content--print" id="bfcd24ba-a4ff-4757-81de-32bb9b0aa521"> </div> </div> </div> <!-- Type: Table --> </div> <script type="text/javascript"> $(document).ready(function () { var url = window.location; if (url.search.includes("media=print")) { $.ajax({ url: '/Redesign/Topic/GetTableBody', type: "GET", dataType: "json", data: { tableId: 'bfcd24ba-a4ff-4757-81de-32bb9b0aa521' }, async: true, success: function (data) { $('#bfcd24ba-a4ff-4757-81de-32bb9b0aa521').html('<div class="modaldialog">'+ data.TableBody + '</div>'); }, error: function (jqxhr, textStatus, errorThrown) { console.error(errorThrown); } }); } }); </script> </div> </section> <section id="v1011140" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1010799_v1011141" class="topic__header--subsection"> <span id="v1011141" class="anchor"></span> Second-line drugs for TB </h3> <div class="topic__content"> <span id="v1011143" class="anchor"></span><div class="para"> <p>Other antibiotics are active against TB and are used primarily when patients have drug-resistant TB (DR-TB) or do not tolerate one of the first-line drugs. Until 2016, the 2 most important classes were the aminoglycosides and the closely related polypeptide drug, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>capreomycin</span> (injectable only), and the fluoroquinolones.</p></div><span id="v1011144" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Streptomycin</span>,</b> the first and once the most commonly used injectable, is now uncommonly used and is increasingly difficult to obtain because of its replacement by newer injectable and oral second-line drugs. It is very effective and bactericidal. Resistance is still relatively uncommon in the US but is more common globally. CSF penetration is poor, and intrathecal administration should not be used if other effective drugs are available. </p></div><span id="v1435212" class="anchor"></span><div class="para"> <p>Dose-related adverse effects of <span class="genericDrug" data-showrollover="false">streptomycin</span> include renal tubular damage, vestibular damage, and ototoxicity. The dose is about 15 mg/kg IM. The maximum is usually 1 g for adults, reduced to 0.75 g (10 mg/kg) for those <span class='symbol'>≥</span> 60 years. To limit dose-related adverse effects, clinicians give the drug only 5 days/week for up to 2 months. Then it may be given twice/week for another 2 months if necessary. In patients with renal insufficiency, dosing frequency should be reduced (eg, 12 to 15 mg/kg/dose 2 or 3 times/week). Patients should be monitored with appropriate testing of balance, hearing, and serum creatinine levels. </p></div><span id="v38408860" class="anchor"></span><div class="para"> <p>Adverse effects of <span class="genericDrug" data-showrollover="false">streptomycin</span> include rash, fever, agranulocytosis, and serum sickness. Flushing and tingling around the mouth commonly accompany injection but subside quickly. <span class="genericDrug" data-showrollover="false">Streptomycin</span> is contraindicated during pregnancy because it may cause vestibular toxicity and ototoxicity in the fetus.</p></div><span id="v1011146" class="anchor"></span><div class="para"> <p><b>Kanamycin</b> and <b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amikacin</span></b> may remain effective even if <span class="genericDrug" data-showrollover="false">streptomycin</span> resistance has developed. Their renal and neural toxicities are similar to those of <span class="genericDrug" data-showrollover="false">streptomycin</span>. <span class="genericDrug" data-showrollover="false">Kanamycin</span> has been a widely used injectable for MDR-TB, but <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amikacin</span> is rapidly replacing it in the increasingly uncommon situations in which injectables are needed.</p></div><span id="v1435214" class="anchor"></span><div class="para"> <p><b><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Capreomycin</span>,</b> a related nonaminoglycoside parenteral bactericidal drug, has dosage, effectiveness, and adverse effects similar to those of aminoglycosides. It was an important drug for MDR-TB because isolates resistant to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>streptomycin</span> are often susceptible to <span class="genericDrug" data-showrollover="false">capreomycin</span>, and it is somewhat better-tolerated than aminoglycosides when prolonged administration is required. Like all injectables, it is painful to administer and less well tolerated than the newer, oral, drug-resistant regimens, which are now typically preferred.</p></div><span id="v1011150" class="anchor"></span><div class="para"> <p>Some <b>fluoroquinolones</b> (<span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>levofloxacin</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span>) are the most active and safest TB drugs after <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>; however, until the introduction of the new 4-month regimen containing <span class="genericDrug" data-showrollover="false">moxifloxacin</span>, fluoroquinolones were not first-line drugs for TB susceptible to <span class="genericDrug" data-showrollover="false">isoniazid</span> and <span class="genericDrug" data-showrollover="false">rifampin</span>. <span class="genericDrug" data-showrollover="false">Moxifloxacin</span> appears to be as active as <span class="genericDrug" data-showrollover="false">isoniazid</span> when used with <span class="genericDrug" data-showrollover="false">rifampin</span> or <span class="genericDrug" data-showrollover="false">rifapentine</span>.</p></div><span id="v1011153" class="anchor"></span><div class="para"> <p><b>Other second-line drugs</b> include <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ethionamide</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>cycloserine</span>, and para-aminosalicylic acid (PAS). These drugs are less effective and more toxic than other anti-TB drugs but were essential until the advent of all-oral regimens (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v11555485" data-toggle="tooltip" title="Drug resistance" data-id="e4dbfd16-1c18-4356-b6a6-700e73b32c01" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">see below</a><span id="e4dbfd16-1c18-4356-b6a6-700e73b32c01" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v11555485"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug resistance </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Drug resistance" loading="lazy"> </span> </a> </span> </span>).</p></div><span id="v11555477" class="anchor"></span><div class="para"> <p><b>Newer anti-TB drugs</b> include <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bedaquiline</span>, delamanid, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pretomanid</span>, and sutezolid. These had been reserved for highly resistant TB or for patients who cannot tolerate other second-line drugs but are increasingly being used in the all-oral drug-resistant regimens. </p></div> </div> </section> <section id="v1011157" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1010799_v1011158" class="topic__header--subsection"> <span id="v1011158" class="anchor"></span> Drug resistance </h3> <div class="topic__content"> <span id="v1011160" class="anchor"></span><div class="para"> <p>Drug resistance is a major concern. It develops through spontaneous genetic mutation. Incomplete, erratic, or single drug therapy and poor adherence select for these resistant organisms. Once a drug-resistant strain has developed and proliferated, it may acquire resistance to additional drugs through subsequent mutations. In this way, the organism can become resistant to multiple antibiotics in steps, a process that can occur rapidly even though plasmid transfer among mycobacteria does not play a role. </p></div><span id="v68425507" class="anchor"></span><div class="para"> <p>However, in any given patient, the most common reason for drug-resistant TB (DR-TB) is acquisition by person-to-person transmission, often from unsuspected, undiagnosed, or inadequately treated people with DR-TB. Globally, only one third of people with MDR-TB have access to effective treatment. In areas where resistance testing is inadequate or unavailable, many patients who do not respond to first-line therapy probably have unrecognized MDR-TB and are contagious to others, including reinfection of people with drug-susceptible TB. The use of rapid molecular testing for TB and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> resistance has been shown to reduce the propagation of DR-TB. </p></div><span id="v68425508" class="anchor"></span><div class="para"> <p>Drug-resistance categories are defined based on the antibiotics to which an organism is resistant. In January 2021, the WHO revised its definition of XDR-TB and formally defined pre-XDR-TB (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542" data-toggle="tooltip" title="Treatment references" data-id="44c10771-06d5-4e2b-a08b-556dd59befa1" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">4</a><span id="44c10771-06d5-4e2b-a08b-556dd59befa1" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment references" loading="lazy"> </span> </a> </span> </span>). In the US in January 2022, the CDC recommended hybrid definitions, allowing use of the WHO definitions or alternatives appropriate in the US: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v68425512" class="anchor"></span><div class="para"> <p><b>Multidrug-resistant TB (MDR-TB):</b> Resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>, the two most effective first-line drugs, with or without resistance to other drugs</p></div></li><li class="topic__listitem"><span id="v68425514" class="anchor"></span><div class="para"> <p><b>Pre-XDR-TB:</b> Resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> and also any fluoroquinolone; CDC alternative definition: Resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>, and a second-line injectable (<span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>amikacin</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>capreomycin</span>, and kanamycin)</p></div></li><li class="topic__listitem"><span id="v68425516" class="anchor"></span><div class="para"> <p><b>Extensively drug-resistant tuberculosis (XDR-TB):</b> Resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span>, rifampicin, any fluoroquinolone, and at least one additional group A drug (The group A drugs are <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>levofloxacin</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bedaquiline</span>, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>linezolid</span>. They are the most potent of the second-line drugs used for drug-resistant TB and require longer treatment regimens.); CDC alternative definition: Resistance to <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>, any fluoroquinolone, and either <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bedaquiline</span> or <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>linezolid</span> (or both)</p></div></li></ul></div><span id="v68425517" class="anchor"></span><div class="para"> <p>The diagnosis of MDR-TB and consequent need to use second-line drugs has great significance in terms of length, cost, and success of treatment. However, the new, shorter, all-oral DR-TB regimens have made treatment less difficult and rendered those issues less of a dividing line between clinical success and failure. </p></div><span id="v68425518" class="anchor"></span><div class="para"> <p>Numerous outbreaks of MDR-TB have been reported, and the global burden remains high, in part because of diagnostic and treatment limitations; in 2020, about 71% of bacteriologically proven cases had access to testing for <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> resistance (a surrogate for identifying MDR-TB), an improvement from the 61% reported in 2019. In 2020, the WHO reported 157,903 new cases of MDR-TB worldwide, but this was only 38% of the estimated total number of cases (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542" data-toggle="tooltip" title="Treatment references" data-id="daa4d289-7631-463d-b946-773455241789" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">3</a><span id="daa4d289-7631-463d-b946-773455241789" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment references" loading="lazy"> </span> </a> </span> </span>). The WHO estimates that only about 1 in 3 people who develop MDR/RR-TB each year are enrolled in treatment (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542" data-toggle="tooltip" title="Treatment references" data-id="67524405-0007-47a2-88bc-8460afc3862a" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">3</a><span id="67524405-0007-47a2-88bc-8460afc3862a" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment references" loading="lazy"> </span> </a> </span> </span>).</p></div><span id="v11555485" class="anchor"></span><div class="para"> <p>The new anti-TB drugs <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bedaquiline</span>, delamanid, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pretomanid</span> and the fluoroquinolone <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span> are oral drugs highly active against drug-resistant strains using shorter treatment duration than other regimens. They rapidly stop transmission and have higher rates of completion and cure and thus are likely to help control the epidemic of DR-TB. However, success will continue to depend on strong global commitments to provide access to molecular diagnostics and effective treatment as well as full treatment supervision. In 2020, 65 countries were using shorter, oral regimens for DR-TB. </p></div><span id="v68425521" class="anchor"></span><div class="para"> <p>The cost to patients of DR-TB and its treatment is estimated to be catastrophic in as high as 49% of cases.</p></div> </div> </section> <section id="v1011165" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Treatment_v1010799_v1011166" class="topic__header--subsection"> <span itemprop="name" id="v1011166" class="anchor"></span> Treatment regimens </h3> <div class="topic__content"> <span id="v1011167" class="anchor"></span><div class="para"> <p>Until the introduction of the new, 4-month regimen, treatment of all patients with new, previously untreated TB had consisted of the following: </p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1011170" class="anchor"></span><div class="para"> <p>2-month initial intensive phase</p></div></li><li class="topic__listitem"><span id="v1011172" class="anchor"></span><div class="para"> <p>4- to 7-month continuation phase</p></div></li></ul></div><span id="v1011173" class="anchor"></span><div class="para"> <p><b>Initial intensive–phase therapy</b> is with 4 antibiotics (see <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010855" data-toggle="tooltip" title="Dosing of Oral First-Line Anti-TB Drugs*" data-id="3aac1ac0-8db5-4c84-89fa-6abce9cb248c" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">table</a><span id="3aac1ac0-8db5-4c84-89fa-6abce9cb248c" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010855"> <span class="tooltip-content"> <span class="tooltip-heading"> Dosing of Oral First-Line Anti-TB Drugs* </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="./Content/Images/Redesign/table/icon_table_red.png?mh=160&mw=160" class="tooltip-Preview" alt="Dosing of Oral First-Line Anti-TB Drugs*" loading="lazy"> </span> </a> </span> </span> for dosing):</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408864" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isoniazid</span> (INH)</p></div></li><li class="topic__listitem"><span id="v38408866" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifampin</span> (RIF)</p></div></li><li class="topic__listitem"><span id="v38408868" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Pyrazinamide</span> (PZA)</p></div></li><li class="topic__listitem"><span id="v38408870" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ethambutol</span> (EMB)</p></div></li></ul></div><span id="v38408872" class="anchor"></span><div class="para"> <p>These drugs can be given daily throughout this 2-month phase or daily for 2 weeks, followed by doses 2 or 3 times/week for 6 weeks. Intermittent administration (usually with higher doses) is usually satisfactory because of the slow growth of tubercle bacilli and the residual postantibiotic effect on growth (bacterial growth is often delayed well after antibiotics are below the minimal inhibitory concentration). However, daily therapy is recommended for patients with MDR-TB or HIV coinfection. Regimens involving less than daily dosing must be carried out as directly observed therapy (DOT) because each dose becomes more important. </p></div><span id="v1011175" class="anchor"></span><div class="para"> <p>After 2 months of intensive 4-drug treatment, PZA and usually EMB are stopped, depending on the drug susceptibility pattern of the original isolate.</p></div><span id="v1011176" class="anchor"></span><div class="para"> <p><b>Continuation-phase treatment</b> depends on</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408875" class="anchor"></span><div class="para"> <p>Results of drug susceptibility testing of initial isolates (where available)</p></div></li><li class="topic__listitem"><span id="v38408877" class="anchor"></span><div class="para"> <p>The presence or absence of a cavitary lesion on the initial chest x-ray</p></div></li><li class="topic__listitem"><span id="v38408879" class="anchor"></span><div class="para"> <p>Results of cultures and smears taken at 2 months</p></div></li></ul></div><span id="v38408880" class="anchor"></span><div class="para"> <p>If positive, 2-month cultures indicate the need for a longer course of treatment.</p></div><span id="v38408881" class="anchor"></span><div class="para"> <p>If both culture and smear are negative, regardless of the chest x-ray, or if the culture or smear is positive but x-ray showed no cavitation, INH and RIF are continued for 4 more months (6 months total).</p></div><span id="v38408882" class="anchor"></span><div class="para"> <p>If the x-ray showed cavitation and the culture or smear is positive, INH and RIF are continued for 7 more months (9 months total).</p></div><span id="v38408883" class="anchor"></span><div class="para"> <p>In either regimen, EMB is usually stopped if the initial culture shows no resistance to any drug. Continuation-phase drugs can be given daily or, if patients are not HIV-positive, 2 or 3 times/week. Patients who have negative culture and smears at 2 months and no cavitation on chest x-ray and who are HIV-negative may receive INH plus <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span> once/week.</p></div><span id="v38408884" class="anchor"></span><div class="para"> <p>Patients who have positive cultures after 2 months of treatment should be evaluated to determine the cause. Evaluation for MDR-TB, a common cause, should be thorough. Clinicians should also check for other common causes (eg, nonadherence, extensive cavitary disease, drug resistance, malabsorption of drugs).</p></div><span id="v1011177" class="anchor"></span><div class="para"> <p>For both initial and continuation phases, the total number of doses (calculated by doses/week times number of weeks) should be given; thus if any doses are missed, treatment is extended and not stopped at the end of the time period.</p></div><span id="v68425523" class="anchor"></span><div class="para"> <p>A <b>new 4-month regimen</b> was described in a clinical trial published in 2021, which reported that a 4-month TB treatment regimen that included <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span> 1200 mg orally once/day and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span> 400 mg orally once/day (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542" data-toggle="tooltip" title="Treatment references" data-id="73d8e196-ff95-482e-941b-009e1a5c6eff" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">1</a><span id="73d8e196-ff95-482e-941b-009e1a5c6eff" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment references" loading="lazy"> </span> </a> </span> </span>, <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542" data-toggle="tooltip" title="Treatment references" data-id="db66f9e2-b663-49cb-9f4c-188c5aee4861" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">2</a><span id="db66f9e2-b663-49cb-9f4c-188c5aee4861" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment references" loading="lazy"> </span> </a> </span> </span>) was noninferior to the standard 6-month regimen of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pyrazinamide</span>, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>ethambutol</span>. There were no differences in serious adverse reactions between the 4- and 6-month regimens. </p></div><span id="v68425526" class="anchor"></span><div class="para"> <p>Considerations before using the shorter <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span>–<span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span> regimen include the following:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v68425529" class="anchor"></span><div class="para"> <p>Testing should show susceptibility to fluoroquinolones, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span>, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span>.</p></div></li><li class="topic__listitem"><span id="v68425531" class="anchor"></span><div class="para"> <p>High-fat foods increase gut absorption of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span>.</p></div></li><li class="topic__listitem"><span id="v68425533" class="anchor"></span><div class="para"> <p>The <span class="genericDrug" data-showrollover="false">rifapentine</span>–<span class="genericDrug" data-showrollover="false">moxifloxacin</span> regimen may be more expensive in the short term than the standard 6-month regimen.</p></div></li></ul></div><span id="v68425536" class="anchor"></span><div class="para"> <p>Because of the cost of the 4-month regimen, it is likely that many public health programs will continue to use the standard 6-month regimen for most cases and reserve the 4-month regimen option for uncomplicated cases where adherence to the 6-month regimen is problematic (eg, when a patient must travel before the 6 months can be completed).</p></div><span id="v1011178" class="anchor"></span><div class="para"> <p><b>Management of drug-resistant TB (DR-TB)</b> had until recently varied with the pattern of drug resistance, was long (18 to 24 months) and arduous for patients because of prolonged injections and severe adverse effects, and was expensive to administer, especially when prolonged hospitalization was required. More so than drug-susceptible TB, DR-TB requires management by specialists in treatment centers with adequate support systems in place. However, the results of recent trials of all-oral regimens for DR-TB using novel drugs is changing the success rate, tolerability, and cost of treating DR-TB. A three-drug regimen consisting of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>bedaquiline</span>, <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>pretomanid</span>, and <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>linezolid</span> (known as the BPaL regimen) had favorable outcomes in an uncontrolled clinical trial of 109 people with extensively drug-resistant TB (XDR-TB) as well as treatment-intolerant or nonresponsive multidrug-resistant TB. In this trial, 90% of patients had a favorable outcome, whereas outcomes for patients with XDR-TB were historically less than 50% favorable, and often much worse when comorbidities were present (<a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542" data-toggle="tooltip" title="Treatment references" data-id="ca7b325c-491a-4cd2-b253-f357de25ad77" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">6</a><span id="ca7b325c-491a-4cd2-b253-f357de25ad77" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v68425542"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment references </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment references" loading="lazy"> </span> </a> </span> </span>). Drug toxicity of <span class="genericDrug" data-showrollover="false">linezolid</span> was the major limitation of the trial, but subsequent trials are testing lower doses of <span class="genericDrug" data-showrollover="false">linezolid</span> and other variations of all-oral regimens for highly DR-TB. The evolution of all-oral, shorter, better tolerated regimens for highly DR-TB is a landmark in global TB control, but a major commitment from countries to diagnose and effectively treat such cases and prevent their spread is still required.</p></div> </div> </section> <section id="v1011180" class="topic__section GHead"> <span></span> <h3 id="Treatment_v1010799_v1011181" class="topic__header--subsection"> <span id="v1011181" class="anchor"></span> Other treatments </h3> <div class="topic__content"> <span id="v1011182" class="anchor"></span><div class="para"> <p><b>Surgical resection</b> of a persistent TB cavity or a region of necrotic lung tissue is occasionally necessary. The main indication for resection is persistent, culture-positive MDR-TB or XDR-TB in patients with a region of necrotic lung tissue into which antibiotics cannot penetrate. Other indications include uncontrollable hemoptysis and bronchial stenosis.</p></div><span id="v68425540" class="anchor"></span><div class="para"> <p>Surgery is not widely available in high-burden areas. But with increasing access to rapid molecular testing for drug resistance and shorter, better-tolerated drug resistance treatment, the numbers of chronic drug-resistant patients with lung destruction requiring surgery is likely to eventually decrease. In the meantime, access to surgeons skilled in TB surgery often means the difference between treatment success and failure in patients who have advanced cases with severe lung destruction. Even with bacteriologic cure, the long-term adverse effects of surgery on cardiorespiratory function require further research. </p></div><span id="v1011183" class="anchor"></span><div class="para"> <p><b>Corticosteroids</b> are sometimes used to treat TB when inflammation is a major cause of morbidity and are indicated for patients with acute respiratory distress syndrome or closed-space infections, such as meningitis and pericarditis. <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Dexamethasone</span> 12 mg orally or IV every 6 hours is given to adults and children <span class='symbol'>></span> 25 kg; children <span class='symbol'>&lt</span> 25 kg are given 8 mg. Treatment is continued for 2 to 3 weeks. Corticosteroids that are needed for other indications pose no danger to patients who have active TB and who are receiving an effective TB regimen.</p></div> </div> </section> <section id="v68425541" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Treatment_v1010799_v68425542" class="topic__header--subsection"> <span itemprop="name" id="v68425542" class="anchor"></span> Treatment references </h3> <div class="topic__content"> <div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v68425545" class="anchor"></span><div class="para"> <p>1. <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282329/">Dorman SE, Nahid P, Kurbatova EV, et al</a>: Four-month <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span> regimens with or without <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span> for tuberculosis. <i>N Engl J Med</i> 384(18):1705–1718, 2021. doi: 10.1056/NEJMoa2033400</p></div></li><li class="topic__listitem"><span id="v68425548" class="anchor"></span><div class="para"> <p>2. <a rel="nofollow" target="_blank" href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7108a1.htm?s_cid=mm7108a1_w">Carr W, Kurbatova E, Starks A, et al</a>: Interim guidance: 4-Month <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span>-<span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>moxifloxacin</span> regimen for the treatment of drug-susceptible pulmonary tuberculosis—United States, 2022. <i>MMWR Morb Mortal Wkly Rep</i> 71(8):285–289, 2022. doi: 10.15585/mmwr.mm7108a1</p></div></li><li class="topic__listitem"><span id="v68425551" class="anchor"></span><div class="para"> <p>3. <a rel="nofollow" target="_blank" href="https://www.who.int/publications/i/item/9789240037021">World Health Organization (WHO)</a>: Global Tuberculosis Report 2021. Accessed on 4/29/2022.</p></div></li><li class="topic__listitem"><span id="v68425554" class="anchor"></span><div class="para"> <p>4. <a rel="nofollow" target="_blank" href="https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis">WHO</a>: WHO announces updated definitions of extensively drug-resistant tuberculosis. Accessed 4/29/2022.</p></div></li><li class="topic__listitem"><span id="v68425557" class="anchor"></span><div class="para"> <p>5. <a rel="nofollow" target="_blank" href="https://www.cdc.gov/tb/publications/letters/2022/surv-def-xdr.html">Centers for Disease Control and Prevention (CDC)</a>: Surveillance definitions for extensively drug resistant (XDR) and pre-XDR tuberculosis. Accessed 4/29/2022.</p></div></li><li class="topic__listitem"><span id="v68425560" class="anchor"></span><div class="para"> <p>6. <a rel="nofollow" target="_blank" href="https://pubmed.ncbi.nlm.nih.gov/32130813/">Conradie F, Diacon AH, Ngubane N, et al</a>: Treatment of highly drug-resistant pulmonary tuberculosis. <i>N Engl J Med</i> 382(10):893–902, 2022. doi: 10.1056/NEJMoa1901814</p></div></li></ul></div> </div> </section> </div> </section> <section id="v1011185" class="topic__section FHead" itemprop="associatedAnatomy" itemscope="" itemtype="http://schema.org/AnatomicalStructure"> <h2 id="Other_v1011186" class="topic__header--section"> <span id="v1011186" class="anchor"></span> Screening for TB </h2> <div class="topic__content"> <span id="v1011188" class="anchor"></span><div class="para"> <p>Screening for latent tuberculosis infection (LTBI) is done with a <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775" data-toggle="tooltip" title="Skin testing" data-id="c041def0-d909-4ea2-8981-c35e8bdade54" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">tuberculin skin test (TST)</a><span id="c041def0-d909-4ea2-8981-c35e8bdade54" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775"> <span class="tooltip-content"> <span class="tooltip-heading"> Skin testing </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Skin testing" loading="lazy"> </span> </a> </span> </span> or <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792" data-toggle="tooltip" title="IGRA (interferon-gamma release assay)" data-id="1e7b9369-7afe-4e16-8d69-7195e36fac00" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">interferon-gamma release assay (IGRA)</a><span id="1e7b9369-7afe-4e16-8d69-7195e36fac00" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010792"> <span class="tooltip-content"> <span class="tooltip-heading"> IGRA (interferon-gamma release assay) </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="IGRA (interferon-gamma release assay)" loading="lazy"> </span> </a> </span> </span>. Indications for screening include</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1011191" class="anchor"></span><div class="para"> <p>Close contact with a person who has active pulmonary TB</p></div></li><li class="topic__listitem"><span id="v1011193" class="anchor"></span><div class="para"> <p>Chest x-ray evidence of past TB infection</p></div></li><li class="topic__listitem"><span id="v1011195" class="anchor"></span><div class="para"> <p>Risk factors for exposure to TB (eg, people who have immigrated within 5 years from high-risk areas, indigent patients, IV drug users, selected health care practitioners such as respiratory therapists and practitioners working with high-risk populations)</p></div></li><li class="topic__listitem"><span id="v1011197" class="anchor"></span><div class="para"> <p>Risk factors for development of active TB (eg, HIV infection or other impaired immunity, gastrectomy, jejunoileal bypass surgery, silicosis, renal insufficiency, diabetes, head or neck cancer, age <span class='symbol'>></span> 70 years)</p></div></li><li class="topic__listitem"><span id="v1011199" class="anchor"></span><div class="para"> <p>Therapeutic immunosuppression with corticosteroids, tumor necrosis factor (TNF) inhibitors, or cancer chemotherapy</p></div></li></ul></div><span id="v1011200" class="anchor"></span><div class="para"> <p>In the US, most children and other people without specific TB risk factors should not be tested to minimize the number of false-positive results.</p></div><span id="v1011201" class="anchor"></span><div class="para"> <p>A positive TST or IGRA result (see <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775" data-toggle="tooltip" title="Skin testing" data-id="1968ee6b-09c4-4625-a20b-91db15039fa8" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">Skin testing</a><span id="1968ee6b-09c4-4625-a20b-91db15039fa8" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010775"> <span class="tooltip-content"> <span class="tooltip-heading"> Skin testing </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Skin testing" loading="lazy"> </span> </a> </span> </span> for criteria) suggests latent TB infection (LTBI). Patients with a positive TST or IGRA result are evaluated for other clinical and epidemiologic risk factors and have a chest x-ray. Those with x-ray abnormalities suggesting TB require <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010744" data-toggle="tooltip" title="Diagnosis" data-id="7c688000-7886-40f4-942d-f162d0ab5a6d" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">evaluation for active TB as above</a><span id="7c688000-7886-40f4-942d-f162d0ab5a6d" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010744"> <span class="tooltip-content"> <span class="tooltip-heading"> Diagnosis </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Diagnosis" loading="lazy"> </span> </a> </span> </span>, including sputum examination by microscopy and culture.</p></div><span id="v38408887" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://www.cdc.gov/tb/topic/testing/whobetested.htm">Updated guidelines for testing of LTBI</a> are available from the CDC.</p></div> <section id="v1011205" class="topic__section GHead"> <span></span> <h3 id="Other_v1011186_v1011206" class="topic__header--subsection"> <span id="v1011206" class="anchor"></span> Booster reaction </h3> <div class="topic__content"> <span id="v1011207" class="anchor"></span><div class="para"> <p>Some patients with remote TB exposure, BCG vaccination, or infection with nontuberculous mycobacteria may have a negative TST or IGRA result; however, the TST itself may serve as an immune booster so that a subsequent test done as little as 1 week or as much as several years later may be positive (booster reaction). Thus, in people who are tested regularly (eg, health care workers), the second routine test will be positive, giving the false appearance of <i>recent</i> infection (and hence mandating further testing and treatment). If recurrent testing for LTBI is indicated, a second TST should be done (on the opposite forearm) 1 to 4 weeks after the first to identify a booster reaction (because conversion due to infection during that brief interval is highly unlikely). Subsequent TST is done and interpreted normally.</p></div><span id="v1011208" class="anchor"></span><div class="para"> <p>The new IGRAs for LTBI do not involve injection of antigens and thus do not cause boosting. They also are not influenced by preexisting hypersensitivity from BCG vaccination or infection with environmental mycobacteria other than <i>M. kansasii</i>, <i>M. szulgai</i>, and <i>M. marinum</i>.</p></div> </div> </section> <section id="v1011212" class="topic__section GHead"> <span itemscope="" itemtype="http://schema.org/MedicalTherapy"></span> <h3 id="Other_v1011186_v1011213" class="topic__header--subsection"> <span itemprop="name" id="v1011213" class="anchor"></span> Treatment of LTBI </h3> <div class="topic__content"> <span id="v1011214" class="anchor"></span><div class="para"> <p>Treatment of latent tuberculosis infection is indicated principally for</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1011217" class="anchor"></span><div class="para"> <p>People whose TST converted from negative to positive within the previous 2 years</p></div></li><li class="topic__listitem"><span id="v1011219" class="anchor"></span><div class="para"> <p>People with x-ray changes consistent with old TB but no evidence of active TB</p></div></li></ul></div><span id="v1228324" class="anchor"></span><div class="para"> <p>Other indications for preventive treatment include</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v1011222" class="anchor"></span><div class="para"> <p>People who, if infected, are at high risk of developing active TB (eg, people with HIV infection, people with drug-induced immunosuppression)</p></div></li><li class="topic__listitem"><span id="v1011224" class="anchor"></span><div class="para"> <p>Any child <span class='symbol'>&lt</span> 5 years old who is a close contact of a person with smear-positive TB, regardless of whether there was TST conversion</p></div></li></ul></div><span id="v1011225" class="anchor"></span><div class="para"> <p>Other people with an incidentally positive TST or IGRA result but without these risk factors are often treated for LTBI, but physicians should balance individual risks of drug toxicity against the benefits of treatment.</p></div><span id="v1011226" class="anchor"></span><div class="para"> <p>Treatment generally consists of <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>isoniazid</span> (INH) unless resistance is suspected (eg, in exposure to a known INH-resistant case). The dose is 300 mg once/day for 9 months for most adults and 10 mg/kg for 9 months for children. An alternative for patients resistant to or intolerant of INH is <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifampin</span> (RIF) 600 mg once/day for 4 months. INH plus <span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>rifapentine</span> taken once/week for 3 months is also effective.</p></div><span id="v68425565" class="anchor"></span><div class="para"> <p><a rel="nofollow" target="_blank" href="https://www.cdc.gov/tb/topic/treatment/ltbi.htm">Current guidelines for treatment of LTBI</a> are available from the CDC.</p></div><span id="v1011227" class="anchor"></span><div class="para"> <p>The main limitations of treatment of LTBI are</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408891" class="anchor"></span><div class="para"> <p>Hepatotoxicity</p></div></li><li class="topic__listitem"><span id="v38408893" class="anchor"></span><div class="para"> <p>Poor adherence</p></div></li></ul></div><span id="v38408894" class="anchor"></span><div class="para"> <p>When used for LTBI, INH causes clinical hepatitis in 1/1000 cases; hepatitis usually reverses if INH is stopped promptly. Patients being treated for LTBI should be instructed to stop the drug if they have any new symptoms, especially unexplained fatigue, loss of appetite, or nausea. Hepatitis due to RIF is less common than with INH, but drug interactions are frequent.</p></div><span id="v38408895" class="anchor"></span><div class="para"> <p>Only about 50% of patients complete the recommended 9-month course of INH. Adherence is better with 4 months of RIF. Monthly visits to monitor symptoms and to encourage treatment completion are standard good clinical and public health practice.</p></div> </div> </section> </div> </section> <section id="v1011229" class="topic__section FHead" itemprop="primaryPrevention" itemscope="" itemtype="http://schema.org/MedicalTherapy"> <h2 id="Prevention_v1011230" class="topic__header--section" data-originaltitle="Prevention"> <span id="v1011230" class="anchor"></span> Prevention of TB </h2> <div class="topic__content"> <span id="v1011232" class="anchor"></span><div class="para"> <p> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010799" data-toggle="tooltip" title="Treatment" data-id="9953068e-bbe1-46f8-8453-920b570b36e0" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">General preventive measures</a><span id="9953068e-bbe1-46f8-8453-920b570b36e0" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1010799"> <span class="tooltip-content"> <span class="tooltip-heading"> Treatment </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Treatment" loading="lazy"> </span> </a> </span> </span> (eg, staying at home, avoiding visitors, covering coughs with a tissue or hand) are followed. </p></div> <section id="v1011234" class="topic__section GHead"> <span></span> <h3 id="Prevention_v1011230_v1011235" class="topic__header--subsection"> <span id="v1011235" class="anchor"></span> Vaccination </h3> <div class="topic__content"> <span id="v1011239" class="anchor"></span><div class="para"> <p>The <b>BCG vaccine,</b> made from an attenuated strain of <i>M. bovis</i> is given to <span class='symbol'>></span> 80% of the world’s children, primarily in high-burden countries. Overall average efficacy is probably only 50%, but BCG clearly reduces the rate of extrathoracic TB in children, especially TB meningitis, and may prevent TB infection. Thus, it is considered worthwhile in high-burden regions. Immunization with BCG has few indications in the US, except unavoidable exposure of a child to an infectious TB case that cannot be effectively treated (ie, <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011158" data-toggle="tooltip" title="Drug resistance" data-id="c574b7d6-69fa-4307-9c10-c5e58af89dbb" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">pre-XDR</a><span id="c574b7d6-69fa-4307-9c10-c5e58af89dbb" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011158"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug resistance </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Drug resistance" loading="lazy"> </span> </a> </span> </span> or <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011158" data-toggle="tooltip" title="Drug resistance" data-id="4e6db8fe-b7bc-4a73-98e8-c79ff85e7693" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">XDR-TB</a><span id="4e6db8fe-b7bc-4a73-98e8-c79ff85e7693" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011158"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug resistance </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Drug resistance" loading="lazy"> </span> </a> </span> </span>) and possibly previously uninfected health care workers exposed to <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011158" data-toggle="tooltip" title="Drug resistance" data-id="a4334311-bb39-412a-8126-a8a4f4a1bba5" data-itemid="1fef1f26-c9f6-41ef-8c18-cb7450e146e0">MDR-TB</a><span id="a4334311-bb39-412a-8126-a8a4f4a1bba5" class="d-none xref"> <span class="tooltip-container"> <a href="./{1FEF1F26-C9F6-41EF-8C18-CB7450E146E0}.html#v1011158"> <span class="tooltip-content"> <span class="tooltip-heading"> Drug resistance </span> Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/m/2/7/m2700245-tuberculosis-chest-x-ray-science-photo-library-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Drug resistance" loading="lazy"> </span> </a> </span> </span> or XDR-TB on a regular basis. </p></div><span id="v11555487" class="anchor"></span><div class="para"> <p>Although BCG vaccination often converts the TST, the reaction is usually smaller than the response to natural TB infection, and it usually wanes more quickly. The TST reaction due to BCG is rarely <span class='symbol'>></span> 15 mm, and 15 years after BCG administration, it is rarely <span class='symbol'>></span> 10 mm. The CDC recommends that all TST reactions in children who have had BCG be attributed to TB infection (and treated accordingly) because untreated latent infection can have serious complications. IGRAs are not influenced by BCG vaccination and should ideally be used in patients who have received BCG to be sure that the TST response is due to infection with <i>M. tuberculosis</i>.</p></div> </div> </section> </div> </section> <section id="v1011242" class="topic__section FHead" itemprop="associatedAnatomy" itemscope="" itemtype="http://schema.org/AnatomicalStructure"> <h2 id="Other_v1011243" class="topic__header--section"> <span id="v1011243" class="anchor"></span> Special Populations </h2> <div class="topic__content"> <section id="v1011244" class="topic__section GHead"> <span></span> <h3 id="Other_v1011243_v1011245" class="topic__header--subsection"> <span id="v1011245" class="anchor"></span> Children </h3> <div class="topic__content"> <span id="v1011249" class="anchor"></span><div class="para"> <p>Children infected with tuberculosis are more likely than adults to develop active disease, which commonly manifests as extrapulmonary disease. Lymphadenitis (scrofula) is the most common extrapulmonary manifestation, but TB may also affect the vertebrae (<a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html#v11555572" data-toggle="tooltip" title="Tuberculosis of bones and joints" data-id="80cfee15-900d-48bd-85cf-b34d10e6d39d" data-itemid="5db9fccd-8e55-41d4-844a-c3552b8447ac">Pott disease</a><span id="80cfee15-900d-48bd-85cf-b34d10e6d39d" class="d-none xref"> <span class="tooltip-container"> <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html#v11555572"> <span class="tooltip-content"> <span class="tooltip-heading"> Tuberculosis of bones and joints </span> <span class="tooltip-readmore"> </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/4/8/4/484-cutaneous-tuberculosis-scrofuloderma-slide-20-springer-high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Tuberculosis of bones and joints" loading="lazy"> </span> </a> </span> </span>), the highly vascular epiphyses of long bones, or the central nervous system and meninges.</p></div><span id="v38408898" class="anchor"></span><div class="para"> <p>Clinical presentation of active TB in children varies, making the diagnosis challenging. Most children have few symptoms other than a brassy cough.</p></div><span id="v11555490" class="anchor"></span><div class="para"> <p>Obtaining a sample for culture often requires one of the following:</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v38408901" class="anchor"></span><div class="para"> <p>Gastric aspiration</p></div></li><li class="topic__listitem"><span id="v38408903" class="anchor"></span><div class="para"> <p>Sputum induction</p></div></li><li class="topic__listitem"><span id="v38408905" class="anchor"></span><div class="para"> <p>A more invasive procedure such as bronchoalveolar lavage</p></div></li></ul></div><span id="v38408906" class="anchor"></span><div class="para"> <p>The most common sign on chest x-ray is hilar lymphadenopathy, but segmental atelectasis is possible. Adenopathy may progress, even after chemotherapy is started, and may cause lobar atelectasis, which usually clears during treatment. Cavitary disease is less common than in adults, and most children harbor far fewer organisms and are not contagious.</p></div><span id="v38408907" class="anchor"></span><div class="para"> <p>Treatment strategies are similar to those for adults except that drugs must be dosed strictly based on the child's weight (see table <span class="multimedia__link mlinkBlock" data-bind="component: { name: 'm-link-text', params: $data }" data-popup-model='{"ItemId":"bfcd24ba-a4ff-4757-81de-32bb9b0aa521","Title":"Dosing%20of%20Oral%20First-Line%20Anti-TB%20Drugs%2A","ShareUrlTitle":"dosing-of-oral-first-line-anti-tb-drugs","Description":"","ImageUrl":null,"ThumbnailUrl":"/Content/Images/Redesign/table/icon_table_red.png","MediaType":"table","MediaNameTranslated":"Table","UniqueId":"v1010853","Placement":null,"IsInCarousel":false,"Edition":0,"ImageWidth":null,"ImageHeight":null,"IframeSrc":null,"Target":null,"Alt":null}' data-popup-options='{"ListName":"TopicMultimedia","LinkText":"%3Cspan%20%3EDosing%20of%20First-Line%20Anti-TB%20Drugs%3C%2Fspan%3E","CssClass":null,"LoadLocations":true,"ShowTooltip":true,"SingleItem":true,"ExcludeFromBrand":"","ShowCredits":true,"ShowDescription":true,"PopupTitle":"Table","ShowTitle":true,"ShowIcon":false,"ShowModalIndicator":false,"ShowTitleInHeader":false,"HideCarousel":false,"Target":"modal","Url":null,"HideMainArrows":false}'></span>).</p></div> </div> </section> <section id="v1011251" class="topic__section GHead"> <span></span> <h3 id="Other_v1011243_v1011252" class="topic__header--subsection"> <span id="v1011252" class="anchor"></span> Older people </h3> <div class="topic__content"> <span id="v1011254" class="anchor"></span><div class="para"> <p>Reactivated disease can involve any organ but particularly the lungs, brain, kidneys, long bones, vertebrae, or lymph nodes. Reactivation may cause few symptoms and can be overlooked for weeks or months, delaying appropriate evaluation. The frequent presence of other disorders in old age further complicates the diagnosis. </p></div><span id="v38408909" class="anchor"></span><div class="para"> <p>Regardless of their age, nursing home residents who previously had a negative TST are at risk of disease due to recent transmission, which may cause apical, middle-lobe, or lower-lobe pneumonia as well as pleural effusion. The pneumonia may not be recognized as TB and may persist and spread to other people while it is being erroneously treated with ineffective broad-spectrum antibiotics.</p></div><span id="v38408910" class="anchor"></span><div class="para"> <p>In the US, miliary TB and TB meningitis, commonly thought to affect mainly young children, are more common among older people.</p></div><span id="v1011255" class="anchor"></span><div class="para"> <p>Risks and benefits of preventive treatment should be carefully assessed before older people are treated. INH causes hepatotoxicity in up to 4 to 5% of patients <span class='symbol'>></span> 65 years old (compared with <span class='symbol'>&lt</span> 1% of patients <span class='symbol'>&lt</span> 65 years old). As a result, chemoprophylaxis is usually given to older people only if the induration after TST increases <span class='symbol'>≥</span> 15 mm from a previously negative reaction. Close contacts of an active case and others at high risk and with a negative TST or IGRA result should also be considered for preventive treatment unless contraindicated. </p></div> </div> </section> <section id="v1011256" class="topic__section GHead"> <span></span> <h3 id="Other_v1011243_v1011257" class="topic__header--subsection"> <span id="v1011257" class="anchor"></span> Patients with HIV infection </h3> <div class="topic__content"> <span id="v1011260" class="anchor"></span><div class="para"> <p>TST sensitivity is generally poor in immunocompromised patients, who may be anergic. In some studies, IGRAs appear to perform better than the TST in immunocompromised patients, although this advantage has not yet been established. </p></div><span id="v1437012" class="anchor"></span><div class="para"> <p>In patients with untreated <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html" data-toggle="tooltip" title="Human Immunodeficiency Virus (HIV) Infection" data-id="23970a8c-992e-41c4-8b5d-9c1996a2a696" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">HIV infection</a><span id="23970a8c-992e-41c4-8b5d-9c1996a2a696" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Human Immunodeficiency Virus (HIV) Infection </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Human Immunodeficiency Virus (HIV) Infection" loading="lazy"> </span> </a> </span> </span> and latent tuberculosis infection (LTBI), active TB develops in about 10%/year, whereas in people who are not immunocompromised, it develops in about the same percentage over a lifetime. In the early 1990s, half of patients coinfected with TB and HIV who were untreated or infected with a multidrug-resistant strain died, with median survival of only 60 days. Now, outcomes are somewhat better in countries where there is better testing and treatment because of earlier TB diagnosis and antiretroviral therapy, but TB in patients with HIV remains a serious concern. In countries with limited access to drugs and testing for TB and HIV infection, mortality continues to be high among patients coinfected with HIV and multidrug-resistant TB or extensively drug-resistant TB.</p></div><span id="v1011261" class="anchor"></span><div class="para"> <p>Dissemination of bacilli during primary infection is usually much more extensive in patients with HIV infection. Consequently, a larger proportion of TB is extrapulmonary. Tuberculomas (mass lesions in the lungs or central nervous system due to TB) are more common and more destructive. HIV infection reduces both inflammatory reaction and cavitation of pulmonary lesions. As a result, a chest x-ray may show a nonspecific pneumonia or even be normal.</p></div><span id="v38408912" class="anchor"></span><div class="para"> <p>Smear-negative TB is more common when HIV coinfection is present. Because smear-negative TB is common, HIV-TB coinfection is often considered a paucibacillary disease state.</p></div><span id="v1011262" class="anchor"></span><div class="para"> <p>TB may develop early in AIDS and may be its presenting manifestation. Hematogenous dissemination of TB in patients with HIV infection causes a serious, often baffling illness with symptoms of both infections. In patients with AIDS, a mycobacterial illness that develops while the CD4 count is <span class='symbol'>≥</span> 200/mcL (0.2 × 10<sup>9</sup>/L) is almost always TB. By contrast, depending on the probability of TB exposure, a mycobacterial infection that develops while the CD4 count is <span class='symbol'>&lt</span> 50/mcL (0.05 × 10<sup>9</sup>/L) is usually due to <i>Mycobacterium avium</i> complex (<a href="./{63A6B149-4646-4855-A582-04E280558007}.html" data-toggle="tooltip" title="Nontuberculous Mycobacterial Infections" data-id="651ec7c1-7f01-4fa0-ade9-a7427f99781f" data-itemid="63a6b149-4646-4855-a582-04e280558007">MAC</a><span id="651ec7c1-7f01-4fa0-ade9-a7427f99781f" class="d-none xref"> <span class="tooltip-container"> <a href="./{63A6B149-4646-4855-A582-04E280558007}.html"> <span class="tooltip-content"> <span class="tooltip-heading"> Nontuberculous Mycobacterial Infections </span> There are over 170 recognized species of mycobacteria, mostly environmental. Environmental exposure to many of these organisms is common, but most exposures do not cause infection and many infections... <span class="tooltip-readmore"> read more </span> </span> </a> </span> </span>). Infection with MAC is not contagious and, in patients with HIV infection, affects primarily the blood and bone marrow, not the lungs.</p></div><span id="v1011265" class="anchor"></span><div class="para"> <p>Patients with HIV infection who were not diagnosed before presenting with TB should receive 2 weeks of antimycobacterial treatment before starting antiretroviral therapy to decrease the risk of developing the <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v26307332" data-toggle="tooltip" title="Immune reconstitution inflammatory syndrome (IRIS)" data-id="dd34c54a-f910-4ed0-8016-a2b785bfd076" data-itemid="f74e7edd-b57e-443c-af88-e04a1f79da48">immune reconstitution inflammatory syndrome</a><span id="dd34c54a-f910-4ed0-8016-a2b785bfd076" class="d-none xref"> <span class="tooltip-container"> <a href="./{F74E7EDD-B57E-443C-AF88-E04A1F79DA48}.html#v26307332"> <span class="tooltip-content"> <span class="tooltip-heading"> Immune reconstitution inflammatory syndrome (IRIS) </span> Human immunodeficiency virus (HIV) infection results from 1 of 2 similar retroviruses (HIV-1 and HIV-2) that destroy CD4+ lymphocytes and impair cell-mediated immunity, increasing risk of certain... <span class="tooltip-readmore"> read more </span> </span> <span class="tooltip-img"> <img src="./~/media/manual/professional/images/3/1/3/313_hiv_slide_3_springer_high.jpg?thn=0&sc_lang=en&mh=160&mw=160" class="tooltip-Preview" alt="Immune reconstitution inflammatory syndrome (IRIS)" loading="lazy"> </span> </a> </span> </span> (IRIS). TB in patients with HIV infection generally responds well to usual regimens when in vitro testing shows drug susceptibility. However, for multidrug-resistant TB strains, outcomes are not as favorable because the drugs are more toxic and less effective. Therapy for susceptible TB should be continued for 6 to 9 months after sputum cultures convert to negative but may be shortened to 6 months if 3 separate pretreatment sputum smears are negative, suggesting a low burden of organisms. Current recommendations suggest that if the sputum culture is positive after 2 months of therapy, treatment is prolonged to 9 months.</p></div><span id="v38408915" class="anchor"></span><div class="para"> <p>Patients with HIV infection whose tuberculin reactions are <span class='symbol'>≥</span> 5 mm (or with a positive IGRA result) should receive chemoprophylaxis.</p></div><span id="v38408916" class="anchor"></span><div class="para"> <p>Current <a rel="nofollow" target="_blank" href="http://www.cdc.gov/tb/publications/guidelines/Treatment.htm">CDC TB treatment guidelines</a> should be consulted.</p></div> </div> </section> </div> </section> <section id="v11555492" class="topic__section topic__section--keypoints FHead"> <h2 id="KeyPoints_v11555493" class="topic__header--section"> <span id="v11555493" class="anchor"></span> Key Points <span class="topic__keypoints--icon"></span> </h2> <div class="topic__content--keypoints"> <div class="list"> <ul data-mmanualobjecttype="List" class="bulleted"><li class="topic__listitem"><span id="v11555496" class="anchor"></span><div class="para"> <p>Tuberculosis causes a primary, often asymptomatic infection followed by latent infection and, in a few patients, an active disease phase.</p></div></li><li class="topic__listitem"><span id="v11555498" class="anchor"></span><div class="para"> <p>About one fourth of the world's population is infected with tuberculosis, and about 15 million have active disease at a given time.</p></div></li><li class="topic__listitem"><span id="v11555500" class="anchor"></span><div class="para"> <p>Active disease is much more likely in patients with impaired immunity, particularly those with HIV infection.</p></div></li><li class="topic__listitem"><span id="v11555502" class="anchor"></span><div class="para"> <p>Suspect the diagnosis based on symptoms, risk factors, tuberculin skin testing, and interferon-gamma release assays; confirm by sputum testing (microscopic examination and culture) and/or nucleic acid amplification tests.</p></div></li><li class="topic__listitem"><span id="v11555504" class="anchor"></span><div class="para"> <p>Treat with multiple drugs for several months.</p></div></li><li class="topic__listitem"><span id="v11555506" class="anchor"></span><div class="para"> <p>Drug resistance is a major concern and is increased by poor adherence, use of inappropriate drug regimens, and inadequate susceptibility testing.</p></div></li></ul></div> </div> </section> <section id="v13952583" class="topic__section FHead"> <h2 id="Further_v13952593" class="topic__header--section"> <span id="v13952593" class="anchor"></span> More Information </h2> <div class="topic__content"> <span id="v68425572" class="anchor"></span><div class="para"> <p>The following are some English-language resources that may be useful. Please note that THE MANUAL is not responsible for the content of these resources.</p></div><div class="list"> <ul data-mmanualobjecttype="List" class="nobulleted"><li class="topic__listitem"><span id="v68425574" class="anchor"></span><div class="para"> <p>Official American Thoracic Society, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America: <a rel="nofollow" target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/27516382"> Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis</a> (2016)</p></div></li><li class="topic__listitem"><span id="v68425577" class="anchor"></span><div class="para"> <p>Centers for Disease Control and Prevention (CDC): <a rel="nofollow" target="_blank" href="https://www.cdc.gov/tb/topic/testing/whobetested.htm">Updated guidelines for testing of latent TB infection</a></p></div></li><li class="topic__listitem"><span id="v13952596" class="anchor"></span><div class="para"> <p>CDC: <a rel="nofollow" target="_blank" href="http://www.cdc.gov/tb/topic/treatment/ltbi.htm">Treatment Regimens for Latent TB Infection (LTBI)</a></p></div></li><li class="topic__listitem"><span id="v13953514" class="anchor"></span><div class="para"> <p>CDC: <a rel="nofollow" target="_blank" href="http://www.cdc.gov/tb/publications/guidelines/Treatment.htm">TB Treatment Guidelines</a></p></div></li></ul></div> </div> </section>
 
 <section class="topic__section">
 <div class="topicswitch topic__patient-education topic__patient-education--bottom hide-on-print" data-icd9="010;011;012;013;014;015;016;017;018;771.2;137">
 <div class="topic__patient-education--container">
 <div class="topic__patient-education--icon"></div>
 <div class="topic__patient-education--text">
 View PATIENT EDUCATION
 </div>
 </div>
 </div>
 </section>
</div>
<script type="text/javascript">
 $(document).ready(function () {
 $(document).on('click', '.topicswitch', function (e) {
 e.preventDefault();
 $.ajax({
 url: '/Custom/Edition/GetSwitchUrl',
 type: "GET",
 dataType: "json",
 data: {
 icd9: '010;011;012;013;014;015;016;017;018;771.2;137',
 title: 'Tuberculosis (TB)',
 itemGuid: '1fef1f26-c9f6-41ef-8c18-cb7450e146e0'
 }
 }).done(function (data) {
 
 // redirect
 location.href = data.href;
 }).fail(function (jqxhr, textStatus, errorThrown) {
 console.error(errorThrown);
 });
 });
 });
</script>
 </article>
 <div class="copyright-print">
 <div class="copyright-print--logo">
<img src="./Content/Images/msd_foot_logo.png" alt="" class="badge msd" loading="lazy" width="240" height="71">
 </div>
 <div class="copyright-print--text">
 Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
 </div>
 </div>
 <section class="bottomnav__wrapper hide-on-print" style="display:none">
 
<div class="bottomnav no-print side-by-side">
 <div class="bottomnav__gotolink bottomnav__gotolink--previous">
 <a href="./{A1350E9A-85CE-481C-897F-C88CDE76FE3F}.html">
 <div class="bottomnav__gotolink--content">
 <div class="bottomnav__icon bottomnav__icon--previous"></div>
 <div class="bottomnav__linktext">Microsporidiosis</div>
 </div>
 </a>
 </div>
 
 <div class="bottomnav__gotolink bottomnav__gotolink--next">
 <a href="./{5DB9FCCD-8E55-41D4-844A-C3552B8447AC}.html">
 <div class="bottomnav__gotolink--content">
 <div class="bottomnav__linktext">Extrapulmonary Tuberculosis (TB)</div>
 <div class="bottomnav__icon bottomnav__icon--next"></div>
 </div>
 </a>
 </div>
</div>
 </section>
</div>
<span id="showpopup"></span>
<span id="showchildpopup"></span>
<div class="box box--marketing marketing-block orderize__candidate hide-on-print" data-orderize="1301">
 <div class="marketing-block-wrapper">
 <div class="box__header">
 <div class="box__headertext"></div>
 </div>
 <div class="box__content">
<div class="marketingblock-quiz hide-on-print">
<div class="marketingblock-quiz-img">
<img alt="quiz link" src="./Content/Images/Redesign/quizzes_lightbulb_red.png" loading="lazy" width="64" height="52">
</div>
<div class="marketingblock-quiz-desc">
<h4>Test your knowledge</h4>
<a href="./{976709AA-1FDC-4953-8B32-2A9E9973AC21}.html">Take a Quiz! </a></div>
</div> </div>
 </div>
</div>
<script type="text/javascript">
 $('img[usemap]').rwdImageMaps();
</script>
<div class="box box--marketing marketing-block orderize__candidate hide-on-print" data-orderize="1550">
 <div class="marketing-block-wrapper">
 <div class="box__header">
 <div class="box__headertext"></div>
 </div>
 <div class="box__content">
 <div class="box__content--mobile">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_pro_326.gif" alt="" id="e5cd0b69-d648-444e-a5d3-4e35a0c6e795_mobile" usemap="#e5cd0b69-d648-444e-a5d3-4e35a0c6e795_mobile" width="326" height="90">
 <map name="e5cd0b69-d648-444e-a5d3-4e35a0c6e795_mobile">
 <area shape="RECT" coords="176,79,90,53" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="ANDROID">
 </map>
 </div>
 <div class="box__content--tablet">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_pro_326.gif" alt="" id="e5cd0b69-d648-444e-a5d3-4e35a0c6e795_tablet" usemap="#e5cd0b69-d648-444e-a5d3-4e35a0c6e795_tablet" width="326" height="90">
 <map name="e5cd0b69-d648-444e-a5d3-4e35a0c6e795_tablet">
 <area shape="RECT" coords="176,79,90,53" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="ANDROID">
 </map>
 </div>
 <div class="box__content--desktop">
 <img loading="lazy" src="./~/media/manual/marketing/mobileqr/en_msd_mobile_qr_pro_326.gif" alt="" id="e5cd0b69-d648-444e-a5d3-4e35a0c6e795_desktop" usemap="#e5cd0b69-d648-444e-a5d3-4e35a0c6e795_desktop" width="326" height="90">
 <map name="e5cd0b69-d648-444e-a5d3-4e35a0c6e795_desktop">
 <area shape="RECT" coords="176,79,90,53" href="https://apps.apple.com/app/msd-professional-version/id1123678257" target="_blank" alt="iOS">
<area shape="RECT" coords="202,51,297,80" href="https://play.google.com/store/apps/details?id=com.msd.professional&referrer=utm_source%3DMMWeb%26utm_medium%3Dbanner%26utm_content%3DTopic1Vertical%26utm_campaign%3DWebAppAds" target="_blank" alt="ANDROID">
 </map>
 </div>
 </div>
 </div>
</div>
<script type="text/javascript">
 $('img[usemap]').rwdImageMaps();
</script>
<a id="autoload" role="button" tabindex="-1"></a>
 <div class="autoload-placeholder hide-on-print" name="Up Next:"></div>
 <a class="next-topic hide-on-print" role="button" aria-hidden="true"></a>
 </div>
</div>
 </section>
 
 </main>
 
 <div class="l-layer l-layer--topscroll">
 <div class="topscroll topscroll--hidden">
 <div class="topscroll__container">
 <div class="topscroll__button">
 <div class="topscroll__content">
 <i class="topscroll__arrow"></i>
 TOP
 </div>
 </div>
 </div>
 <div class="topscroll__bar"></div>
</div>
 </div>
 </div>
 
 <div class="flyout hide-on-print" tabindex="0">
 <nav class="flyout__menu" role="application" aria-label="Menu">
 </nav>
 </div>
 <div class="print">
 <div id="print__content">
 </div>
 </div>
 <div class="multimedia__popup l-viewport" data-bind="component: { name: 'multimedia-popup'}">
 <!-- Placeholder for media players. -->
</div>
 <script type="text/javascript">
 //global value for translating the 'Read More' value
 var MMReadMore = "read more";
 var MMMaxTeaseCount = 250;
 </script>
 
 
<div class="sticky-footer hide-on-print">
 <ul>
 <li class="sticky-footer--topic">
 <button aria-label="Topic" class="sticky-footer-topicmenu" aria-expanded="false">
 <span class="footer-bar__icon topic-ico"></span>
 </button>
 <div class="footer-expand-cont footer-parent-cont topicList">
 <button aria-label="close" class="footer-expand-cont__close"></button>
 <div class="footer-topicList-wrapper">
 <div class="in-this-topic-sidebar">
 <div class="box__header">
 <span>IN THIS TOPIC</span>
 <span class="in-this-topic-togggle-btn" aria-label="IN THIS TOPIC" aria-expanded="false"></span>
 </div>
 </div>
 </div>
 </div>
 </li>
 <li class="sticky-footer--version-switcher nontopicpage">
 <a data-id="HE" href="/home" target="_self" aria-label="Version Switch">
 <span class="footer-bar__icon versionSwitcher-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--version-switcher topicpage">
 <a class="topicswitch" href="#" target="_self" aria-label="Version Switch">
 <span class="footer-bar__icon versionSwitcher-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--vetFilter"></li>
 <li>
 <a href="./{218352E5-01E6-4C81-9542-33CF998B22E9}.html" target="_self" aria-label="Resources">
 <span class="footer-bar__icon resources-ico"></span>
 </a>
 </li>
 <li class="sticky-footer--social">
 <aside class="actiontoolbar hide-on-print">
 <!--<a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--bookmark" onclick="bookmarkPage(this);" href="#"></a>-->
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--download" style="display: none" href="#"></a>
 
 <ul>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--share a2a_dd" href="https://www.addtoany.com/share" rel="noopener" role="button" aria-expanded="false" aria-label="Share in"></a>
 </li>
 <li>
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--print" href="#" onclick="window.print(); MManual.analytics.notifyOpenModal(MManual.analytics.eventPrintAnArticle);" role="button" title="print"></a>
 </li>
 <li class="a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-icon-color="transparent,transparent">
 <a class="actiontoolbar__button actiontoolbar__icon actiontoolbar__icon--email a2a_button_email" href="#" role="button" title="Mail"></a>
 </li>
 <li class="scroll-to-top">
 <a href="#top" role="button" aria-label="Go To Top" title="Go To Top"><span class="scroll-to-top-img"></span></a>
 </li>
 <li class="scroll-to-bottom">
 <a href="#" role="button" aria-label="Go To Top"><span class="scroll-to-bottom-img"></span></a>
 </li>
 </ul>
 </aside>
 </li>
 <li class="sticky-footer--moreCont">
 <button aria-label="More" class="sticky-footer--more" aria-expanded="false">
 <span class="footer-bar__icon more-ico"></span>
 </button>
 <div class="footer-expand-cont more-footer-container">
 <ul>
 <li>
 <a href="./{F01A9F26-96C0-45E2-8ACC-403ACDB78022}.html" target="_self" aria-label="Home">
 <span class="footer-bar__icon home-ico"></span>
 </a>
 </li>
 <li>
 <a href="./{FF41B506-E267-4A7F-8357-F8C0474115E2}.html" target="_self" aria-label="info">
 <span class="footer-bar__icon info-ico"></span>
 </a>
 </li>
 <li>
 <button aria-label="Settings" aria-expanded="false">
 <span class="footer-bar__icon settings-ico"></span>
 </button>
 <div class="footer-sub-cont settings-footer-cont"></div>
 </li>
 <li class="language-footer">
 <button aria-label="Select Language" aria-expanded="false">
 <span class="footer-bar__icon language-ico"></span>
 </button>
 <div class="footer-sub-cont language-footer-cont"></div>
 </li>
 </ul>
 </div>
 </li>
 </ul>
</div>
 
 
 
<!--[if (gte IE 9)|!(IE)]><!-->
<script type="text/javascript">
 function downloadJSAtOnload() {
 
 MManual.deferredScripts.push("./bundles/redesign/libsdeferredjsv4.1.2.2-13178e13ca.js?v=0HKp-yFnKaDEueCLP27J6D4rHb3-AAxm6cmzEE3Gmb41");
 
 
 MManual.deferredScripts.push("./bundles/redesign/mmanualdeferredjsv4.1.2.2-13178e13ca.js?v=-hMvtQA9NJy1WdyRhBfBFzrPaWL44SkinQI4pIY9AWk1");
 
 
 MManual.deferredScripts.push("./bundles/redesign/mmanualTopicdeferredjsv4.1.2.2-13178e13ca.js?v=wDzP134aC3i-5gwHvRAsARMyhcs_em3XWcSsRyzYpYQ1");
 
 MManual.utils.loadScripts(MManual.deferredScripts);
 }
 $(document).ready(downloadJSAtOnload);
</script>
<!--<![endif]-->
<!--[if lt IE 9]>
 
 <script src="/Content/Scripts/Lib/mediaelement-and-player.min.js?v4.1.2.2-13178e13ca" type="text/javascript"></script>
 <script src="/Content/Scripts/Lib/zoomerang.js?v4.1.2.2-13178e13ca" type="text/javascript"></script>
 <script type="text/javascript">
 function downloadJSAtOnload() {
 
 MManual.deferredScripts.push("/bundles/redesign/mmanualdeferredjsv4.1.2.2-13178e13ca.js?v=-hMvtQA9NJy1WdyRhBfBFzrPaWL44SkinQI4pIY9AWk1");
 
 
 MManual.deferredScripts.push("/bundles/redesign/ie8libsdeferredjsv4.1.2.2-13178e13ca.js?v=0HKp-yFnKaDEueCLP27J6D4rHb3-AAxm6cmzEE3Gmb41");
 
 
 MManual.deferredScripts.push("/bundles/redesign/mmanualTopicdeferredjsv4.1.2.2-13178e13ca.js?v=wDzP134aC3i-5gwHvRAsARMyhcs_em3XWcSsRyzYpYQ1");
 
 for (var i = 0; i < MManual.deferredScripts.length; i++) {
 var element = document.createElement("script");
 element.src = MManual.deferredScripts[i];
 element.classList.add("optanon-category-C0002");
 document.body.appendChild(element);
 }
 }
 $(document).ready(downloadJSAtOnload);
 </script>
<![endif]-->
 <!-- Current instance name : ue-p-sc-cd02
 Current application version : 4.1.2.2-13178e13ca
 -->
 <!--[if (gte IE 9)|!(IE)]><!-->
<script src="./bundles/redesign/libsEndjsv4.1.2.2-13178e13ca.js?v=NWrOPHpqntlKhYlvryw8nEPZpRaWQrScEY3i127KnfI1"></script>
<!--<![endif]-->
<input id="MediaFramework_ItemId" name="MediaFramework_ItemId" type="hidden" value="1FEF1F26C9F641EF8C18CB7450E146E0">
</div><div id="hiddentblcontents" style="display:none"><div id='hidden_v1010853'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v1010855"></span> <div class="TableFullPage" id="v1010853"> <h3 class="title">Dosing of Oral First-Line Anti-TB Drugs*</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228030" class="anchor"></span><div class="para"> <p>Drug</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228033" class="anchor"></span><div class="para"> <p>Adults or Children</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228036" class="anchor"></span><div class="para"> <p>Daily†</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228039" class="anchor"></span><div class="para"> <p>Once/Week</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228042" class="anchor"></span><div class="para"> <p>2 Times/Week</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228045" class="anchor"></span><div class="para"> <p>3 Times/Week</p></div></p></th></tr></thead> <tbody><tr class="odd"><td rowspan="2"><span id="v1010873" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isoniazid</span></p></div></td><td><span id="v1010875" class="anchor"></span><div class="para"> <p>Adults (maximum)</p></div></td><td><span id="v1010877" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td><td><span id="v1010879" class="anchor"></span><div class="para"> <p>15 mg/kg (900 mg)</p></div></td><td><span id="v1010881" class="anchor"></span><div class="para"> <p>15 mg/kg (900 mg)</p></div></td><td><span id="v1010883" class="anchor"></span><div class="para"> <p>15 mg/kg (900 mg)</p></div></td></tr><tr class="even"><td><span id="v1010888" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1010890" class="anchor"></span><div class="para"> <p>10–20 mg/kg (300 mg)</p></div></td><td><span id="v1010892" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010894" class="anchor"></span><div class="para"> <p>20–40 mg/kg (900 mg)</p></div></td><td><span id="v1010896" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010899" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifampin</span></p></div></td><td><span id="v1010901" class="anchor"></span><div class="para"> <p>Adults (maximum)</p></div></td><td><span id="v1010903" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td><td><span id="v1010905" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010907" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td><td><span id="v1010909" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td></tr><tr class="even"><td><span id="v1010914" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1010916" class="anchor"></span><div class="para"> <p>10–20 mg/kg (600 mg)</p></div></td><td><span id="v1010918" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010920" class="anchor"></span><div class="para"> <p>10–20 mg/kg (600 mg)</p></div></td><td><span id="v1010922" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010925" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifabutin</span></p></div></td><td><span id="v1010927" class="anchor"></span><div class="para"> <p>Adults (maximum)</p></div></td><td><span id="v1010929" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td><td><span id="v1010931" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010933" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td><td><span id="v1010935" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td></tr><tr class="even"><td><span id="v1010940" class="anchor"></span><div class="para"> <p>Children</p></div></td><td><span id="v1010942" class="anchor"></span><div class="para"> <p>10–20 mg/kg (300 mg)</p></div></td><td><span id="v1010944" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010946" class="anchor"></span><div class="para"> <p>10–20 mg/kg (300 mg)</p></div></td><td><span id="v1010948" class="anchor"></span><div class="para"> <p>10–20 mg/kg (600 mg)</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010951" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifapentine</span>‡</p></div></td><td><span id="v1010953" class="anchor"></span><div class="para"> <p>Adults</p></div></td><td><span id="v1010955" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010957" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td><td><span id="v1010959" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010961" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="even"><td><span id="v1010966" class="anchor"></span><div class="para"> <p>Children</p></div></td><td><span id="v1010968" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010970" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010972" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010974" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="5"><span id="v1010977" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Pyrazinamide</span></p></div></td><td><span id="v1010979" class="anchor"></span><div class="para"> <p>Adults (whole tablets):</p></div></td><td><span id="v1010981" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1010983" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1010985" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1010987" class="anchor"></span><div class="para"> <p></div></td></tr><tr class="even"><td><span id="v1010992" class="anchor"></span><div class="para"> <p>40–55 kg</p></div></td><td><span id="v1010994" class="anchor"></span><div class="para"> <p>1 g</p></div></td><td><span id="v1010996" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010998" class="anchor"></span><div class="para"> <p>2 g</p></div></td><td><span id="v1011000" class="anchor"></span><div class="para"> <p>1.5 g</p></div></td></tr><tr class="odd"><td><span id="v1011005" class="anchor"></span><div class="para"> <p>56–75 kg</p></div></td><td><span id="v1011007" class="anchor"></span><div class="para"> <p>1.5 g</p></div></td><td><span id="v1011009" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011011" class="anchor"></span><div class="para"> <p>3 g</p></div></td><td><span id="v1011013" class="anchor"></span><div class="para"> <p>2.5 g</p></div></td></tr><tr class="even"><td><span id="v1011018" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 76 kg§</p></div></td><td><span id="v1011020" class="anchor"></span><div class="para"> <p>2 g</p></div></td><td><span id="v1011022" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011024" class="anchor"></span><div class="para"> <p>4 g</p></div></td><td><span id="v1011026" class="anchor"></span><div class="para"> <p>3 g</p></div></td></tr><tr class="odd"><td><span id="v1011031" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1011033" class="anchor"></span><div class="para"> <p>15–30 mg/kg (2 g)</p></div></td><td><span id="v1011035" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011037" class="anchor"></span><div class="para"> <p>50 mg/kg (2 g)</p></div></td><td><span id="v1011039" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="even"><td rowspan="5"><span id="v1011042" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ethambutol</span></p></div></td><td><span id="v1011044" class="anchor"></span><div class="para"> <p>Adults (whole tablets):</p></div></td><td><span id="v1011046" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1011048" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1011050" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1011052" class="anchor"></span><div class="para"> <p></div></td></tr><tr class="odd"><td><span id="v1011057" class="anchor"></span><div class="para"> <p>40–55 kg</p></div></td><td><span id="v1011059" class="anchor"></span><div class="para"> <p>800 mg</p></div></td><td><span id="v1011061" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011063" class="anchor"></span><div class="para"> <p>2000 mg</p></div></td><td><span id="v1011065" class="anchor"></span><div class="para"> <p>1200 mg</p></div></td></tr><tr class="even"><td><span id="v1011070" class="anchor"></span><div class="para"> <p>56–75 kg</p></div></td><td><span id="v1011072" class="anchor"></span><div class="para"> <p>1200 mg</p></div></td><td><span id="v1011074" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011076" class="anchor"></span><div class="para"> <p>2800 mg</p></div></td><td><span id="v1011078" class="anchor"></span><div class="para"> <p>2000 mg</p></div></td></tr><tr class="odd"><td><span id="v1011082" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 76 kg§</p></div></td><td><span id="v1011084" class="anchor"></span><div class="para"> <p>1600 mg</p></div></td><td><span id="v1011086" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011088" class="anchor"></span><div class="para"> <p>4000 mg</p></div></td><td><span id="v1011090" class="anchor"></span><div class="para"> <p>2400 mg</p></div></td></tr><tr class="even"><td><span id="v1011095" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1011097" class="anchor"></span><div class="para"> <p>15–20 mg/kg (1 g)</p></div></td><td><span id="v1011099" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011101" class="anchor"></span><div class="para"> <p>50 mg/kg (2.5 g)</p></div></td><td><span id="v1011103" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010873" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Moxifloxacin</span></p></div></td><td><span id="v1010875" class="anchor"></span><div class="para"> <p>≥ 12 years of age</p></div></td><td><span id="v1010877" class="anchor"></span><div class="para"> <p>400 mg</p></div></td><td><span id="v1010879" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010881" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010883" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr></tbody> <tfoot><tr><td colspan="6"><span id="v1011107" class="anchor"></span><div class="para"> <p>* Specific regimens are discussed in text.</p></div></td></tr><tr><td colspan="6"><span id="v1011110" class="anchor"></span><div class="para"> <p>† Daily is considered either 5 or 7 days/week. All dosing <span class='symbol'></span> 7 days/week must be given as directly observed therapy.</p></div></td></tr><tr><td colspan="6"><span id="v1011113" class="anchor"></span><div class="para"> <p>‡ Continuation phase only.</p></div></td></tr><tr><td colspan="6"><span id="v1011116" class="anchor"></span><div class="para"> <p>§ Maximum dose.</p></div></td></tr><tr><td colspan="6"><span id="v1011119" class="anchor"></span><div class="para"> <p>N/A <span class='symbol'>=</span> not applicable.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div><div id="hiddentblcontents" style="display:none"><div id='hidden_v1010853'> <div data-mmanualobjecttype="Table" class="table-box"> <span id="v1010855"></span> <div class="TableFullPage" id="v1010853"> <h3 class="title">Dosing of Oral First-Line Anti-TB Drugs*</h3> <div class="tableWrapper"> <table> <thead><tr tablehead1=""><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228030" class="anchor"></span><div class="para"> <p>Drug</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228033" class="anchor"></span><div class="para"> <p>Adults or Children</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228036" class="anchor"></span><div class="para"> <p>Daily†</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228039" class="anchor"></span><div class="para"> <p>Once/Week</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228042" class="anchor"></span><div class="para"> <p>2 Times/Week</p></div></p></th><th style='text-align:left' scope='col'><p class="tableHead1"><span id="v1228045" class="anchor"></span><div class="para"> <p>3 Times/Week</p></div></p></th></tr></thead> <tbody><tr class="odd"><td rowspan="2"><span id="v1010873" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Isoniazid</span></p></div></td><td><span id="v1010875" class="anchor"></span><div class="para"> <p>Adults (maximum)</p></div></td><td><span id="v1010877" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td><td><span id="v1010879" class="anchor"></span><div class="para"> <p>15 mg/kg (900 mg)</p></div></td><td><span id="v1010881" class="anchor"></span><div class="para"> <p>15 mg/kg (900 mg)</p></div></td><td><span id="v1010883" class="anchor"></span><div class="para"> <p>15 mg/kg (900 mg)</p></div></td></tr><tr class="even"><td><span id="v1010888" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1010890" class="anchor"></span><div class="para"> <p>10–20 mg/kg (300 mg)</p></div></td><td><span id="v1010892" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010894" class="anchor"></span><div class="para"> <p>20–40 mg/kg (900 mg)</p></div></td><td><span id="v1010896" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010899" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifampin</span></p></div></td><td><span id="v1010901" class="anchor"></span><div class="para"> <p>Adults (maximum)</p></div></td><td><span id="v1010903" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td><td><span id="v1010905" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010907" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td><td><span id="v1010909" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td></tr><tr class="even"><td><span id="v1010914" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1010916" class="anchor"></span><div class="para"> <p>10–20 mg/kg (600 mg)</p></div></td><td><span id="v1010918" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010920" class="anchor"></span><div class="para"> <p>10–20 mg/kg (600 mg)</p></div></td><td><span id="v1010922" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010925" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifabutin</span></p></div></td><td><span id="v1010927" class="anchor"></span><div class="para"> <p>Adults (maximum)</p></div></td><td><span id="v1010929" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td><td><span id="v1010931" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010933" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td><td><span id="v1010935" class="anchor"></span><div class="para"> <p>5 mg/kg (300 mg)</p></div></td></tr><tr class="even"><td><span id="v1010940" class="anchor"></span><div class="para"> <p>Children</p></div></td><td><span id="v1010942" class="anchor"></span><div class="para"> <p>10–20 mg/kg (300 mg)</p></div></td><td><span id="v1010944" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010946" class="anchor"></span><div class="para"> <p>10–20 mg/kg (300 mg)</p></div></td><td><span id="v1010948" class="anchor"></span><div class="para"> <p>10–20 mg/kg (600 mg)</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010951" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Rifapentine</span>‡</p></div></td><td><span id="v1010953" class="anchor"></span><div class="para"> <p>Adults</p></div></td><td><span id="v1010955" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010957" class="anchor"></span><div class="para"> <p>10 mg/kg (600 mg)</p></div></td><td><span id="v1010959" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010961" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="even"><td><span id="v1010966" class="anchor"></span><div class="para"> <p>Children</p></div></td><td><span id="v1010968" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010970" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010972" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010974" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="5"><span id="v1010977" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Pyrazinamide</span></p></div></td><td><span id="v1010979" class="anchor"></span><div class="para"> <p>Adults (whole tablets):</p></div></td><td><span id="v1010981" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1010983" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1010985" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1010987" class="anchor"></span><div class="para"> <p></div></td></tr><tr class="even"><td><span id="v1010992" class="anchor"></span><div class="para"> <p>40–55 kg</p></div></td><td><span id="v1010994" class="anchor"></span><div class="para"> <p>1 g</p></div></td><td><span id="v1010996" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010998" class="anchor"></span><div class="para"> <p>2 g</p></div></td><td><span id="v1011000" class="anchor"></span><div class="para"> <p>1.5 g</p></div></td></tr><tr class="odd"><td><span id="v1011005" class="anchor"></span><div class="para"> <p>56–75 kg</p></div></td><td><span id="v1011007" class="anchor"></span><div class="para"> <p>1.5 g</p></div></td><td><span id="v1011009" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011011" class="anchor"></span><div class="para"> <p>3 g</p></div></td><td><span id="v1011013" class="anchor"></span><div class="para"> <p>2.5 g</p></div></td></tr><tr class="even"><td><span id="v1011018" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 76 kg§</p></div></td><td><span id="v1011020" class="anchor"></span><div class="para"> <p>2 g</p></div></td><td><span id="v1011022" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011024" class="anchor"></span><div class="para"> <p>4 g</p></div></td><td><span id="v1011026" class="anchor"></span><div class="para"> <p>3 g</p></div></td></tr><tr class="odd"><td><span id="v1011031" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1011033" class="anchor"></span><div class="para"> <p>15–30 mg/kg (2 g)</p></div></td><td><span id="v1011035" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011037" class="anchor"></span><div class="para"> <p>50 mg/kg (2 g)</p></div></td><td><span id="v1011039" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="even"><td rowspan="5"><span id="v1011042" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Ethambutol</span></p></div></td><td><span id="v1011044" class="anchor"></span><div class="para"> <p>Adults (whole tablets):</p></div></td><td><span id="v1011046" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1011048" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1011050" class="anchor"></span><div class="para"> <p></div></td><td><span id="v1011052" class="anchor"></span><div class="para"> <p></div></td></tr><tr class="odd"><td><span id="v1011057" class="anchor"></span><div class="para"> <p>40–55 kg</p></div></td><td><span id="v1011059" class="anchor"></span><div class="para"> <p>800 mg</p></div></td><td><span id="v1011061" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011063" class="anchor"></span><div class="para"> <p>2000 mg</p></div></td><td><span id="v1011065" class="anchor"></span><div class="para"> <p>1200 mg</p></div></td></tr><tr class="even"><td><span id="v1011070" class="anchor"></span><div class="para"> <p>56–75 kg</p></div></td><td><span id="v1011072" class="anchor"></span><div class="para"> <p>1200 mg</p></div></td><td><span id="v1011074" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011076" class="anchor"></span><div class="para"> <p>2800 mg</p></div></td><td><span id="v1011078" class="anchor"></span><div class="para"> <p>2000 mg</p></div></td></tr><tr class="odd"><td><span id="v1011082" class="anchor"></span><div class="para"> <p><span class='symbol'>≥</span> 76 kg§</p></div></td><td><span id="v1011084" class="anchor"></span><div class="para"> <p>1600 mg</p></div></td><td><span id="v1011086" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011088" class="anchor"></span><div class="para"> <p>4000 mg</p></div></td><td><span id="v1011090" class="anchor"></span><div class="para"> <p>2400 mg</p></div></td></tr><tr class="even"><td><span id="v1011095" class="anchor"></span><div class="para"> <p>Children (maximum)</p></div></td><td><span id="v1011097" class="anchor"></span><div class="para"> <p>15–20 mg/kg (1 g)</p></div></td><td><span id="v1011099" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1011101" class="anchor"></span><div class="para"> <p>50 mg/kg (2.5 g)</p></div></td><td><span id="v1011103" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr><tr class="odd"><td rowspan="2"><span id="v1010873" class="anchor"></span><div class="para"> <p><span class='disableDrug' tabindex='0' role='link' onclick='javascript:void(0);'>Moxifloxacin</span></p></div></td><td><span id="v1010875" class="anchor"></span><div class="para"> <p>≥ 12 years of age</p></div></td><td><span id="v1010877" class="anchor"></span><div class="para"> <p>400 mg</p></div></td><td><span id="v1010879" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010881" class="anchor"></span><div class="para"> <p>N/A</p></div></td><td><span id="v1010883" class="anchor"></span><div class="para"> <p>N/A</p></div></td></tr></tbody> <tfoot><tr><td colspan="6"><span id="v1011107" class="anchor"></span><div class="para"> <p>* Specific regimens are discussed in text.</p></div></td></tr><tr><td colspan="6"><span id="v1011110" class="anchor"></span><div class="para"> <p>† Daily is considered either 5 or 7 days/week. All dosing <span class='symbol'></span> 7 days/week must be given as directly observed therapy.</p></div></td></tr><tr><td colspan="6"><span id="v1011113" class="anchor"></span><div class="para"> <p>‡ Continuation phase only.</p></div></td></tr><tr><td colspan="6"><span id="v1011116" class="anchor"></span><div class="para"> <p>§ Maximum dose.</p></div></td></tr><tr><td colspan="6"><span id="v1011119" class="anchor"></span><div class="para"> <p>N/A <span class='symbol'>=</span> not applicable.</p></div></td></tr></tfoot> </table> </div> </div> <button class="btn print" onclick="printPopupContent();"><i class="fa fa-print"></i></button> <button class="btn show-tab"><i class="fa fa-arrows-alt"></i><i class="fa fa-times"></i></button> </div></div></div></body>
<div class="bottomnav__gotolink bottomnav__gotolink--next"></div>  <div class="fixed-footer fixed-width" align="right" id="setbackgrnd"><table class="fixed-width"><tr class="fixed-width"><td id="tdsearch" align="right" class="tdsearch"><input type="text" id="search" onkeyup="search(id)" placeholder="Find on page..." class="form-control search"></td><td id="tdbtn" align="left" class="tdbtn"><button onclick="myFunction()" id="button" class="button"></button></td></tr></table></div>
</html>